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GENER AL INTRODUCTION
Cerebrovascular disorders are defined as focal cerebral injury with an underlying vascular 
basis and can be divided in stroke resulting from arterial ischemic event, cerebral sinove-
nous thrombosis and hemorrhage1. Stroke at young age (< age 18) is not common, but is an 
important cause of lifelong morbidity and is among the top ten causes of death in child-
hood2-4. It has an incidence of approximately 1.3-13 per 100.000 per year in the developed 
countries. Causes, risk factors and pathogenic mechanisms of pediatric stroke differ in the 
perinatal period or in childhood.
Pediatric arterial ischemic stroke
Arterial ischemic stroke (AIS) in childhood is usually non-atherosclerotic, which is differ-
ent from the adult population. In half of the children with AIS, a pre-existing condition 
can be identified, such as congenital heart disease or sickle cell disease; in the other part it 
remains uncertain and may be due to an interplay of both genetic and environmental factors. 
AIS can occur for example in the presence of genetic prothrombotic disorders, but also in 
the context of a metabolic disease (Fabry disease, congenital disorders of glycosylation) 
or other underlying genetic cerebral arteriopathies. In the perinatal period, most relevant 
risk factors are linked to maternal risk factors, such as autoimmune disease, preeclamp-
sia, traumas, and neonatal, such as infection, systemic illness (including inborn errors of 
metabolism) and complex congenital heart disease. Very few genetic causes are known. In 
the first part of this thesis, two examples of genetic disorders leading to ischemic cerebral 
arteriopathy, Incontinentia pigmenti and ACTA2 mutations, are described in more detail. 
Pediatric Hemorrhagic stroke
In the main part of this thesis, we will focus on processes underlying cerebral hemorrhage 
occurring at young age, mostly in the perinatal and infantile period. In the childhood pop-
ulation, the proportion of hemorrhagic stroke is approximately 50%, versus only 15% in 
the adult population1,2,4. Hemorrhagic stroke (bleeding) is the result of a weakened vessel 
that ruptures and bleeds into the surrounding brain. Overall mortality of hemorrhagic 
stroke in children is approximately 25% and of those who survive, 42% shows signifi-
cant disability5. Hemorrhagic stroke comprises spontaneous intracerebral (parenchymal 
and intraventricular) hemorrhage (ICH) and non-traumatic subarachnoid hemorrhage 
(SAH)2. A parenchymal hemorrhage is located within the brain parenchyma, whereas an 
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intraventricular hemorrhage is located inside the brain’s ventricular system. Subarachnoi-
dal hemorrhages are located in the subarachnoidal space, the area between the arachnoid 
membrane and the pia mater, that surrounds the brain and are most often due to intracra-
nial aneurysms6. Common risk factors for hemorrhagic stroke at young age are listed in 
Table 17. Most of them undely occurrence in childhood. Besides common risk factors, rare 
genetic causes of cerebral hemorrhage have been identified at any age, from pregnancy to 
adulthood and are summarized in Table 2, together with the known genetic causes of arte-
rial ischemic stroke and our newly identified genes, which will be discussed in detail in this 
thesis.
Neonatal/ infantile cerebral hemorrhage is a subset of the childhood intracerebral (paren-
chymal or intraventricular) hemorrhage and among all types pediatric strokes is the least 
well characterized. It is often regarded as non-genetic, and risk factors include low birth 
weight and prematurity8-11. It usually presents as a germinal matrix hemorrhage or intraven-
tricular hemorrhage. The germinal matrix a highly vascularized, transient layer near the 
ventricles that is present between 8 and 36 weeks of gestation. It has a role in the production 
of neurons and glial cells. The structure of the germinal matrix is selectively vulnerable to 
hemorrhage, which can be explained by limited astrocyte end-feet coverage of microvessels, 
reduced expression of fibronectin, an extracellular matrix component, and immature tight 
junctions12. In approximately 15% of infants these hemorrhages lead to venous infarction 
Table 1. Risk factors for pediatric hemorrhagic stroke
Arteriovenous malformations 14-50%
Cerebral aneurysms 10-13%
Cavernous malformations 15-25%
Hematological abnormalities 10-30%
 Thrombocytopenia
  Idiopathic thrombocytopenia purpura (ITP)
 Hemophilia
 Coagulopathies
  Liver failure
  Disseminated intravascular coagulation
  Iatrogenic
 Sickle cell anemia
Brain tumors 13%
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due to occlusion of the periventricular collector veins, subsequent tissue destruction and 
the development of porencephaly, defined as a cavity in the brain parenchyma commu-
nicating with the lateral ventricle13. This process is depicted in Figure 1. The hemorrhage 
usually occurs at late pregnancy or around birth14. In case of early extensive hemorrhage, 
the destruction can extend to the cortex and can lead to major destructive lesions such as 
hydranencephaly15. Affected neonates have a high chance of developing long term com-
plications, such as hydrocephaly, motor impairment such as cerebral palsy, intellectual 
disability or epilepsy, depending on the extension of the lesions. 
Already since the 1980s, familial occurrence of cerebral hemorrhage has been documented, 
for instance familial cases of porencephaly16-21. The discovery of an underlying genetic cause 
of childhood cerebral hemorrhage is of importance for appropriate genetic counselling. 
Expanding the knowledge on underlying mechanisms will hopefully result in the develop-
ment of specific treatment and preventive options in the future. To achieve this, it is crucial 
to elucidate the pathogenic mechanisms underlying these disorders. By investigating the 
childhood population, we expect to find a greater influence of genetic factors compared to 
Figure 1. Schematic overview of pathogenic mechanism leading to porencephaly119,120. The 
lateral ventricles with surrounding deep veins are depicted in A. Porencephaly originates from 
a germinal matrix hemorrhage, often followed by intraventricular hemorrhage. This leads to 
deep venous infarctions and destruction of white matter in that area, eventually leading to a cyst 
communicating with the ventricle (B)
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the adult population, since the role of additional environmental factors contributing to the 
hemorrhage is smaller. However, a common genetic factor may underly both neonatal and 
adult onset cerebral hemorrhage, due to variable expression, which is, for example, docu-
mented for COL4A1 and COL4A2 mutations. 
Pathophysiological processes underlying the disorders described in this 
thesis
The identification of genetic causes of cerebrovascular disease has led to the identification 
of different pathophysiological processes. We will focus on two major pathophysiological 
processes that are mostly related to cerebral vascular integrity and are the subject of this 
thesis: structural changes affecting the blood vessel and blood-brain barrier integrity and 
dysregulation of immune response, which secondarily affects blood vessel integrity. A short 
overview of these processes will be provided.
Structural changes affecting blood- brain barrier integrity
The blood-brain-barrier consists of specific physical barriers, enzymes and transporters, 
that together form/ maintain the extracellular environment of the central nervous system. 
The main physical barrier consists of the endothelial cells of the blood vessel walls within 
the central nervous system. Of great importance for this barrier are tight junctions, which 
connect the endothelial cells and impair transport of large molecules across the barrier. 
Other components of the blood-brain barrier are astrocytes, pericytes and the extracellu-
lar matrix, especially the subendothelial basement membrane. This basement membrane 
is a complex formed by collagens, lamin, fibronectin, entactin, thrombospondin, heparin 
sulphate proteoglygans such as agrin, and chondroitin sulphate proteoglycans such as 
versican22. Collagen IV, a major component of the basement membrane, influences tight 
junction formation and stimulates expression of a major tight junction component, named 
occludin. The loss or dysfunction of one of the extracellular matrix components can lead to 
dysfunction of the endothelial cells of the cerebral vasculature23. 
The basement membrane: COL4A1 and COL4A2
An important component of the basement membrane of the (brain) blood vessels is collagen 
IV, mainly collagen IV alpha-1 and collagen IV alpha-2. These proteins form triple helices 
with a ration of two collagen IV alpha-1 and one collagen IV alpha-2 chain. These helices 
in turn form a network that gives stability to basement membranes and provides binding 
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sites for other extracellular matrix proteins24,25. These networks are not only important for 
vascular basement membrane stability, but they also play a role in the stability of cerebral 
membranes (pia mater). This latter function is important for brain developmental processes, 
since, during brain development, these membranes are used as anchoring points for glia 
cells, enabling the migration of neurons to their position in the brain cortex26,27.  
In COL4A1 and COL4A2 mutations, a disturbed network formation of the basement mem-
brane is presumed, either due to an abnormal triple helix formation leading to a decrease 
of normal triple helices in the basement membrane, or due to a change in binding sites of 
the triple helix with disturbed binding of other extracellular matrix components. These 
processes are presumed to cause the vascular dysfunction, with disruption leading to hem-
orrhage, and small vessel disease28. Instability of the pial basement membranes can lead to 
brain developmental defects26,27.
In 2005, COL4A1 mutations were discovered as a cause of autosomal dominant hereditary 
porencephaly29-31. Over the years, the phenotype of COL4A1 mutations has expanded from 
porencephaly to a multisystem disorder, comprising a broad spectrum of cerebrovascu-
lar abnormalities, including aneurysms and small vessel disease, parenchyme and cortex 
abnormalities, including calcifications, schizencephaly and hydranencephaly, ophthalmo-
logical abnormalities including cataract, microphthalmia and retinal vessel abnormities, 
renal abnormalities including cysts and hematuria, muscular findings including muscle 
cramps and myopathy and cardiac findings such as arrhythmias. In 2012, in several parallel 
studies, both familial and sporadic porencephaly were also attributed to COL4A2 muta-
tions32-34. The phenotype in both COL4A1 and COL4A2 mutations is extremely variable in 
expression, with broad intra-familial variations and evidence for reduced penetrance. 
The tight junctions: Occludin and JAM3
Dysfunction of the tight junction components has been associated with cerebral hemor-
rhage and childhood cerebrovascular disease. Important tight junction components are 
occludin and junctional adhesion molecules (JAMs). Three types of JAMs are known: 
JAM1, which is expressed in both endothelial and epithelial cells, and JAM2 and JAM3, 
who are expressed in vascular endothelial cells. Occludin and JAMs play a major role in the 
regulation of the barrier function of the blood- brain- barrier, including the regulation of 
permeability and the extravasation of leucocytes. The function and position of occludin in 
the cell membrane is dependent on the function of microtubules and the actin cytoskeleton. 
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Homozygous mutations in both OCLN and JAM3 cause syndromes resembling congenital 
infection, and are therefore named pseudo- TORCH syndromes. Mutations in OCLN lead 
to a syndrome with microcephaly, polymicrogyria and a band of gray matter calcification. 
Polymicrogyria is a cortical malformation which is presumed to be related to ischemic or 
vascular insults around five months of pregnancy. Mutations in JAM3 cause a syndrome of 
hemorrhagic destruction of brain parenchyma, subependymal calcification and congenital 
cataracts. The precise pathophysiological mechanism in both syndromes is unknown, but 
dysfunction of the blood- brain- barrier is presumed to be one underlying factor35,36.
The actin cytoskeleton
One of the major components of the cellular cytoskeleton is actin. Actin filaments are 
organized into polymerized fibers. These fibers are responsible for the anchoring of the 
cytoskeleton into the plasma membrane. Actin is essential for cell motility and the main-
tenance of cell shape. In the blood- brain barrier, it plays a role in the integrity of the tight 
junction complex by regulating the position of tight junction proteins in the cell mem-
brane35,37,38. 
There are different subtypes of actins. One of them is ACTA2, which is expressed in vascular 
smooth muscle cells, but also in other organ systems, including the brain. The phenotype 
in ACTA2 mutations includes thoracic aortic aneurysms and dissections (TAAD), coro-
nary artery disease and cerebral infarctions, cerebral aneurysms and small vessel disease. 
Recently, a multisystem disorder caused by specific changes in the ACTA2 gene was identi-
fied. Cerebrovascular anomalies in this disorder comprise an abnormal course of cerebral 
arteries, including a moyamoya-like phenotype, diffuse periventricular leukoencephalop-
athy and multifocal infarcts. In addition, a broad spectrum of developmental defects can 
be appreciated, most due to smooth muscle cell dysfunction39,40. The phenotype in ACTA2 
mutations has been attributed to an abnormal function of the vascular smooth muscles. 
However, an abnormal function of the tight junctions may contribute to the brain pheno-
type, i.e. the small vessel disease.
Immune response dysregulation
Immune response in the central nervous system (CNS), comprising the brain, spinal cord, 
optic nerves and retina, is different from that in different organs. Due to the delicacy of the 
post-mitotic, non-regenerating cells within the CNS, it is of great importance that destruc-
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tive, inflammatory reactions are carefully controlled. The CNS lacks lymphatic vessels, and 
cerebrospinal fluid functions as an equivalent of lymph41. Since the early 1970s, reports 
on the TORCH complex appeared, reporting on the concept that intrauterine infections 
(Toxoplasmosis gondii, Rubella, Cytomegalovirus, Herpes viruses and later also HIV) can 
have severe effects on the central nervous system (CNS), leading to cerebrovascular and 
cerebrodevelopmental disorders. Although the CNS is partly protected from toxic sub-
stances and pathogens by the blood-brain barrier, neurotropic viruses may be able to enter 
the CNS by crossing the barrier, by exploiting motile infected cells as Trojan horses or by 
using axonal transport42. 
Neuroimaging findings in the TORCH complex include intracranial calcifications, both 
periventricular or parenchymal, hydrocephalus and a variety of cortical anomalies, includ-
ing polymicrogyria, schizencephaly, hydranencephaly, pachygyria, lissencephaly, focal 
cortical dysplasia, cerebellar hypoplasia and cerebral hemorrhage43,44. 
Over the years, several reports have appeared on patients with a “pseudo-TORCH” phenotype, 
but with absent infection parameters. These phenotypes are grouped as “pseudo-TORCH 
syndrome”. Cardinal findings are congenital cerebral calcification, microcephaly, enlarged 
ventricles, cerebellar hypoplasia or atrophy and the development of icterus, hyperbilirubin-
emia, thrombocytopenia and hepatomegaly (in 50%) short after birth45. 
A high percentage (35%) of consanguinity in this group of patients is seen, suggesting 
genetic, autosomal recessive underlying conditions.
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IFN type I signalling
In both viral infections, and the Aicardi-Goutières syndrome, an autosomal recessive syn-
drome that is one of the known genetic “pseudo-TORCH” syndromes, as well as in our 
newly identified “pseudo-TORCH” syndrome due to USP18 mutations, an up-regulation of 
the IFN type I signalling pathway is seen. 
Type I and type III interferons (IFNs) are cytokines that are critical to control early steps 
of viral infections42. Basal activity of IFNs are within the CNS appear to be low, proba-
bly owing to the toxicity of IFN to this organ42. IFNs act on specific cell receptors, and 
binding activate transduction pathways to enhance the expression of hundreds of Interfer-
on-Stimulated Genes (ISGs), which lead the cell into an antiviral state46. Type I interferon 
comprises IFNα, produced by leucocytes, and IFNβ, produced by fibroblasts. They exhibit 
various biological functions, including antiviral, anti-proliferative, immunomodulatory 
and developmental activities. They interact with the human IFN alpha receptor (IFNAR), 
that is composed of two subunits (IFNAR-1 and IFNAR-2), which are present in almost any 
cell type46. 
The Aicardi-Goutières syndrome is caused by mutations in TREX1, RNASEH2A, 
RNASEH2B, RNASEH2C, SAMHD1 or ADAR1. Mutations in one of these genes cause 
an inadequate processing of cellular nucleic acid debris, which triggers indirectly, by mech-
anisms not clarified to date, the innate immune response, leading to induction of IFNα 
expression and an up-regulation of the IFN type I signalling pathway47. 
In its classical form, the Aicardi-Goutières syndrome phenotype manifests in infancy with 
progressive microcephaly, spasticity and psychomotor retardation. Brain imaging includes 
intracranial calcification, white matter destruction and brain atrophy. Systemic manifes-
tations are thrombocytopenia, hepatosplenomegaly, elevated hepatic transaminases and 
intermittent fevers. In its classis form, it has a poor prognosis, with death in early childhood 
in approximately 40% of cases48. However, several milder clinical phenotypes have been 
identified since the discovery of the underlying genetic defects, including retinal vasculop-
athy with cerebral leukodystrophy, familial chilblain lupus, systemic lupus erythematosus 
and non-specific inflammatory arthropathy. Only mutations in SAMHD1 (AGS5) have 
been associated with a cerebral vasculopathy involving the large arteries, showing either 
stenosis of intracerebral large arteries with evidence of basal collaterals consistent with 
moyamoya syndrome, or intracranial aneurysms without occlusive disease49-51. Childhood 
cerebral hemorrhage has been reported in several patients50,52.
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NF-κB signalling
Another component that is upregulated in response to inflammation is NF-κB. NF-κB sig-
nalling is induced in response to multiple stimuli, including tumor necrosis factor α (TNFα), 
bacterial lipopolysaccharide (LPS) and genotoxic agents. Active NF-κB can translocate to 
the nucleus and activate transcription of target genes. In the CNS, NF-κB is present in 
neurons, astrocytes, migroglia and oligodendrocytes. It plays an important role in immune 
responses and protection against neuronal damage and apoptosis caused by ischemic or 
inflammatory brain injury and excitotoxicity caused by seizures53. Interestingly, NF-κB was 
recently identified as an important factor in the signalling pathway induced by the cyto-
kine Interleukin (IL)-15 in cerebral vascular endothelial cells composing the blood- brain 
barrier, which is in turn induced by TNF α. This IL-15 signalling in endothelial cells exerts 
cytoprotective effects against inflammation and consequently impaired function of the 
blood-brain barrier54. 
Absent NF-κB activation is seen in cells harbouring a NEMO mutation. This is the underly-
ing genetic cause of Incontinentia Pigmenti, a rare X-linked disorder that can present with 
neurological features, such as microcephaly, small-vessel disease and hemorrhagic necrosis. 
The cerebral abnormalities are thought to result from a combination of vascular injury/ 
insufficiency, inflammation and a possibly disturbed apoptosis during cerebral develop-
ment55. 
SCOPE OF THE THESIS
In the last decade, young patients (including neonates, infants and children) with cere-
brovascular disease of unknown cause (mostly hemorrhagic stroke) were evaluated at the 
Departments of Clinical Genetics, Child Neurology, Pediatric Neuroradiology and Neona-
tology of the Erasmus University Medical Center and the Department of Neonatology of 
the University Medical Center Utrecht. After the discovery of COL4A1 mutations in famil-
ial porencephaly, a close collaboration started between these departments, aiming to better 
understand the cause and mechanisms of perinatal hemorrhagic stroke. Our original goal 
was to identify the genetic factors involved in cerebral hemorrhage at young age starting 
from our patient´ s cohort and to characterize the phenotypic spectrum of collagen IV-re-
lated cerebral disorder and other genetic cerebral vascular disorders in our young patient 
cohort. The results would be important to improve the diagnostics in this group of patients, 
to provide better counselling of families and to identify future therapeutic targets for this 
group of disorders. 
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The first part of the thesis focusses on observations on the genetic causes of ischemic cerebral 
arteriopathies. The second, main part of the thesis, focusses on genetic causes of perinatal, 
infantile and childhood cerebral hemorrhage. The third part comprises the discussion of 
the results. 
PART I Genetic causes of ischemic stroke
Chapter 2 includes descriptions of the phenotypic variability of gene mutations normally 
classified among the causes of ischemic arteriopathies, but revealing themselves as broader 
cerebrovascular disease at young age]. In chapter 2.1 a case report is provided on a toddler 
girl with a systemic disorder, including cerebral and vascular developmental defects and 
leukoencephalopathy, who harboured an ACTA2 mutation. Chapter 2.2 comprises a 
review of literature about neurological complications of Incontinentia Pigmenti, classically 
thought to result from ischemic damage and instead revealing an important hemorrhagic 
component.
PART II Genetic causes of hemorrhagic stroke
In chapter 3, an overview is provided of the current knowledge on COL4A1 and COL4A2 
mutations is provided. In particular, a review of the clinical spectrum of COL4A1 and 
COL4A2 mutations and our experiences in a patient cohort is illustrated. Several clinical 
phenotypes are described in detail. A protocol for clinical management of COL4A1 and 
COL4A2 patients is provided.
In chapter 4, our experience with several specific COL4A1 mutation phenotypes is described. 
Chapter 4.1 describes the most severe end of the COL4A1 mutation spectrum, comprising 
of severe brain destruction resembling hydranencephaly due to de novo mutations in four 
affected infants. Chapter 4.2 gives a description of the severe ophthalmological phenotype 
leading to cataract, microcornea, microphthalmia and tunnel vision in a family with three 
affected patients. Chapter 4.3 provides the description of the first patient harbouring a 
homozygous COL4A1 mutation affecting a specific part of the gene, the NC1-domain.
In chapter 5, we describe the identification of COL4A2 mutations as a second cause of 
hereditary porencephaly and small vessel disease, using a candidate gene approach. The 
clinical, neuroradiological and biochemical findings in two families are reported, including 
findings in skin fibroblasts.
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In chapter 6, the identification of USP18 as a novel genetic cause of pseudo-TORCH syn-
drome with cerebral hemorrhage is illustrated. The clinical and molecular findings in two 
families including five affected individuals with severe cerebrovascular disease and early 
demise are summarized. 
Chapter 7 comprises the general discussion of the thesis, in which the most important con-
clusions, implications of the study for clinical practice and suggestions for future research 
are presented. 
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 d
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o
cc
lu
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o
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o
rt
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o
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, o
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b
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is
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 D
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T
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u
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 c
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o
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n
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 d
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b
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, p
at
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 p
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m
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ro
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Table 2. G
enetic causes of cerebrovascular disease (continued from
 previous page)
(continued on next page)
L
ysyl h
yd
ro
xylase-3 (L
H
3) 
d
eficien
cy (A
R
)
P
L
O
D
3 (612394)
7q
22
P
ro
co
llagen
-L
ysin
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O
xo
glu
tarate 5-D
io
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3
E
n
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h
yd
ro
xylatio
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u
es in
 
co
llagen
-lik
e p
ep
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k
k
in
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C
A
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H
F
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p
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eu
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y, fractu
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ren
cep
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D
)
C
O
L
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34
C
o
llagen
, T
yp
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A
lp
h
a 1
E
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ro
tein
s, 
m
ajo
r co
m
p
o
n
en
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en
t 
m
em
b
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C
A
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o
ren
cep
h
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o
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m
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p
h
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m
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p
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p
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yp
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lp
h
a 2
A
u
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m
al D
o
m
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t 
P
o
lycystic K
id
n
ey D
isease 
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D
)
P
K
D
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16p
13.3
P
o
lycystic K
id
n
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T
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e p
ro
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 ren
al tu
b
u
lo
gen
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m
 
regu
latio
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C
A
A
B
ilateral ren
al cysts, ren
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P
K
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eu
ro
fib
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m
ato
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D
)
N
F
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N
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m
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C
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p
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u
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th
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T
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A
A
m
acro
cep
h
aly, caf'e-au
-lait sp
o
ts, axillary 
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lin
g, L
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 n
o
d
u
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lexifo
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n
eu
ro
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as, sk
eletal ab
n
o
rm
alities,  learn
in
g 
d
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M
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h
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d
ysp
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o
rd
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d
w
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e II (A
R
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P
C
N
T
 (210720)
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P
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tegral co
m
p
o
n
en
t o
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so
m
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C
A
A
, m
o
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o
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w
th
 retard
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, m
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h
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n
o
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o
rm
al in
telligen
ce/d
evelo
p
m
en
tal 
d
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b
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N
F
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E
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u
b
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u
it
in
-p
ro
te
in
 li
ga
se
 t
h
at
 
m
ay
 p
la
y 
a 
ro
le
 i
n
 a
n
gi
o
ge
n
es
is
. 
M
ay
 a
ls
o
 h
av
e 
an
 A
T
P
as
e 
ac
ti
vi
ty
M
o
ya
m
o
ya
, i
sc
h
em
ic
 
st
ro
k
e 
82
Chapter 134
Table 2. G
enetic causes of cerebrovascular disease (continued from
 previous page)
(continued on next page)
M
etab
o
lic cau
ses o
f cereb
ral vascu
lar d
isease
S
yn
d
ro
m
e (in
h
eritan
ce)
G
en
e (O
M
IM
) 
C
h
o
m
o
so
m
e
P
ro
tein
P
ro
tein
 fu
n
ctio
n
C
ereb
ro
vascu
lar 
p
h
en
o
typ
e
A
d
d
itio
n
al featu
res
R
efs
G
lu
taric acid
u
ria typ
e 1 
(A
R
)
G
C
D
H
 (231670)
19p
13.2
G
lu
tayl-C
o
A
 d
eh
yd
ro
gen
ase
C
atalyzes a step
 in
 th
e d
egrad
ative 
p
ath
w
ay o
f lysin
e, h
yd
ro
xylysin
e, 
an
d
 tryp
to
p
h
an
 m
etab
o
lism
SD
H
C
ereb
ral atro
p
h
y, su
b
ep
en
d
ym
al p
seu
d
o
cysts, 
w
h
ite m
atter an
d
 b
asal gan
glia ch
an
ges, 
m
acro
cep
h
aly, m
etab
o
lic en
cep
h
alo
p
ath
y
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M
en
k
es d
isease 
(X
-L
)
A
T
P
7A
X
q
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C
o
p
p
er-T
ran
sp
o
rtin
g 
A
T
P
ase 1
T
ran
sm
em
b
ran
e p
ro
tein
 th
at 
fu
n
ctio
n
s in
 co
p
p
er tran
sp
o
rt 
acro
ss m
em
b
ran
es.
B
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H
, SA
H
D
elayed
 cereb
ral m
yelin
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n
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ral an
d
 
cereb
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p
h
y, sh
o
rt statu
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icro
cep
h
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k
in
k
y h
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in
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d
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yp
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o
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b
o
n
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h
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in
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ith
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u
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M
o
lyb
d
en
u
m
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facto
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d
eficien
cy (A
R
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M
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M
o
lyb
d
en
u
m
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facto
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syn
th
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 1
E
n
zym
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o
n
sib
le fo
r th
e 
fo
rm
atio
n
 o
f m
o
lyb
d
en
u
m
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facto
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o
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d
en
u
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r th
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ctio
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xid
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th
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e d
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p
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 d
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P
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23.3
General introduction and outline of the thesis 35
Ta
bl
e 2
. G
en
et
ic
 ca
us
es
 o
f c
er
eb
ro
va
sc
ul
ar
 d
ise
as
e (
co
nt
in
ue
d 
fro
m
 p
re
vi
ou
s p
ag
e)
(co
nt
in
ue
d 
on
 n
ex
t p
ag
e)
F
ab
ry
 (
X
-L
)
G
L
A
 (
30
15
00
)
X
q
22
.1
A
lp
h
a-
ga
la
ct
o
si
d
as
e 
A
R
o
le
 i
n
 g
ly
co
sp
h
in
go
li
p
id
 
ca
ta
b
o
li
sm
 
T
ra
n
si
en
t 
is
ch
em
ic
 
at
ta
ck
s,
 i
sc
h
em
ic
 
st
ro
k
es
, m
ic
ro
b
le
ed
s
C
ar
d
ia
c 
le
ft
 v
en
tr
ic
u
la
r 
h
yp
er
tr
o
p
h
y,
 
p
ro
gr
es
si
ve
 r
en
al
 f
ai
lu
re
, n
eu
ro
p
at
h
y,
 s
k
in
 
le
si
o
n
s
90
D
ih
yd
ro
p
yr
im
id
in
e 
d
eh
yd
ro
ge
n
as
e 
d
ef
ic
ie
n
cy
 
(A
R
)
D
P
Y
D
 (
27
42
70
)
1p
21
.3
D
ih
yd
ro
p
yr
im
id
in
e 
d
eh
yd
ro
ge
n
as
e
In
it
ia
l a
n
d
 r
at
e-
li
m
it
in
g 
en
zy
m
e 
in
 
th
e 
ca
ta
b
o
li
sm
 o
f 
th
e 
p
yr
im
id
in
e 
b
as
es
 u
ra
ci
l a
n
d
 t
h
ym
in
e
C
er
eb
ra
l i
n
fa
rc
ti
o
n
, 
w
h
it
e 
m
at
te
r 
ab
n
o
rm
al
it
ie
s
M
ic
ro
ce
p
h
al
y,
 m
en
ta
l r
et
ar
d
at
io
n
, 
o
p
th
al
m
o
lo
gi
ca
l a
b
n
o
rm
al
it
ie
s,
 a
u
ti
sm
, s
ei
zu
re
s,
 
h
yp
er
ac
ti
vi
ty
91
C
o
n
ge
n
it
al
 d
is
o
rd
er
s 
o
f 
gl
yc
o
sy
la
ti
o
n
, t
yp
e 
1a
 (
A
R
)
P
M
M
2 
(2
12
06
5)
16
p
13
.2
P
h
o
sp
h
o
m
an
n
o
m
u
ta
se
-2
E
n
zy
m
e 
n
ec
es
sa
ry
 f
o
r 
th
e 
sy
n
th
es
is
 
o
f 
G
D
P
-m
an
n
o
se
St
ro
k
e-
li
k
e 
ep
is
o
d
es
, 
ce
re
b
ra
l i
n
fa
rc
ti
o
n
F
ai
lu
re
 t
o
 t
h
ri
ve
, r
et
in
it
is
 p
ig
m
en
to
sa
, l
iv
er
 
fi
b
ro
si
s 
an
d
 s
te
at
o
si
s,
 c
ar
d
io
m
yo
p
at
h
y,
 i
n
ve
rt
ed
 
n
ip
p
le
s,
 a
b
n
o
rm
al
 f
at
 t
is
su
e 
d
is
tr
ib
u
ti
o
n
, r
en
al
 
p
ro
b
le
m
s,
 c
o
ag
u
lo
p
at
h
y,
 n
eu
ro
p
at
h
y
92
.9
3
Chapter 136
Table 2. G
enetic causes of cerebrovascular disease (continued from
 previous page)
(continued on next page)
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enetic causes of cerebrovascular disease (continued from
 previous page)
(continued on next page)
SA
M
H
D
1
20q
11.23
SA
M
 D
o
m
ain
 A
n
d
 H
D
 
D
o
m
ain
 1
R
o
le in
 m
ed
iatio
n
 o
f im
m
u
n
e 
resp
o
n
se
m
o
yam
o
ya syn
d
ro
m
e, 
C
A
A
, IC
H
Id
em
A
D
A
R
1
1q
21.3
A
d
en
o
sin
e D
eam
in
ase, R
N
A
-
Sp
ecific
T
h
is en
zym
e d
estab
ilizes d
o
u
b
le-
stran
d
ed
 R
N
A
 th
ro
u
gh
 co
n
versio
n
 
o
f ad
en
o
sin
e to
 in
o
sin
e
In
tracran
ial 
calcificatio
n
s
Id
em
B
an
d
-lik
e calcificatio
n
 w
ith
 
sim
p
lified
 gyratio
n
 an
d
 
p
o
lym
icro
gyria (A
R
)
O
C
L
N
 (251290)
5q
13.2
O
cclu
d
in
P
lays a ro
le in
 th
e fo
rm
atio
n
 an
d
 
regu
latio
n
 o
f th
e tigh
t ju
n
ctio
n
 (T
J) 
p
aracellu
lar p
erm
eab
ility b
arrier
B
an
d
-lik
e in
tracran
ial 
calcificatio
n
s
P
o
lym
icro
gyria, sim
p
lified
 gyral p
attern
, 
p
ro
gressive m
icro
cep
h
aly
35
In
co
n
tin
en
tia P
igm
en
ti
(X
-L
)
N
E
M
O
 (308300)
X
q
28
N
F
-K
ap
p
aB
 E
ssen
tial 
M
o
d
u
lato
r
R
egu
lato
ry su
b
u
n
it o
f th
e in
h
ib
ito
r 
o
f k
ap
p
aB
 k
in
ase (IK
K
) co
m
p
lex, 
w
h
ich
 activates N
F
-k
ap
p
aB
, 
resu
ltin
g in
 activatio
n
 o
f gen
es 
in
vo
lved
 in
 in
flam
m
atio
n
, 
im
m
u
n
ity, cell su
rvival, an
d
 o
th
er 
p
ath
w
ays
IC
H
, p
eriven
tricu
lar 
an
d
 su
b
co
rtical w
h
ite 
m
atter d
isease, cereb
ral 
in
farcts
C
o
rp
u
s callo
su
m
 h
yp
o
p
lasia, cereb
ral atro
p
h
y, 
h
air, n
ail an
d
 d
en
tal ab
n
o
rm
alities, 
o
p
h
th
alm
o
lo
gical ab
n
o
rm
ailies, p
ath
o
gn
o
m
o
n
ic 
sk
in
 in
flam
m
atio
n
/ h
yp
er- an
d
 
h
yp
o
p
igm
en
tatio
n
100,
101
C
ereb
ro
retin
al 
m
icro
an
gio
p
ath
y w
ith
 
calcificatio
n
s an
d
 cysts (A
R
)
C
T
C
1 (612199 )
17p
13.1
C
T
S T
elo
m
ere M
ain
ten
an
ce 
C
o
m
p
lex C
o
m
p
o
n
en
t 1
Su
b
u
n
its o
f an
 alp
h
a accesso
ry 
facto
r (A
A
F
), th
at stim
u
lates th
e 
activity o
f D
N
A
 p
o
lym
erase-alp
h
a-
p
rim
ase, th
e en
zym
e th
at in
itiates 
D
N
A
 rep
licatio
n
L
eu
k
o
en
cep
h
alo
p
ath
y, 
b
rain
 cysts, in
tracran
ial 
calcificatio
n
s
R
etin
al telan
giectasia an
d
 exu
d
ates , o
steo
p
en
ia, 
vascu
latu
re ectasias in
 th
e sto
m
ach
, sm
all 
in
testin
e an
d
 liver, an
em
ia, th
ro
m
b
o
cyto
p
en
ia
109
L
eu
k
o
en
cep
h
alo
p
ath
y, 
cystic, w
ith
o
u
t 
m
egalen
cep
h
aly (A
R
)
R
N
A
SE
T
2 (612951)
6q
27
R
ib
o
n
u
clease T
2
E
n
xym
e w
ith
 rib
o
n
u
clease activity. 
P
ro
b
ab
ly in
vo
lved
 in
 lyso
so
m
al 
d
egrad
atio
n
o
f rib
o
so
m
al R
N
A
.
C
ystic 
leu
k
o
en
cep
h
alo
p
ath
y, 
m
u
ltifo
cal w
h
ite m
atter 
lesio
n
s, ven
tricu
lar 
en
largem
en
t, 
in
tracran
ial 
calcificatio
n
s
M
icro
cep
h
aly, h
earin
g lo
ss
110
General introduction and outline of the thesis 39
Ta
bl
e 2
. G
en
et
ic
 ca
us
es
 o
f c
er
eb
ro
va
sc
ul
ar
 d
ise
as
e (
co
nt
in
ue
d 
fro
m
 p
re
vi
ou
s p
ag
e)
H
er
ed
it
ar
y 
p
o
re
n
ce
p
h
al
y 
(A
D
)
C
O
L
4A
1 
(1
75
78
0,
 
61
17
73
)
13
q
34
C
o
ll
ag
en
, T
yp
e 
IV
, A
lp
h
a 
1
E
xt
ra
ce
ll
u
la
r 
m
at
ri
x 
p
ro
te
in
s,
 
m
aj
o
r 
co
m
p
o
n
en
t 
o
f 
b
as
em
en
t 
m
em
b
ra
n
es
 
C
A
A
, p
o
re
n
ce
p
h
al
y,
 
sm
al
l v
es
se
l d
is
ea
se
, 
IC
H
, s
ch
iz
en
ce
p
h
al
y,
 
in
tr
ac
ra
n
ia
l 
ca
lc
if
ic
at
io
n
s
R
et
in
al
 a
rt
er
ia
l t
o
rt
u
o
si
ty
, c
at
ar
ac
t,
 
m
ic
ro
p
h
th
al
m
ia
, g
la
u
co
m
a,
 m
u
sc
le
 c
ra
m
p
s,
 
m
yo
p
at
h
y,
 r
en
al
 c
ys
ts
, h
em
at
u
ri
a,
 R
ay
n
au
d
 
p
h
en
o
m
en
o
n
29
,3
3,
70
C
O
L
4A
2 
(6
14
48
3)
13
q
34
C
o
ll
ag
en
, T
yp
e 
IV
, A
lp
h
a 
2
P
se
u
d
o
-T
O
R
C
H
 s
yn
d
ro
m
e 
w
it
h
 c
er
eb
ra
l h
em
o
rr
h
ag
e
U
SP
18
22
q
11
.2
U
b
iq
u
it
in
 S
p
ec
if
ic
 P
ro
te
in
 
18
U
p
re
gu
la
te
d
 u
p
o
n
 I
F
N
 t
yp
e 
I 
si
gn
al
li
n
g,
 f
u
n
ct
io
n
s 
in
 
d
eI
SG
yl
at
io
n
 a
n
d
 i
s 
an
 i
n
h
ib
it
o
r 
o
f 
IF
N
A
R
 r
ec
ep
to
r
C
er
eb
ra
l a
n
d
 c
er
eb
el
la
r 
h
em
o
rr
h
ag
e,
 
in
tr
ac
ra
n
ia
l 
ca
lc
if
ic
at
io
n
s,
 w
h
it
e 
m
at
te
r 
ab
n
o
rm
al
it
ie
s,
 
n
ec
ro
si
s
T
h
ro
m
b
o
cy
to
p
en
ia
, l
iv
er
 f
ai
lu
re
 w
it
h
 a
sc
it
is
, 
re
sp
ir
at
o
ry
 d
is
tr
es
s
(co
nt
in
ue
d 
on
 n
ex
t p
ag
e)
Chapter 140
A
rterial isch
em
ic stro
k
e/ an
g
io
p
ath
y
S
yn
d
ro
m
e (in
h
eritan
ce)
G
en
e (O
M
IM
) 
C
h
o
m
o
so
m
e
P
ro
tein
P
ro
tein
 fu
n
ctio
n
C
ereb
ro
vascu
lar 
p
h
en
o
typ
e
A
d
d
itio
n
al featu
res
R
efs
C
A
D
A
SIL
 (A
D
)
N
O
T
C
H
3 
19p
13.12
N
O
T
C
H
3
F
u
n
ctio
n
s as a recep
to
r fo
r 
m
em
b
ran
e-b
o
u
n
d
 ligan
d
s Jagged
1, 
Jagged
2 an
d
 D
elta1 to
 regu
late cell-
fate d
eterm
in
atio
n
L
acu
n
ar in
farcts, 
m
icro
b
leed
s, 
leu
k
o
en
cep
h
alo
p
ath
y
Seizu
res, m
igrain
e, d
em
en
tia
106
C
A
R
A
SIL
 (A
R
)
H
T
R
A
1 (600142)
10q
26.13
H
trA
 Serin
e P
ep
tid
ase 1
M
em
b
er o
f th
e tryp
sin
 fam
ily o
f 
serin
e p
ro
teases
Su
b
co
rtical lacu
n
ar 
in
farcts, d
iffu
se w
h
ite 
m
atter an
o
m
alies, acu
te 
stro
k
e
W
h
ite m
atter d
em
yelin
atio
n
, ataxia, d
em
en
tia, 
p
ro
gressive en
cep
h
alo
p
ath
y, lo
w
 b
ack
 p
ain
, 
p
rem
atu
re b
ald
n
ess
107
M
ito
ch
o
n
d
rial m
yo
p
ath
y, 
en
cep
h
alo
p
ath
y, lactic 
acid
o
sis, an
d
 stro
k
e-lik
e 
ep
iso
d
es (M
E
L
A
S)(M
it)
M
ito
ch
o
n
d
rial gen
es 
M
T
T
L
1, M
T
T
Q
, 
M
T
T
H
, M
T
T
K
, 
M
T
T
C
, M
T
T
S1, 
M
T
T
S2, M
T
N
D
1, 
M
T
N
D
5, M
T
N
D
6 
(540000)
Stro
k
e-lik
e ep
iso
d
es, 
en
cep
h
alo
p
ath
y
C
ataract, h
earin
g lo
ss, m
yo
p
ath
y, m
igrain
e, 
seizu
res, d
em
en
tia, lactic acid
o
sis
113
A
rterial T
o
rtu
o
sity 
Syn
d
ro
m
e (A
R
)
SL
C
2A
10 (208050)
20q
13.12
G
lu
co
se tran
sp
o
rter 
G
L
U
T
10
P
lays a ro
le in
 regu
latio
n
 o
f glu
co
se 
h
o
m
eo
stasis
A
rterial to
rtu
o
sity, 
cereb
ral in
farctio
n
, 
arterial an
eu
rysm
A
rterial to
rtu
o
sity, arterial an
eu
rysm
s, 
d
o
w
n
slan
tin
g p
alp
eb
ral fissu
res, h
yp
ertelo
rism
, 
p
ectu
s d
efo
rm
ity, jo
in
t laxity, d
iap
h
ragm
atic 
h
ern
ia
114
W
illiam
s-B
eu
ren
 syn
d
ro
m
e 
(C
H
R
)
7q
11.23 d
eletio
n
 
(194050)
C
ereb
ral in
farctio
n
, 
IC
H
In
tellectu
al d
isab
ility, facial d
ysm
o
rp
h
ism
s, 
gro
w
th
 retard
atio
n
, co
n
gen
ital h
eart d
isease, iris 
stellata, ren
al an
o
m
alies, h
earin
g lo
ss
115,116
C
ereb
ral A
m
ylo
id
 
A
rterio
p
ath
y (A
D
)
A
P
P
 (605714)
21q
21.3
A
m
ylo
id
 b
eta (A
4) 
p
recu
rso
r p
ro
tein
 
tran
sm
em
b
ran
e p
recu
rso
r p
ro
tein
 
th
at is cleaved
 b
y secretases to
 fo
rm
 
a n
u
m
b
er o
f p
ep
tid
es. So
m
e o
f 
th
ese p
ep
tid
es are secreted
 an
d
 
p
ro
m
o
te tran
scrip
tio
n
al activatio
n
, 
w
h
ile o
th
ers fo
rm
 th
e p
ro
tein
 b
asis 
o
f th
e am
ylo
id
 p
laq
u
es.
C
ereb
ral am
ylo
id
 
an
gio
p
ath
y, cereb
ral 
in
farctio
n
, recu
rren
t 
stro
k
es, m
icro
b
leed
s, 
cereb
ral an
d
 cereb
ellar 
h
em
o
rrh
age
D
em
en
tia
117
C
ST
3 (105150)
20p
11.21
C
ystatin
 C
A
n
 in
h
ib
ito
r o
f lyso
so
m
al cystein
e 
p
ro
tein
ases
C
ereb
ral h
em
o
rrh
age
D
em
en
tia, am
ylo
id
 d
ep
o
sitio
n
118
IC
H
, in
tracereb
ral h
em
o
rrh
age; SA
H
, su
b
arach
n
o
id
al h
em
o
rrh
age; IC
A
, in
tern
al caro
tid
 artery; SD
H
, su
b
d
u
ral h
em
o
rrh
age; IV
H
, in
traven
tricu
lar h
em
o
rrh
age
A
D
, au
to
so
m
al d
o
m
in
an
t; A
R
, au
to
so
m
al recessive; X
-L
, X
-lin
k
ed
; C
H
R
, ch
ro
m
o
so
m
al; M
IT
, m
ito
ch
o
n
d
rial; M
F
, m
u
ltifacto
rial
Table 2. G
enetic causes of cerebrovascular disease (continued from
 previous page)


PART I
GENETIC CAUSES OF 
ISCHEMIC STROKE

Chapter 2.1
1. Dept. of Clinical Genetics, Erasmus University Medical Center, Rotterdam.
2. Dept. of Radiology, Erasmus University Medical Center, Rotterdam. 
3. Dept. of Pediatrics, Erasmus University Medical Center, Rotterdam. 
4. Dep. of Obstetrics and Prenatal Medicine, Erasmus University Medical Center, Rotterdam.
5. Dept. of Cardiology, Erasmus University Medical Center, Rotterdam. 
6. Dept. of Neurology, Erasmus University Medical Center, Rotterdam.
7. Netherlands Institute for Neuroscience, Amsterdam.
 * These authors equally contributed to this manuscript.
European Journal of Human Genetics Part A 161A:1376–1380.
Marije E.C. Meuwissen1, Maarten H. Lequin2, Karen Bindels-de Heus3, Hennie T. Bruggen-
wirth1, Maarten F.C.M. Knapen4, Michiel Dalinghaus5, Rene de Coo6, Yolande van Bever1, 
Beerend H.J. Winkelman7, and Grazia M.S. Mancini1*
ACTA2 MUTATION WITH CHILDHOOD 
CARDIOVASCULAR, AUTONOMIC 
AND BRAIN ANOMALIES AND SEVERE 
OUTCOME
ABSTR ACT
Thoracic aortic aneurysm and dissection (TAAD) are associated with connective 
tissue disorders likeMarfan syndrome and Loeys–Dietz syndrome, caused by muta-
tions in the fibrillin-1, the TGFb-receptor 1- and -2 genes, the SMAD3 and TGFb2 
genes, but have also been ascribed to ACTA2 gene mutations in adults, spread 
throughout the gene. We report on a novel de novo c.535C>T in exon 6 leading to 
p.R179C aminoacid substitution in ACTA2 in a toddler girl with primary pulmo-
nary hypertension, persistent ductus arteriosus, extensive cerebral white matter 
lesions, fixed dilated pupils, intestinal malrotation, and hypotonic bladder. Recently, 
de novo ACTA2 R179H substitutions have been associated with a similar phenotype 
and additional cerebral developmental defects including underdeveloped corpus 
callosum and vermis hypoplasia in a single patient. The patient here shows previ-
ously undescribed abnormal lobulation of the frontal lobes and position of the gyrus 
cinguli and rostral dysplasis of the corpus callosum; she died at the age of 3 years 
during surgery due to vascular fragility and rupture of the ductus arteriosus. Alto-
gether these observations support a role of ACTA2 in brain development, especially 
related to the arginine at position 179. Although all previously reported patients with 
R179H substitution successfully underwent the same surgery at younger ages, the 
severe outcome of our patient warns against the devastating effects of the R179C 
substitution on vasculature.
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INTRODUCTION 
ACTA2 is a major component of actin filaments of the contraction units of vascular smooth 
muscle cells (SMC), which is also expressed in other organs including brain with highest 
levels of expression in late pregnancy and neonatal period. Actin filaments are organised 
in polymerized fibers across the cell, they interact with myosin and mediate anchoring 
of the cytoskeleton to the plasma membrane, all processes necessary for cell motility and 
maintenance of cell shape1. Autosomal dominant mutations in the ACTA2 gene were first 
described in adult thoracic aortic aneurysms and dissection (TAAD) patients. Additional 
features are livedo reticularis, iris flocculi, patent ductus arteriosus (DA) and bicuspid 
aortic valves, early onset coronary artery disease, ischemic stroke, cerebral aneurysms and 
Moyamoya disease2-4.
Recently, the de novo heterozygous R179H substitution in ACTA2 was associated with 
a severe phenotype in childhood, including ascending aorta aneurysms, patent ductus 
arteriosus, and disruption of SMC-dependent organs leading to congenital mydriasis, 
hypotonic bladder and congenital intestinal malrotation, as well as dilated pulmonary 
arteries, cystic lung disease and pulmonary hypertension5,6. Gastrointestinal prune belly 
was present in one patient6. Also tortuosity and dilatation of retinal arterioles in childhood 
are reported23. Childhood-onset cerebrovascular disease including fusiform dilatation of 
the internal carotid artery (ICA) and tapering of the terminal ICA, indicative of stenosis 
(Moyamoya-like) are described5,7.  Brain MRI findings are (progressive) periventricular leu-
comalacia and incidentally a thin corpus callosum, colpocephaly, small cerebellar vermis 
or Chiari I malformation5,7. 
We report on a patient with a novel de novo ACTA2 missense leading to substitution of 
arginine with cysteine at position 179 (R179C), presenting with pulmonary hypertension, 
patent DA, mydriasis, intestinal malrotation, bladder dysfunction and cerebral develop-
mental anomalies of the corpus callosum and cortical gyri.
PATIENT DESCRIPTION
The girl was born at 36+3 weeks gestation from Caucasian, non-consanguineous parents. 
Pregnancy was complicated by recurrent vaginal blood loss in the first trimester. Labour 
was induced prematurely because of maternal pre-eclampsia. Antenatal ultrasound at 20 
weeks gestation was normal. At 32 weeks gestation an enlarged bladder, a right sided hydro-
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Figure 1. Prenatal ultrasound images (at 32 weeks gestation) showing an enlarged bladder, 6.13 
cm in diameter (a), a umbilical vein varix, 1.25 cm in diameter (b) and a thickened placenta, 6.00 
cmin diameter (c).
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nephrosis, an umbilical vein varix and placental thickening were noted (Figure 1a,b,c). Birth 
weight was 2925 grams (+1 SD), OFC was 33 cm (0SD) and Apgar scores were 9 and 9 after 1 
and 5 minutes. Postpartum she became oxygen dependent for three days with spontaneous 
recovery. In contrast to prenatal findings, abdominal ultrasound was normal. Cerebral 
ultrasound showed prominent striate vessels and a small choroid plexus cyst. TORCHES 
screen was negative. Ophthalmological examination showed wide, non-responsive pupils 
with partial aniridia, iris/ lens adhesions and hypermetropia. At the age of 10 months, she 
was admitted with a RS-bronchiolitis. At 16 months she was readmitted with an airway 
infection and quickly developed respiratory insufficiency with ventilation difficulties due to 
extreme bronchospasm. Pulmonary hypertension was seen, requiring temporary mechani-
cal ventilation. Thoracic CT-scans showed pulmonary emphysema. A pulmonary perfusion 
scan at the age of 1.5 years showed a diminished perfusion. Echocardiography showed a 
patent DA. Cardiac catheterisation at this stage revealed an increased pulmonary vascular 
resistance (PVR) with bidirectional ductal shunt; PVR was reactive to inhaled oxygen and 
NO with abolishment of the right-to-left shunt across the DA. Before deciding to close the 
patent DA, treatment was started with continuous oxygen and Bosentan. 
She had feeding difficulties necessitating intermittent gastric tube feeding and an intestinal 
malrotation was suspected.
Her motor, cognitive and speech development were normal. At age 2 years, height was at 
-1 SD, weight at -2 SD and head circumference at -1.8 SD. Facial features included a high 
forehead, full eyelids with downslanting palpebral fissures, epicanthic folds, a full nasal tip 
and she had a soft, doughy skin. Neurologic examination was normal. Brain MRI at the age 
of 2 years revealed an abnormal corpus callosum with a small genu, absent rostrum and 
lamina terminalis but a normal anterior commissure. The gyrus cinguli was abnormally 
positioned, the rostral dorsal cingulum looked absent. The medial cerebral hemispheric 
sulcation was very abnormal resulting in symmetrically distorted architecture of the 
frontal lobes (Figure 2a,b,c). Vasculature was also abnormal, with straight arteries radi-
ating from the A2 segment of the anterior cerebral arteries and M2, M3 and M4 segments 
of the medial cerebral arteries (Figure 2b). No Moyamoya-like occlusive lesions were seen. 
Additionally, extensive confluent periventricular white matter lesions (leukoencephalopa-
thy) were present (Figure 2c). A repeat funduscopy at the age of two years revealed retinal 
arterial tortuosity, raising the suspicion of a vascular connective tissue disorder (Figure 3). 
During the diagnostic work up of our patient the paper from Milevicz et al was published5, 
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which triggered us to test ACTA2. At the age of 3 years, shortly after identifying the ACTA2 
mutation, the pulmonary situation appeared stable, leading to the assumption that is was 
safe to close the patent DA. However, during surgery the DA appeared to be too wide to clip 
or ligate and lead, together with unexpected extremely fragile vasculature, to rupture and 
massive bleeding, resulting in patient’s demise.
MOLECULAR STUDIES 
Sequencing analysis of PAX6 and COL4A1, FISH analysis of the PAX6/WT1 locus, and 
genomic Affymetrix 250k SNP microarray CNV analysis were normal. Sequencing of the 
coding exons and exon/intron boundaries of ACTA2 (NM_001613.1) identified the het-
Figure 2. T2-weighed (a,b) and FLAIR (c) patient images showing a small genu, absent rostrum, 
and lamina terminalis (b) and abnormal ‘‘steep’’ course (a,c) of the corpus callosum. An abnor-
mal fornix and aberrant orientation of the cingulum gyrus, due to absence of the rostral dorsal 
part can be noted (b). An abnormal, straightened course of the frontal branches of the ante-
rior cerebral artery, including the pericallosal arteries (b) is seen. On FLAIR image, extensive 
confluent hyperintensities of the periventricular white matter, which can be interpreted as con-
fluent leukoencephalopathy, can be appreciated (c). Also, bilateral underdevelopment of the 
hippocampal region is present (c). T2-weighed axial and sagittal (d,e) and coronal FLAIR (f) 
image of age-matched control.
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erozygous sequence variant c.535C>T in exon 6, substituting an arginine with a cysteine 
(p.R179C). The sequence variant was absent in WBC DNA from both parents, suggesting 
a de novo event. The mutation affects the same codon as the previously reported p.R179H 
substitution5.  
DISCUSSION
We identified a previously unreported de novo ACTA2 substitution changing the arginine 
at position 179 (R179C). Since the phenotype in our patient is similar to that of R179H sub-
stitutions, a genotype-phenotype correlation involving Arginine 179 changes is supported. 
Arginine 179 is located at the macromolecular surface of the alpha-actin near a key pro-
tein-protein interaction site5.  Substitutions at this amino acid causes a severe systemic 
disorder in early childhood, different from the adult presentation. One of the characteristic 
features of this disorder is the extensive cerebral white matter lesion5,7. A distinctive vascu-
lar phenotype has been associated with Arg179 substitution in a large scale study [Munot 
et al., 2012]. 
Based on the cerebral white matter abnormalities and the extensive vascular phenotype a 
connective tissue disorder was considered in our patient. Disorders like Arterial Tortuosity 
Figure 3. An image of the retina shows 
tortuosity of the retinal vessels.
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Syndrome (OMIM 208050) and Loeys-Dietz syndrome (OMIM 609192) have overlapping 
features such as arterial tortuosity, pulmonary artery dysfunction with stenosis or aneu-
rysm formation8,9. 
The cerebral vasculopathy and white matter lesions of the Arginine 179 substitutions, 
although distinctive, resemble to a certain extent those of COL4A1, COL4A2 and are possi-
bly based on silent microbleeds.  In COL4A1 and COL4A2 mutations, cerebral aneurysms, 
cerebral hemorrhage, porencephaly and leukoencephalopathy are described10-13, as well as 
retinal arterial tortuosity12. 
One of the major proteins responsible for the cross-linking of actin filaments in F-actin net-
works and to cellular membranes, by binding to transmembrane receptor or ion channels, 
is filamin A. The F-actin/ filamin A complex hereby regulates cell morphology, membrane 
integrity and cell locomotion14,15. Phenotypic features in FLNA and ACTA2 mutations show 
similarities, such as patent DA, vascular anomalies such as (cerebral) aneurysms and stroke, 
aortic stenosis and coarctation16. Also severe congenital cystic lung disease with pulmonary 
arterial hypertension17,18 and intestinal pseudo-obstruction, resembling SMC-related mal-
rotation or hypoperistalsis19 were reported in FLNA patients. 
The brain MRI in our patient shows, besides severe leukoencephalopathy, a develop-
mental defect of the frontal lobes and rostral part of the corpus callosum. A thin corpus 
callosum, colpocephaly, small cerebellar vermis and Chiari I malformation were previ-
ously reported in sporadic ACTA2 patients5,7. Although a distinctive straight and steely 
appearance of intracerebral arteries has previously been reported, the associated rostral 
and gyral malformation have not been appreciated [Munot et al., 2012]. Since the callosal 
and gyral abnormalities follow the straight pattern of the anterior cerebral artery (most 
evident in Figure 2b), we suggest that both vascular and structural abnormalities in this 
region share a common pathogenesis and might be more common than previously reported 
in Arg179 substitutions, This MRI presentation can be a diagnostic clue in children with 
isolated pulmonary hypertension or other non-specific symptomatology, lacking neuro-
logical symptoms. This observation underscores the role of ACTA2 in brain development20 
and broadens the cerebral phenotype related to ACTA2 mutations. It is possible that the 
Arginine 179 resides in an actin-2 domain primary involved in protein interactions during 
brain development21. The role of other actins in brain development is demonstrated by the 
identification of  de novo mutations in ACTB and ACTG1 in Baraitser Winter syndrome 
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(OMIM 243310), associated with anterior-predominant brain developmental defects (liss-
encephaly)22.
At the age of 3 years our patient died during surgical intervention of the patent DA due 
to extreme vascular fragility and rupture. The previously reported cases with the ACTA2 
R179H substitution all successfully underwent this operation, on ages varying from 20 days 
to 4 months. Later on, three patients underwent surgery for thoracic aorta aneurysms, at 
reported ages of 10-12 years5-7. In striking contrast to our experience, no complications of 
surgery were reported. It is possible that the vasculature becomes more damaged due to 
the disease process, and that surgical intervention for patent DA should be performed as 
early as possible. However, surgeons should be cautious of possible severe complications of 
vascular interventions of ACTA2 patients at young age.
In conclusion, we describe a patient with a novel heterozygous p.R179C substitution in 
ACTA2. The severe phenotype including brain developmental defects and the severely 
affected vasculature, suggests an additional function of this specific amino acid and/or 
protein domain. Furthermore, our experience recommends caution regarding surgical 
intervention, since there is an increased risk of bleeding and vascular rupture. 
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NEUROLOGICAL FINDINGS IN INCONTINENTIA 
PIGMENTI; A REVIEW
ABSTR ACT
Incontinentia Pigmenti is a rare X-linked multisystem disorder with well described 
and pathognomonic skin manifestations. Neurological manifestations are found in 
30% of IP patients, forming one of the major causes of morbidity and mortality of the 
condition. In this review, clinical and brain imaging data of 45 IP patients with a neu-
rological phenotype are reviewed. Several clinical presentations could be identified, 
comprising seizures, infantile encephalopathy, acute disseminated encephalomyeli-
tis and ischaemic stroke. Most neurological features presented during the neonatal 
period. No patients presented during adolescence or at adult age. Seizures of differ-
ent type are reported in about 20% of the patients at young age and seem to correlate 
with the degree of cerebrovascular damage. Brain MRI findings include periventric-
ular and subcortical white matter disease, haemorrhagic changes, corpus callosum 
hypoplasia, cerebral atrophy and cerebellar hypoplasia. Ocular findings comprise a 
range of retinal vascular changes and optic atrophy, but also developmental defects 
like microphthalmia and cataract. Most findings may reflect changes following brain 
injury. Both (ischaemic) vascular and inflammatory components may play a role in 
the cerebral and ocular phenotype. However, a role of disturbed apoptosis during 
development may also be a contributing factor.
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INTRODUCTION 
Incontinentia Pigmenti (IP) (also known as Bloch-Sulzberger syndrome, OMIM 308300) 
is an uncommon X-linked multisystem disorder, affecting the skin in all patients, but 
also other ectodermal tissues comprising teeth, hair and nails, the eyes and the central 
nervous system. The inheritance pattern is X-linked dominant, with usually male lethality. 
Some affected males, however, have been reported; some have a concomitant diagnosis of 
Klinefelter syndrome, in others somatic mosaicism is demonstrated1,2. The dermatological 
features are well defined, occurring in four successive stages, comprising of erythema and 
vesicles in a linear distribution in the first stage, verrucous, hyperkeratotic papules and 
plaques in the second stage, linear hyperpigmentation (not necessarily in the areas affected 
in the first two stages) in stage 3 and pallor and atrophy in the last stage. In 1993, Landy and 
Donnai defined criteria for IP. Although not truly validated, these criteria still seem very 
useful in establishing a clinical diagnosis of IP3-5 (Table 1). In 2000, the molecular defect 
underlying IP was identified; mutations in the NEMO gene on chromosome Xq28 (officially 
IKBKG (inhibitor of ĸB kinase gamma), also known as IKKγ) were shown to cause IP6. It 
was demonstrated that, with rare exceptions, mutations causing IP severely truncate the 
NEMO protein, leading to a loss of function6. In approximately 70% of IP patients, NEMO 
mutations can be identified7. In 60-88% of IP patients harboring a mutation, a common 
deletion of exon 4-10 is found6,7. Male lethality is assumed, however, some affected males 
have been reported; some have a concomitant diagnosis of Klinefelter syndrome, in others 
somatic mosaicism is demonstrated1,2. However, hypomorphic NEMO mutations in males 
lead to a different phenotype of X-linked hypohydrotic ectodermal dysplasia and immuno-
deficiency (OMIM 300291).
Although not admitted in the clinical criteria of Landy and Donnai, the central nervous 
system manifestations in IP patients may have a great impact on the quality of life. Overall, 
the prevalence of central nervous system manifestations is approximately 30%4,8. Ophthal-
mological abnormalities are another major cause of disability in IP patients. Ocular defects, 
comprising strabismus, retinopathy, congenital cataract and microphthalmia, are present 
in approximately 20%-37% of IP patients, with severe presentation in 8%4,9. A relation is 
postulated between the severity of the ophthalmological findings and the neurological phe-
notype9.  In this review, we want to give an overview of the various central nervous system 
presentations associated with IP and reflect on possible pathogenic mechanisms.
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MATERIALS AND METHODS; SEARCH STR ATEGY 
AND SELECTION CRITERIA
Literature references were identified through a search on Pubmed with the terms “Incon-
tinentia pigmenti and seizures”, Incontinentia pigmenti and epilepsy”, “incontinentia 
pigmenti and neurological”, “Incontinentia pigmenti and MRI”. Reference lists of relevant 
articles were also reviewed. Cases were selected when the diagnosis IP was documented by 
skin biopsy or DNA-analysis of the NEMO-gene, or when the clinical findings were doc-
umented well enough to establish a clinical diagnosis, and when the neurological disease 
was documented by brain imaging (CT/ MRI). Only articles in the English language were 
Table 1. Diagnostic criteria for Incontinentia Pigmenti (IP) (Landy and Donnai)
No incidence of I in at least 1 first degree 
Female Relative
Evidence of IP in a first degree female rel-
ative
Major criteria
Typical neonatal rash Suggestive history or evidence of typical 
rash
 Erythema, vesicles, eosinophilia Skin manifestations of IP
Typical truncal hyperpigmentation  Hyperpigmentation
 Mainly on trunk  Scarring
 Following Blaschko’s lines  Hairless streaks
 Fading in adolescence  Alopecia at vortex
Linear, atrophic, hairless lesions Anomalous dentition
Woolly hair
Retinal disease
Multiple male miscarriages
Minor criteria (supportive evidence)
Dental involvement
Alopecia
Woolly hair/abnormal nails
Retinal disease
At least one major criterion is necessary to make a firm diagnosis of sporadic incontinen-
tia pigmenti. The minor criteria, if present, will support the diagnosis but because of their 
high incidence complete absence should induce a degree of uncertainty
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selected.  Using these criteria, we selected 29 reports, describing 44 IP patients with neuro-
logical features. Of these patients, 43 are female, one is male. 
R ESULTS
Neurological findings associated with IP are variable, ranging from a single seizure 
episode to psychomotor delay, intellectual disability, hemiplegia, epilepsy, cerebellar ataxia, 
microcephaly, neonatal encephalopathy, childhood encephalomyelitis and neonatal and 
childhood ischaemic stroke. There are only a few studies reporting the neurological phe-
notype in groups of IP patients. In 1976, Carney reviewed 653 patients with at that time a 
clinical diagnosis of IP. In 142/465 cases with sufficient information on neurological status, 
CNS involvement was present (30.5%)8. Landy and Donnai (1993) questioned this number, 
suggesting that it may be too high due to misdiagnosis of e.g. hypomelanosis of Ito. From 
their experience in their series of over 100 subjects, the overall incidence of intellectual or 
physical disability is less than 10%, with a higher incidence of intellectual disability in the 
sporadic cases (15%) compared to the familial cases (3%)5.  Hadj-Rabia performed a clin-
ical study in 40 IP patients fitting the Landy and Donnai criteria. In 13 of the 40 (32.5%) 
patients CNS involvement was noted4. Seizures were present in 10 of the 13 patients with 
neurological deficits; 2 patients eventually died due to vascular cerebral damage. Chronic 
sequelae of IP are incompletely reported. Delayed psychomotor retardation was present 
in 7 of the 13 patients, intellectual disability in 3 and spastic hemiplegia in 24. Phan et al 
Table 2. Incidence of neurological manifestations
Carney Landy and 
Donnai
Hadj-Rabia et al Phan et al
Spastic paraly-
sis/ hemiplegia
53/465 (11.4%) ND 3/40 (7.5%) 5/47 (11.6%)
(Psycho)motor delay 35/465 (7.5%) <10% 7/40 (17.5%) ND
Mental retardation 57/ 465 (12.3%) 3% (familial cases) 3/40 (7.5%) 4/48 (8.3%)
15%(sporadic cases)
Microcephaly 22/465 (4.7%) ND ND ND
Seizure disorder 62/465 (13.3%) ND 10/40 (25%) 11/47 (23.4%)
Cerebellar ataxia 2/465 (0.4%) ND ND 1/47 (2%)
Overall incidence of 
neurological features
142/465 (30.5%) ND 13/40 (32.5%) ND
ND = Not documented
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reported a retrospective case series in which they describe 25 probands and an additional 
28 female family members fulfilling the Landy and Donnai criteria of IP. Of the patients 
with sufficient data on neurological status, 23% had a history of at least one seizure, 8% had 
intellectual disability and 11% had significant physical disability such as spastic hemiplegia. 
The same patients with intellectual disability also showed ophthalmological abnormalities. 
Interestingly, none of the relatives with IP had a history of seizures, intellectual or physical 
disability, suggesting that there may be an underrecognition of IP in patients with a milder 
phenotype lacking neurological manifestations9 (Table 2).  Since data on outcome of IP 
patients in the case reports or case series that we identified in our Pubmed search are greatly 
lacking, we will mainly discuss data on initial neurological presentations in the following 
sections. Variable degrees of vascular insufficiency, documented on brain imaging, seem to 
underly the neurological presentations in IP patients. 
Initial CNS clinical manifestation
Many authors reports neurological symptoms of “pseudo-encephalitis”, with acute neuro-
logical manifestations, at times associated with a comatose state and apnoea, mimicking 
encephalitis. Evidence of brain necrosis and multiple infarcts was reported10-13.
Ischemic stokes seems therefore to underlie the neurological manifestation in the neonatal 
period. In 5 of the 7 cases in which ischaemic stroke was documented, the onset was in 
the first week of life14-17 (Table 3). One of these patients had recurrent strokes, at the age of 
5 days, 10 days and 3 months14. The other 2 cases experienced ischemic stroke at the age of 
respectively 2 months18 and 4,5 years19.  The infarcts affected the deep and subcortical white 
matter in 4 cases4,15,20. In 3 cases, ischaemic stroke affecting larger cerebral arteries (middle 
cerebral artery, anterior cerebral artery)17-19 and in one case also affecting the left cerebellar 
hemisphere17, were documented.  
Acute disseminated encephalomyelitis (ADEM), which represents an acute inflammatory 
and demyelinative disease involving brain and spinal cord, has also been reported in two 
IP patients, with an onset at the ages of 6 and 7 months and subsequent recovery21,22 (Table 
3). In one of the patients, serum and CSF were positive for M. Pneumoniae22. Both patients 
were unresponsive to all stimuli in the acute phase, except for deep pain. One of the patients 
presented with seizures. CSF myelin basic protein was elevated in both patients, indica-
tive for a CNS pathology characterized by demyelination. In one patient, nerve conduction 
Neurological Findings in Incontinentia Pigmenti; a review 63
defects were detected21. Brain MRI in one patient revealed scattered lesions, hyperintense 
on T2- and diffusion-weighed images, mainly in the subcortical and periventricular white 
matter. After treatment with high-dosage corticosteroids and antimicrobial therapy against 
M. Pneumoniae, the patient responded well. Brain MRI revealed an almost complete dis-
appearance of the initially abnormal signals. The patient did not have any neurological 
sequelae. In the other patient, CT-scan revealed areas of hypodensity in the central white 
matter and ventricular enlargement at the age of 4 years and symptoms were not responsive 
to ACTH-therapy, but spontaneously improved later. Retrospectively,  the child had experi-
enced a similar episode of lethargy, antedated by diarrhea and minor head trauma21 at the 
age of 6 months. Based on these reports, ADEM should be considered early in the differen-
tial diagnosis of IP patients with neurological symptoms such as seizures22.   
Seizures
Seizure disorder is reported in 13.3-25% of IP patients4,8,9. In reports of 44 IP patients with 
CNS involvement10-39, seizures were reported in 37, with information about age of onset in 
35. Onset of seizures varied from 12 hours postpartum to 10 years. However, in the majority 
of patients (23 patients), seizures presented in the first week postpartum, an additional 5 
presented in the first two months and another 4 in the first year. Two patients presented 
at ages 4 (after brain infarction), and 10 years. In this last patient a concomitant diagnosis 
of sarcoidosis was made at the age of 20 years, although no signs of neurosarcoidosis were 
found. Focal clonic seizures were most frequently reported, in 22 of the 29 cases in which 
description of the seizure type was present. Partial complex or generalized seizures were 
also reported.  In 3 children with early onset seizures (day 2-3), the diagnosis of hypsar-
rhythmia at EEG or the clinical diagnosis of West syndrome was made (Table 3). In 16 cases, 
information on the duration of the first seizure episode was documented, which varied 
from 12 hours to 2 weeks. In only 11 cases of the 25 cases  recurrence of seizures was reported. 
The remaining 14 cases only experienced one seizure episode. Treatment of seizures is most 
often initialized using phenobarbital as mono- or polytherapy. This is not surprising, con-
sidering that phenobarbital has long been the treatment of choice in infantile seizures and 
most patients experienced seizures in infancy40.  
In 25 of the 37 patients described with seizures, EEG registration results were documented. 
EEG patterns however, are not specific and could reflect multiple types of brain damage 
(Table 3).  
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Brain imaging data were present in 37 patients with seizures. In 36 patients, brain imaging 
showed abnormalities compatible with variable degrees of vascular insufficiency due to 
ischaemia or necrosis. In only 1 patient brain MRI was reported normal16. 
In general we can conclude that in most cases seizures are a manifestation of cerebrovascu-
lar damage, thus symptomatic, and are mostly present in childhood i.e. in the most severely 
affected patients. The seizure disorder can be self-limiting but in a few cases a severe epi-
lepsy (e.g. West syndrome) can occur.  
Ophthalmological finding
Ophthalmological findings are speculated to increase the chance of neurological abnor-
malities in IP patients. Also, the pathogenic mechanism leading to ophthalmological 
abnormalities is also thought to be implicated in the neurological phenotype op IP. Therefore, 
we provide an overview of the documented findings (Table 3). In 29 cases, ophthalmological 
findings were documented10,11,13,15-17,20,21,23,24,26,33,36-38. Of these, 9 patients showed no ophthal-
mological abnormalities10,13,16,24,26,36-38. In 4 patients, retinal haemorrhage was noted16-18,21,27. In 
four patient, retinal vascular abnormalities without haemorrhage were seen, two of them 
showed arteriovenous anastomoses, one showed vessel dilatation11,16,18,20. In 6 patients, isch-
aemic retinal lesions were seen15-17,20, in 2 patients, (peripheral) avascularity of the retina 
was documented27,30.  Microphthalmia was a finding in 2 patients3,34. In 6 patients, retinal 
detachment was noted16,23,34. In two patients, irregularities of the retinal pigment epithelium 
were appreciated16,21. Optic atrophy was a finding in 3 patients16. Strabismus was documented 
in three patients11,15,23. Signs of conjunctivitis were found in 2 patients29,33. Finally, cataract 
was described in 1 patient34. Most patients with ophthalmological manifestations also have 
brain abnormalities at MRI (Table 3). However, abnormalities at brain MRI were regularly 
seen also in patients without reported ophthalmological abnormalities16. There is only one 
patient reported with a normal brain MRI , who showed a small chorioretinal scar on oph-
thalmological examination16. Most of the reported ophthalmological manifestations reflect 
vascular dysfunction. Since a reasonable proportion of patients have both opthalmological 
as well as central nervous system lesions, it is likely that a similar pathological mechanism 
is involved.    
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Brain imaging 
Literature findings about brain imaging are summarized in Table 3.  We will briefly discuss 
the major abnormalities. 
White matter and corpus callosum abnormalities and cerebral atrophy.
The white matter seems to be especially vulnerable in patients with IP. In 27 of the 43 
patients of which brain MRI data were documented, abnormalities of the white matter 
could be identified10-16,20,22-25,28,32-34,36,37,39.  Periventricular white matter changes, consistent 
with periventricular leukomalacia, were most often present, but subcortical white matter 
changes were also frequent findings. In one patients, a white matter abnormality, com-
prising of a small lesion in the semioval center,  was present without any neurological 
abnormalities39. In some patients, the white matter changes eventually led to cyst or cavity 
formation in the white matter, suggesting tissue destruction, possibly due to microbleeds 
or microinfarctions10,13,32,33,39. Prominent Virchow Robin spaces were seen in one patient36, 
a finding suggestive of small-vessel disease41. A delay in myelination was present in two 
patients13,16. Ventricular dilatation was seen unilaterally in 5 patients10,16,23and bilaterally in 
6 patients10,16,21,23,33,34 .  Cerebral atrophy was documented in 6 patients10,16,30,33,35, in 4 of them 
located unilaterally. Both ventricular dilatation and cerebral atrophy can result from gen-
eralized tissue loss following a vascular event.
In patients with seizures, on brain imaging, findings compatible with vascular insufficiency, 
including periventricular leukomalacia, patchy gliotic white matter changes, white matter 
cavitations, basal ganglia damage, diffuse haemorrhagic necrosis with tissue destruction 
were seen10-13,20,21,23,25,28,30,32-34,36-38. Also infarction  affecting both small vessels affected the 
deep and subcortical white matter14,15,20 as well as larger cerebral arteries (middle cerebral 
artery, anterior cerebral artery)17-19 and in one case also the left cerebellar hemisphere17, were 
documented. One of these patients had recurrent strokes, at the age of 5 days, 10 days and 
3 months14. 
Hypoplasia of the corpus callosum was a finding in 8 patients10,16,20,23,24,34. In addition, all 
these patients exhibited hemisphere white matter abnormalities and in 5 patients uni- or 
bilateral ventricular enlargement, with reduced volume of the cerebral white matter was 
seen. Therefore, it is likely that the corpus callosum hypoplasia is secondary to white matter 
loss, rather than a primary developmental defect . However,, corpus callosum agenesis was 
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reported in 1 patient26. This patient had, besides the corpus callosum agenesis, a second 
unusual presentation with a midline posterior skull defect and a protruding encephalocele. 
Cutaneous findings, including a histological examination of a skin biopsy were consistent 
with the diagnosis of IP.  Since it is only described once, it remains to be elucidated whether 
the encephalocele and corpus callosum agenesis, both developmental defects, are part of 
the IP phenotype or unrelated concomitant findings in this patient.
Cerebral haemorrhage 
In 8 patients, a haemorrhagic component was seen on brain imaging. In most of these 
patients however, haemorrhagic necrosis was present, most likely secondary to an isch-
aemic event. Encephalomalacia with bilateral haemorrhagic necrosis and widespread tissue 
destruction was noted in 5 patients12,13,16,25,28. Another patient presented 3 days postpartum 
with bilateral encephalomalacia, but in addition a moderate subarachnoidal haemorrhage 
was seen29.  Also, more subtle microvascular haemorrhagic infarcts of the periventricular 
white matter are described11. One patient presented during the first day with a right sided 
grade I intraventricular haemorrhage with a germinolytic cyst30. The pregnancy of this last 
patient, however, was complicated by maternal drug and alcohol abuse. Germinal matrix 
cysts and haemorrhage are also described in association with maternal cocaine abuse 
during pregnancy, making it difficult to correlate these findings in the patient with IP42,43.
A supraclinoid right internal carotid artery aneurysm was demonstrated in a 56-year-old 
woman with classical dermatological features consistent of IP without neurological symp-
toms16. It is unclear whether carotid aneurysms are part of the phenotypic spectrum of IP 
cerebrovascular lesions , or whether this is an occasional finding in this patient. 
Cerebellar abnormalities 
Only one of the reported patients had cerebellar hemispheres and vermis atrophy, which 
was already seen on brain MRI at the age of 6 weeks17. Additional findings on neonatal brain 
ultrasound in the same patient were striatal arteriopathy, suggesting inflammation, and 
on MRI gliosis of the white matter of the centrum semi-ovale and a thin corpus callosum. 
Cerebellar underdevelopment might be therefore secondary to intrauterine cerebrovascular 
damage4,45.
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Cortical malformation
In one of the patients, brain MRI in the first week of life showed polymicrogyria in the 
perisylvian area with cortical dysplasia7. Cranial ultrasound on day 5 in this patient already 
demonstrated bilateral multiple echogenic foci in temporal and thalamic areas. Polymi-
crogyria was alo described in neuropathology data by O’Doherty et al (see section 3.5)46. 
Known etiologies involved in the development of polymicrogyria, a brain developmental 
disorder that arises from the second trimester of pregnancy, are, beside genetic, acquired 
brain injury due to abnormal perfusion and/ or oxygenation of the fetal brain, and infec-
tion during fetal life47. Both polymicrogyria and cerebellar hypoplasia implicate that the 
cerebral pathology in IP can develop even antenatally. 
Neuronal heterotopias of the left parietal lobe were documented, although not very clear in 
the presented data, in one male patient on brain MRI at the age of 3 and 5 years, which was 
performed because of seizures at the age of 3 and 5 years34.  Although the diagnosis in this 
patient was based on clinical criteria, such as suggestive skin lesions and unilateral cataract 
with microphthalmia, no DNA analysis was performed and the report remains until now 
isolated.
Neuropathology findings
Only a few authors report on neuropathological findings in IP. O’Doherty and Norman 
report on the postmortem pathology in a 7 weeks-old infant with IP. Structural abnormal-
ities such as polymicrogyria of the left hemisphere were seen. Calcification of nerve fibers, 
Purkinje cells and microglia cells were present.  In addition, focal areas of cerebral and 
cerebellar necrosis and neuronal loss were seen, indicative of vascular insufficiency. No 
pathological changes were seen in blood vessels46. In 1977, Hauw et al reported neuropatho-
logical findings in a 3 month-old infant with IP confirmed in a skin biopsy 48. They found 
signs of a destructive process secondary to vascular insufficiency, comprising of ulegyria, 
white matter cavities and patchy scar softening of the cerebellar cortex with loss of Purkinje 
fibers and granule cells. Interestingly, signs of a diffuse inflammatory process involving 
pia and brain parenchyma were found, with perivascular cuffs of lymfocytes, histiocytes 
and eosinophilic polymorphs, and mononuclear nodules, indicating that inflammation, in 
addition to ischemia, may contribute to the vascular insuficiency. Hence, the interpretation 
of the MRI findings confirms this hypothesis.  
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Genetics and pathophysiology
In 11 of the 44 patients with neurological involvement, sequence analysis of the NEMO 
gene was performed. In 10/11 patients, the common deletion of exon 4-10 was identified 
14,17,22,24,27,28,32,35,37,38. One patient did not harbor a mutation17. In one additional patient, DNA 
analysis in the (asymptomatic) mother was performed, without identifying a mutation15. 
The NEMO (IKK-γ, NFĸB essential modulator) protein is an important regulator of the 
NF-ĸB signaling pathway. The NF-ĸB transcription factor family is important in many 
signal transduction pathways, regulating genes involved in critical developmental processes, 
innate and adaptive immune responses, cell adhesion and protection against apoptosis. 
In most resting cell types, NF-ĸB is kept inactive in the cytoplasm through interaction 
with inhibitory IĸB-molecules. Phosphorylation of these inhibitory molecules leads to IĸB 
ubiquitination and degradation by the proteasome pathway, leading to a release of active 
NF-ĸB. NEMO is an important regulatory subunit of the IĸB kinase (IKK) complex, that 
can phosphorylate IĸB49. This IĸB phosphorylation, and subsequent activation of NF-ĸB 
can be initiated in response to multiple stimuli, including tumor necrosis factor α (TNFα), 
bacterial lipopolysaccharide (LPS) and genotoxic agents. Active NF-ĸB  can translocate to 
the nucleus and activate transcription of its target genes6,49-52. Absence of NEMO leads to 
a complete inhibition of NF-ĸB signaling, reflecting its major role in the activation of the 
IKK-complex6. Recently, an additional role has been ascribed to NEMO as the principle 
molecule signaling the presence of double strand DNA breaks (DSB)  in the nucleus to the 
NF-ĸB complex in the cytoplasm, leading to transport of NFĸB to the nucleus to stimulate 
transcription of anti-apoptotic genes53,54,
Functional NF-ĸB complexes are present in essentially all cell types. In the nervous system, 
it is present in neurons, astrocytes, microglia and oligodendrocytes. In the nervous system, 
besides TNFα, additional neuron-specific NF-ĸB-activating signals exist, including nerve 
growth factor (NGF), and the secreted form of β-amyloid precursor protein (βAPP), sAPPα. 
Also electrical activity within neurons and synaptic transmission between neurons possi-
bly lead to a relatively high constitutive activity of NF-ĸB in brain tissue55. An important 
role of NF-ĸB is postulated in the control of neuronal death during development of the 
nervous system and in the modulation of synaptic function following glutamate receptor 
stimulation55. Bradykinin, an inflammatory mediator produced in the brain in response to 
ischemia and trauma, is also a potent stimulator or NF-ĸB-activation, inducing the produc-
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tion of several inflammation-related cytokines by microglia. This is counterbalanced by the 
production of anti-inflammatory cytokines, including TGF-β and IL-10. 
In general, injury to the brain induces a cascade of signaling events that stimulate 
NF-ĸB-activation in injured neurons and injury-responsive glial cells.  After ischemic brain 
injury, NF-ĸB activation promotes ischemic neuronal degeneration in glial cells, but has a 
neuroprotective function in neurons, leading to an increased survival of neurons55. After 
(kainite-induced) seizures, an increase of NF-ĸB activity protects neurons from excitotox-
icity, by reducing neuronal sensitivity to glutamate55. 
In summary, NEMO plays an important role in the activation of NF-ĸB. In the nervous 
system, active NF-ĸB is important in processes like immune responses and protection 
against neuronal damage and apoptosis caused by brain injury, hypoxia and excitotoxicity 
induces by seizures. Therefore, it is likely that dysfunction of these processes in IP patients 
contribute to the neurological phenotype and seizure disorder in IP patients. Studies inves-
tigating NF-ĸB activation and its role in the cerebral phenotype in IP-patients are lacking. 
Even in mouse models, neuropathology data are not present. In female NEMO+/- mice 
findings suggestive of neurological dysfunction were reported by day 8, comprising of 
spasm, tremors and locomotor difficulties56. Many female mice die within the first 6-10 
days. Some of the female NEMO+/- mice also contained high numbers of apoptotic cells56, 
confirming the hypothesis that cells lacking NEMO-protein are more prone to apoptosis. 
Since apoptosis is a major mechanism during brain development, this may also lead to 
cerebral damage before birth. 
 This has also been demonstrated in skin lesions in IP. Due to lyonisation, a mosaic pattern 
of NEMO-deficient and wild-type cells are present in IP-patients. It has  been postulated 
that the skin phenotype originates when NEMO-deficient cells start to produce pro-inflam-
matory interleukins, mostly IL-2. As a response, the wild-type cells start an inflammatory 
reaction, producing TNF, a known stimulus of IĸB phosphorylation leading to NF-ĸB sig-
naling and the transcription of anti-apoptotic genes. The NEMO-deficient cells, however, 
undergo apoptosis. This leads to a transient inflammatory reaction of the wild-type cells, 
leading to an eradication of the NEMO-deficient cells. If a few NEMO-deficient cells 
survive, in time, a second episode of inflammation can be expected3,57. 
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Besides data on skin histopathology,  the ocular histopathology in heterozygous NEMO-de-
ficient mice was recently described. These data are interesting, since, although studies 
confirming this are lacking, similar processes may play a role in the cerebral vasculature in 
IP patients. Although the ocular phenotype in mice seems to be somewhat milder than in 
humans, without complete vaso-occlusion or neovascularisation, the findings are similar 
to findings in human IP patients. By 3 months of age, arteriolar tortuosity and irregular 
configurations were seen, associated with cellular changes such as thickened and irregular 
walls with highly irregular lumens. This thickening appeared to be caused by a redundancy 
of hypertrophic vascular endothelial cells and reduplication of their basement membrane. 
This eventually led to impingement of the vascular lumen, in some cases cross sections of 
arterioles revealed only the remaining of a slit-like lumen. The retinal venules appeared 
normal58.
Management
No specific treatment is available for neurological symptoms of IP. Treatment of sei-
zures is symptomatic. Anecdotal treatment with antiplatelet medication in one patient 
did not protect from recurrent stroke13. Administration of corticosteroids instead led to 
improvement in one patient with acute disseminated encephalomyelitis30.  Spontaneous 
improvement has been documented in patients with seizures and the two ADEM patients.   
DISCUSSION
Since the NF-ĸB signaling pathway, and therefore the NEMO gene, is of great importance 
in preventing neurons from undergoing apoptosis following (ischaemic, inflammatory or 
excitotoxic) brain injury, NEMO-deficient cells probably are more prone to inflammation 
and apoptosis. The neurological and brain MRI features can reflect tissue damage due to 
small vessel disease, but also the larger cerebral arteries can be involved. Ischaemia due 
to vascular changes, as described in mouse retinal vasculature, may underly this damage. 
However, in some cases the lesions are more diffuse and do not seem to follow a certain vas-
cular pattern. An inflammatory component, as seen in skin lesions of IP patients, may also 
contribute to the cerebral damage. This was demonstrated in the neuropathology findings 
described by Hauw et al48, who demonstated signs of an inflammatory process of pia and 
brain parenchyma. Many of the described abnormalities, such as cerebral, cerebellar and 
corpus callosum atrophy, optic nerve hypoplasia and polymicrogyria may represent the 
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endstage of (ischaemic and/ or inflammatory) brain injury. However, in addition, develop-
mental defects comprising microcephaly, microphthalmia, cataract and heterotopia may 
also be the consequence of aberrant apoptosis in NEMO-deficient cells. Data supporting 
this in IP patients are lacking. Increased apoptosis, however, has previously been described 
as a mechanism underlying neuronal heterotopia and microcephaly59-61. Polymicrogyria, 
heterotopia, microphthalmia and microcephaly are indicative of a disease process that 
already started in the antenatal period.  
In conclusion, neurological findings are frequently reported in IP patients, in some cases 
leading to major morbidity and even mortality.  The symptoms mostly manifest in infancy, 
only rarely in late childhood and are not reported in adolescence or adulthood. Seizures 
usually correlate with the severity of the neurological sympoms and mostly occur in child-
hood. Inflammatory mechanisms, vascular injury and possibly a disturbed apoptosis 
during development apparently contribute to pathogenesis of cerebral manifestations. The 
cells with NEMO mutation are destroyed by an inflammatory mechanism, which might 
explain why the disease is self-limiting and symptoms occur between the fetal period 
and childhood. The prognosis and outcome is dependent on the damage to the brain and 
other organs in this period and is mostly favorable if no neurological problems occur 
until childhood. Magnetic resonance imaging is recommended in the clinical evaluation 
of infants with IP and neurological symptoms. Since the neurological manifestations are 
polymorphic and can occur at or soon after birth, while initial skin lesions can be mild, it 
is recommended to carefully search for dermatological signs of IP in any newborn with 
unexplained neurologic deterioration, stroke or seizures.  Further studies involving neuro-
pathology and the role of inflammation and apoptosis in the neurological phenotype in IP 
patients are needed to further elucidate the precise pathophysiological mechanism of the 
central nervous system manifestations in IP patients.
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THE EXPANDING PHENOTYPE OF COL4A1 
AND COL4A2 MUTATIONS; CLINICAL DATA 
ON 13 NEWLY IDENTIFIED FAMILIES AND 
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ABSTR ACT
Collagen IV alpha-1 protein (COL4A1) filaments form an triple helix together with 
collagen IV alpha-2 (COL4A2) and are constituents of the main mesh-type colla-
gen of the extracellular matrix in many tissues. Since 2005, COL4A1 mutations are 
known as an autosomal dominant cause of hereditary porencephaly. COL4A1 and 
COL4A2 mutations have been reported with a much broader spectrum of cere-
brovascular, renal, ophthalmological, cardiac and muscular abnormalities, which 
prompted the term “COL4A1 mutation related disorders”. Genetic counseling is 
challenging, due to the broad phenotypic variation and reduced penetrance.
In the Erasmus University Medical Center, diagnostic DNA analysis of both COL4A1 
and COL4A2 in 183 index patients has been performed between 2005 and 2013. In 
total, 21 COL4A1 and 3 COL4A2 mutations were identified, mostly in children 
with porencephaly or other patterns of parenchymal hemorrhagic involvement. The 
observations in 13 novel families harboring either COL4A1 or COL4A2 mutations 
prompted us to review the clinical spectrum. We observed several recognizable phe-
notypic patterns and propose a screening protocol at diagnosis. 
Our data show a relatively high rate of de novo mutations and underscore the impor-
tance of COL4A1 and COL4A2 mutations as causes of cerebrovascular disease, also 
in sporadic patients. Follow-up data on symptomatic and asymptomatic mutation 
carriers are still needed for prognosis and appropriate surveillance.
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INTRODUCTION
Already from the 1980s, investigators described recurrence of hemorrhagic stroke within 
families, manifesting as porencephalic cavities on CT-scan or MRI1-6. Before these observa-
tions, the presence of congenital porencephaly, a cyst which commuticates with the lateral 
ventricle and is (usually) seen following parenchymal hemorrhage, had often been con-
sidered the result of an external insult, e.g. postanoxic perinatal bleeding, without genetic 
substrate and, in the absence a coagulopathy, with low recurrence risk. Only in 2005, after 
observations in mouse models, COL4A1 mutations were discovered as a cause of poren-
cephaly, with an apparent autosomal dominant inheritance7-9. Over the years, it became 
clear that disorders of additional organs can result from mutations in this gene. The disor-
der related to COL4A1 mutations is now known as a systemic disease, including a broad 
spectrum of cerebrovascular lesions including porencephaly and transmantle lesions, 
causing hydranencephaly or schizencephaly; lesions of the kidneys, leading to nephrosis 
and hematuria; lesions of the eyes, causing cataract, microphthalmia and blindness; of the 
heart, causing arrhythmia and of the skeletal muscles, causing dystrophic changes, weak-
ness and myoglobinuria10-22. 
COL4A1 and COL4A2 encode procollagen IV alpha-1 and IV alpha-2 chains, respectively, 
which assemble to form a heterotrimeric helix with a constant 2:1 ratio [alpha1(IV)]2[al-
pha2(IV)]. This type IV collagen is a component of the non-fibrillary collagen, as main 
constituent of extracellular matrix of many tissues, among them vascular endothelia. Mice 
harbouring heterozygous mutations in Col4a1 or Col4a2 suffer from hemorrhage in the eye, 
brain, and skin, already occurring during gestation and sometimes leading to developmen-
tal defects of eye and brain. Therefore, similarities in phenotypes between COL4A1 and 
COL4A2 mutations were to be expected. In 2012, several parallel genetic, epidemiologic 
and functional studies revealed COL4A2 mutations in both familial and sporadic poren-
cephaly23-25. 
The disease resulting from both COL4A1 and COL4A2 mutations is extremely variable, 
with broad intra-and interfamilial variation and evidence for reduced penetrance. Sporadic 
individuals with severe presentation may harbor a de novo mutation. 
At the department of Clinical Genetics of the Erasmus University Medical Center in Rot-
terdam, sequence analysis of both COL4A1 and COL4A2 has been offered since 2005 in a 
diagnostic setting. In this review, the clinical and genetic data of newly identified mutations 
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in the past 8 years are summarized. Although many reports have been published on the 
mutation spectrum, no clear recent guidelines regarding genetic counselling and manage-
ment of affected patients exists. We here provide an up to date overview on the genotypic 
and phenotypic spectrum in order to improve clinical management and surveillance guide-
lines. 
PATIENTS AND METHODS
At the Clinical Genetics laboratory of the Erasmus University Medical Center in Rotterdam, 
183 index patients (and whenever available both parents), mostly with cerebral hemor-
rhage or porencephaly, were referred for testing of COL4A1 (NM_001845.4) and COL4A2 
(NM_001846.2). This was done by Sanger sequencing or by application of a next generation 
sequencing panel encompassing 87 genes for brain developmental disorders including genes 
for porencephaly and Aicardi-Goutières syndrome (capturing of exons and intron-exon 
boundaries by eArray Sure Select (Agilent) and sequencing on the MiSeq platform (paired-
end, 150bp, Illumina) followed by conformation of mutations with Sanger sequenencing). A 
total of 21 COL4A1 and 3 COL4A2 putative pathogenic genomic variants were identified 
between 2005 and June 2013. We previously reported on 2 of the COL4A2 and 9 of the 
COL4A1 mutations7,12,15,24,26. Of the remaining 13 novel mutation families, clinical data were 
collected using a questionnaire sent to the referring physicians according to IRB regula-
tions of our center. 
Furthermore, we reviewed the literature, focussing on the clinical phenotypes of COL4A1 
and COL4A2 mutations. For this, a PubMed search was performed, identifying 27 manu-
scripts with clinical and mutation data on COL4A17,8,10-22,26-37 and 3 manuscripts with data 
on COL4A2 mutations23-25. A total of 137 individuals with a COL4A1 mutation and 15 with 
a COL4A2 mutation have been reported. Several clinical phenotypes were identified and 
described in more detail. In addition, both neurologic and systemic features and brain MRI 
findings were available for review. 
R ESULTS
Mutation data on 13 newly identified families
In the literature, most reported COL4A1 and COL4A2 mutations are missense changes 
leading to a substitution of a glycine in the G-X-Y triple helix domain. In analogy to 
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other collagenopathies, these mutations are predicted to be pathogenic and are assumed 
to have a dominant-negative effect. In addition, splice site and frameshift mutations 
have been reported, indicating that haploinsufficiency of either COL4A1 or COL4A2 
is another pathogenic mechanism24,35 (Fig 1). COL4A1 and COL4A2 sequence vari-
ants in our cohort were considered pathogenic when de novo, when truncating or when 
previously described and proven to be pathogenic by de novo occurrence or func-
tional studies. Most missense changes that were either predicted (ALAMUT package, 
http://www.interactive-biosoftware.com) or proven to be pathogenic disrupted the Gly-X-Y 
repeat of the triple helix. 
In total, 21 COL4A1 mutations, 12 of them novel, and 3 COL4A2 mutations were identi-
fied. All the known COL4A1 and COL4A2 mutations, including those reported here, are 
depicted in Figure 1. The pedigrees of the newly identified families are shown in Figure 2.
Of the 13 cases associated with novel COL4A1 mutations, 5 were sporadic and shown to de 
novo (Fig 2; family D, E, H, I and K) and 7 were familial. Of the 7 familial mutations, the 
one in family B occurred de novo in patient I.1. Of the mutations in Fig 2, only the COL4A2 
mutation in family L was previously reported in a sporadic adult patient with intracere-
bral hemorrhage23. It introduces a glycine at the triple helix domain of the protein and was 
shown to be pathogenic using functional studies23. All but one of the COL4A1 mutations 
missense changes led to substitution of glycine in the triple helix domain of the protein 
(family A, B, C, G, H, I, K and M). The changes in families A, C, G and M have an official 
status of “variant of unknown clinical significance”, although they are likely pathogenic 
in view of their predicted effect on the protein. In addition, segregation with the pheno-
type has been observed in families A and C. In family E, a de novo missense mutation was 
present affecting the NC1-domain. In family D, a de novo splice site mutation was identified, 
family G harboured an inherited frameshift mutation. 
Identified clinical phenotypes in our cohort and in the literature 
A total number of 183 index patients were tested for COL4A1 and COL4A2 mutations. A 
diagnosis was possible in 24/183 (13%) of index patients (published and unpublished), of 
which 10/24 (42%) were de novo. The 12 novel COL4A1 families and 1 COL4A2 family com-
prise 21 individuals with a (suspected) pathogenic mutation. Of these, 5 (24%) developed 
symptoms antenatally, leading to a termination of pregnancy in 1, 8 (38%) presented with 
symptoms soon after birth, 3 (14%) developed symptoms at a later age and 3 (14%) are clin-
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ically asymptomatic until now. (Of 2 patients (family G), clinical data on onset are lacking. 
However, brain MRI has not been performed in these asymptomatic carriers till now and 
brain damage cannot be fully excluded. Seizures were the most common clinical symptom, 
present in 9 patients (43%). Also, a high percentage of motor dysfunction was present: hemi-
paresis in 6 (29%) and tetraparesis in 3 (14%). Developmental delay was present in 8 cases 
(38%). The clinical phenotypes and mutations of the newly identified families are summa-
rized in Table 1. A summary of the brain MRI findings, associated ophthalmological, renal, 
cardiac and muscular findings, as well as incidentally reported findings in both our patients 
and literature is provided in Table 2. We provide an overview of several observed pheno-
types in our cohort. The reported data on these phenotypes in literature are discussed later, 
together with additionally reported phenotypes. 
Prenatal and neonatal intracerebral hemorrhage and porencephaly
Porencephaly has been reported as a result of both COL4A1 and COL4A2 mutations, most 
often due to germinal matrix hemorrhage leading to deep venous infarction with subse-
quent tissue necrosis and porencephalic cavitation. The first reports suggested an onset 
around birth8, later reports also describe patients with an onset in late pregnancy12,21,26.
In our cohort, 12 patients from 10 families (A, B, D, E, G, H, I, J, K, M) presented with 
early intracerebral hemorrhage and porencephaly; in 5 patients (family A-II.1, D-II.1, E-II.1, 
G-II.1, H-II.1) this was already seen prenatally (in 2 of them, the COL4A1 mutation was also 
identified prenatally), 6 patients were diagnosed after birth (family B-I.1 and B-II.1,J-II.1, 
J-II.1, K-II.1, M-II.1) and showed hemi- or tetraplegia and/ or seizures. Although most 
patients with an antenatal diagnosis presented after 30 weeks of pregnancy, one patient 
(family D-II.1) presented at 25 weeks. 
Of interest, in patient A-II.1 the porencephalic cyst showed enlargement on MRI scanning 
of the brain in his first year of life. Patient D-II.1 developed severe hydrocephalus second-
ary to the hemorrhage. Recurrence of cerebral hemorrhage was documented in patient 
E-II.1. This patient presented with antenatal cerebral hemorrhage and porencephaly on 
antenatal brain MRI. She developed a severe hypoxic-ischemic encephalopathy, for which 
she received cooling therapy; she died soon after birth. Postmortem examination showed 
a novel parenchymal hemorrhage (Fig 3M,N).   Patient II.2 from family C had a congenital 
tetraplegia, however, data on brain imaging are lacking.
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Sporadic extensive bilateral porencephaly resembling hydranencephaly
Hydranencephaly is defined as the end result of massive hemispheric necrosis and extreme 
ventricular dilation, with most of the hemispheres replaced by a CSF-filled membranous 
sac, and relative preservation of the diencephalic and posterior cranial fossa brain struc-
tures, with a variable onset, even starting in the first trimester38. In our cohort, patient II.1 
from family H showed severe brain destruction with undetectable medial cerebral arteries, 
resembling hydranencephaly, at 33 gestation weeks (GW). The child was stillborn with 34 
weeks of gestational age.
Periventricular leukomalacia with intracranial calcification
Periventricular leukomalacia (PVL) is defined as post-hypoxic-ischemic leukoencephalop-
athy resulting from a pre-or perinatal hypoxic-ischemic insult39. PVL is characterized by 
focal periventricular necrosis and gliosis in the surrounding white matter40. Also, intra-
cranial calcifications are reported in this context14.  In our cohort, patients A-I.2 and C-II.1 
both show PVL without porencephaly (Fig 3B, E). Brain calcifications were not present. 
Additional features in patient A-I.2 were congenital cataracts. Patient C-II.1 also showed 
ophthalmological features comprising microcornea, congenital cataract and posterior 
embryotoxon. In both patients, this combination, together with the family history, sug-
gested the diagnosis.
Axenfeld Rieger anomaly with leukoencephalopathy
Axenfeld Rieger anomaly comprises a constellation of ocular findings affecting the anterior 
chamber, including the anterior chamber angle and aqueous drainage structures (iridogo-
niodysgenesis), iris hypoplasia, eccentric pupil, iris tears and iridocorneal tissue adhesions 
traversing the anterior chamber. A frequent association consists with a posterior embryo-
toxon and a high risk of glaucoma and secondary blindness. In our newly reported family C, 
the 3 individuals with the COL4A1 change (C-I.2, C-II.2, C-II.2) were affected with similar 
ophthalmological findings from the Axenfeld Rieger spectrum, cataract and microcornea. 
The neurological symptoms, however, varied greatly, from absence in patient C-I.2, to PVL 
and normal cognition in patient C-II.1, to severe mental retardation and spastic hemiplegia 
in patient C-II.2. 
Cortical malformations; schizencephaly
Although cortical lesions secondary to tissue necrosis have been described in COL4A1 
mutations 15, however, malformations of the cortex, in particular schizencephaly, have only 
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been appreciated recently to be associated with COL4A1 mutations34,36, Schizencephaly is 
defined as a cleft extending from the pial surface to the lateral ventricle, lined by heterotopic 
gray matter41. 
In our cohort, we observed two patients with focal cortical malformations. The first has a 
maternally inherited c.1964G>A (p.G655E) COL4A1 mutation and presented with schizen-
cephaly, porencephaly and intraventricular hemorrhage (family H-II.1, Fig 3H). The mother 
has a severe hypermetropia of +10 Dpt. The second patient (family L-II.1) has a paternally 
inherited c.3368A>G (p.E1123G) COL4A2 mutation and presented with porencephaly of the 
left frontal ventricle and overlying dysplastic cortex resembling transmantle heterotopia 
on brain MRI (Fig 3L). The father is asymptomatic, except for ptosis. The same COL4A2 
mutation was previously reported in two single adult patients with intraparenchymal hem-
orrhage; the mutation was proven to be pathogenic in in vitro functional studies23. 
Previously unreported findings in our cohort 
Patient II.1 from family K had a severe neonatal neurological presentation with seizures 
due to intracerebral hemorrhages. At the age of 6 months, he was diagnosed with neu-
roblastoma, which has not been previously associated with COL4A1 mutations, but is a 
relatively frequent tumor in childhood. We mention this because of the occurrence of other 
neurological tumors in this cohort (meningioma in patient A-1.2 and in another COL4A1 
carrier7). Whether neural tumors are part of the phenotypic spectrum does not seem likely 
from these data, but remains unclear.  
The index patient from family J presented with a left-sided germinal matrix and intraven-
tricular hemorrhage and posthemorrhagic venous infarction after birth. Interestingly, also 
supraventricular tachycardia was noted at this young age, requiring sotalol treatment. It is 
unclear whether the tachycardia is causally related to the COL4A1 mutation, however it has 
also been reported in HANAC syndrome16.
DISCUSSION
In a cohort of 183 index patients, mostly porencephaly patients or patients with infantile 
hemorrhage, we identified 21 COL4A1 and 3 COL4A2 pathogenic or likely pathogenic 
mutations. This suggests a high prevalence (13%) of mutations in this patient population. 
The clinical data of 13 families are novel, and 12 COL4A1 mutations have not been described 
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previously. A high percentage of de novo mutations (38%) was found in our cohort; 5 index 
patients harbour a de novo mutation (family D,E,H,I,K). One other mutation appeared 
de novo in a carrier father of an index patient (family B). No clear genotype-phenotype 
correlation is present. A high percentage (12/20, 60%) of severe perinatal presentation was 
observed. The clinical phenotypes of our patients greatly overlap the phenotype previously 
reported in the literature. We will discuss the reported phenotypes in the literature in the 
following sections. 
Prenatal and neonatal intracerebral hemorrhage and porencephaly
Porencephaly is one of the most frequently reported findings, described in 53 
COL4A17,8,12,14,15,17,18,21,34-36 and 6 COL4A2 patients24,25 (Table 2). However, since porencephaly 
was the first reported associated phenotype, there may be a bias in the inclusion of patients 
for COL4A1 and COL4A2 testing. Intraventricular hemorrhage (IVH) is a common com-
plication of very low birth weight preterm infants and a group of 40 preterm infants was 
tested for the presence of COL4A1 mutations. Only one pathogenic mutation was identi-
fied10. This result indicates that COL4A1 mutations are probably only minor contributors 
to IVH in very low birth weight preterm infants. A recent report of COL4A1 screening in a 
group of 61 porencephaly patients revealed mutations in 10 patients (16%) aged 3 months to 
14 years. All these patients had additional features including focal cortical dysplasia, intra-
cranial calcification, hemolytic anemia, elevated CK, myopathy, ophthalmological features 
or hematuria36. A complication of the hemorrhage can be the development of secondary 
hydrocephalus, as seen in patient D-II.1 and previously reported13,15,42. 
Sporadic extensive bilateral porencephaly resembling hydranencephaly
We previously described a subset of patients with extensive prenatal porencephaly and gray 
and white matter loss, cortical destruction and cerebellar and brain stem atrophy, resem-
bling hydranencephaly. A pathogenic mechanism was suggested, consisting of massive 
germinal matrix hemorrhage followed by extensive venous infarction with compression, 
edema and secondary ischemia of larger parenchymal areas leading to white matter and 
cortical destruction. Interestingly, we found de novo COL4A1 mutations in all these 
patients, including a case of germline mosaicism in the mother of one patient15.  
PVL with intracranial calcification
Subtle periventricular, basal ganglia and/ or deep white matter calcifications are reported 
in COL4A1 mutations, together with PVL, also in the absence of porencephaly14,30,34,36,43. 
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The diagnosis in patients with this PVL phenotype without a contributing family history 
or additional findings could easily be missed. Associated features, such as elevated CK con-
centration or microbleeds may help in suspecting the diagnosis in the absence of other 
major findings such as porencephaly14,30,34,36. These associated findings may also help in dis-
criminating COL4A1 related calcifications and leukoencephalopathy from disorders with 
partially overlapping manifestations, such as Aicardi-Goutières syndrome, CMV infection 
or cystic leukoencephalopathy without megalencephaly14,44. 
Axenfeld Rieger anomaly with leukoencephalopathy
Axenfeld Rieger anomaly, as well as cataracts, microcornea and retinal detachment have 
been reported as consistent findings in several other families harbouring COL4A1 muta-
tions. Although major cerebral findings, such as porencephaly or hemorrhagic stroke can 
be present these patients, all  patients showed leukoencephalopathy and small vessel disease, 
even in the absence of neurological symptoms. This indicates that brain MRI in Axenfeld 
Rieger patients may provide a clue for the diagnosis of a COL4A1 related disorder11,18. 
HANAC (Hereditary Angiopathy with Nephropathy, Aneurysm and muscle Cramps) syn-
drome
The HANAC syndrome comprises a specific combination of features, and is attributed to 
mutations in COL4A1 affecting glycine residues in close proximity of exons 24 and 25, later 
reported to be the triple helical CB3[IV] domain, encompassing major integrin binding 
sites16,29,32.  The angiopathy in HANAC syndrome comprises retinal vessel arterial tortuos-
ity and cerebral small and large vessel disease with aneurysms of the carotid syphon. The 
nephropathy consists of persistent hematuria and/ or proteinuria with or without bilat-
eral, large renal cysts. Other associated findings are muscle cramps with elevated CK levels, 
Raynaud’s phenomenon and cardiac arrhytmia. Interestingly, HANAC syndrome patients 
do not present with infantile hemiplegia or porencephaly. Also, the risk of major (hemor-
rhagic) stroke is thought to be lower than in other COL4A1 mutations16,29,32. In our cohort, 
no patients displaying the HANAC phenotype were identified, possibly due to referral 
bias, as our cohort comprises mostly neurological patients. Possibly, the clinical picture of 
HANAC is insufficiently known to be associated with COL4A1 mutations among referring 
physicians. 
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Stroke in childhood and young adulthood 
Besides prenatal hemorrhage leading to porencephaly, strokes in the form of cerebral 
bleeding at later age can occur with COL4A1 and COL4A2 mutations17,20,28,31. In our cohort, 
stroke in later childhood and young adulthood was not reported. In the literature, cere-
bral hemorrhages in childhood or in young adulthood have been documented in COL4A1 
mutations. Differential diagnostic considerations in these cases comprise other genetic 
cerebrovascular malformation syndromes, such as cerebral cavernous hemangiomas or 
hereditary hemorrhagic telangiectasia. The hemorrhagic strokes typically affect the deep 
white matter, in combination with diffuse leukoencephalopathy and microbleeds17,20,28,31. 
Recurrence of strokes has been reported20,28. Two of the documented cases were sporadic20,31, 
the others were familial17,28.
Sporadic late-onset hemorrhagic stroke  
Sporadic intracerebral hemorrhage generally occurs in the elderly with a worldwide inci-
dence of 24.6 per 100.000 person-years45, frequently in the setting of risk factors such as 
cerebral amyloid angiopathy or hypertensive vasculopathy, alcohol consumption or ciga-
rette smoking. 
In our cohort, patients with adult onset cerebral hemorrhage are lacking. This may very well 
be due to selection bias, probably due to the fact that most patients were referred by clinical 
geneticists and neonatologists because of pre- and perinatal hemorrhage or porencephaly. 
In a cohort of 96 sporadic patients with intracerebral hemorrhage not caused by arteriove-
nous malformations, tumors or impaired coagulation, COL4A1 and COL4A2 were tested, 
leading to the detection of 2 COL4A1 mutations in 2 patients and 3 COL4A2 mutations 
in 4 patients22,23. These findings indicate that COL4A1 and COL4A2 mutations contribute 
to approximately 6% of sporadic late onset intracerebral hemorrhage. Since intracerebral 
hemorrhage constitutes approximately 15% of all intracranial hemorrhages in this group of 
patients, the contribution of COL4A1 and COL4A2 mutations in the total group of intra-
cranial hemorrhage is approximately 1%. Although the portion may seem small, general 
prevalence of COL4A1 and -2 mutations may be quite high, since intracerebral hemorrhage 
in the elderly is not a rare event.  The mutations identified in the patients are missense muta-
tions, that probably have a milder effect on collagen IV function, and not the frequently 
identified triple helical domain glycine changes22,23. However, pathogenicity of these milder 
missense mutations has only been tested in an in vitro expression system. 
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Focal cortical dysplasia and schizencephaly
In the literature, COL4A1 mutations were identified as the first genetic cause of schizen-
cephaly34,36 ; mutations were found in 5 out of 10 schizencephaly patients tested. We describe 
the first patient with cortical dysplasia harbouring a COL4A2 mutation (L-II.1). The local-
ization of the cortical dysplasia and the association with an underlying porencephalic 
enlargement of the frontal part of the lateral ventricle in our patient suggest a causal rela-
tion between the COL4A2 mutation and the cortical malformation (Fig 3L). Interestingly, 
the father also carries the mutation and is asymptomatic, but no MRI has been performed. 
Probably, the pathogenesis of this malformation is similar to that of the schizencephaly 
and hydranencephaly reported in COL4A1 mutations. Our findings indicate that COL4A2 
mutations can also lead to dysplastic cortex, hereby broadening the COL4A2 phenotypic 
spectrum. The role of COL4A2 mutations in cortical dysplasia associated with porenceph-
aly needs to be investigated in a larger patient cohort. 
Issues in genetic counselling and management of affected families
There are several plausible, non-mutually exclusive pathogenic mechanisms of various 
COL4A1 and COL4A2 mutations, which are summarized in a recent review46. The patho-
genic mechanism, is still not elucidated completely, and may be different depending on 
mutation type. 
Another unresolved question is the matter of the reduced penetrance. The same mutation 
can lead to a severely affected infant, while the carrier parent is hardly affected. This leads 
to the hypothesis that COL4A1 and COL4A2 mutations must be regarded as risk factors, 
which, together with additional modifying factors, lead to a phenotype. Mouse models 
support this hypothesis, showing that penetrance and disease severity is related to the 
genetic context13,47. 
Due to the reduced penetrance with possible modifying factors and the variable pheno-
type, the counselling of affected patients and their families remains a challenge. We suggest 
an initial workup in mutation families, including neurological, ophthalmological, renal 
and cardiac screening in mutation carriers and first degree relatives with a 50% chance 
of harbouring the mutation (the latter taking into account the social consequences of pre-
symptomatic DNA testing) (Table 3). Neurological screening should include a medical 
history and physical examination, followed by brain MRI if abnormalities are found. We 
recommend adding susceptibility-weighted imaging, since this improves the detection of 
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microbleeds48. Performing MRA to identify cerebral aneurysms is still under debate; up 
till now no ruptured aneurysms have been reported in mutation carriers, suggesting a slow 
progression rate and discouraging the use of MRA. Follow-up data on the course of identi-
fied aneurysms in this specific group of patients, however, are lacking. 
Another subject under debate is the perinatal management of pregnancies in which the 
child or the mother harbours a COL4A1 or COL4A2 mutation. Prenatal testing can be 
offered in high risk pregnancies after genetic counselling, with special attention for the 
variable phenotypic expression and reduced penetrance. Delivery by caesarean section 
has been proposed in order to prevent brain vascular injury attributable to birth trauma27. 
However, evidence that this will lead to prevention of cerebral hemorrhage is lacking and 
several patients have now been reported who had established lesions long before delivery. 
Further studies on the clinical course of individuals with COL4A1 or COL4A2 mutations 
are needed in order to determine the follow-up in more detail. 
CONCLUSIONS
In conclusion, our data confirm that COL4A1 mutations and COL4A2 mutations are 
important causes of cerebrovascular disease with a high mutation detection rate in poren-
cephaly and childhood cerebral hemorrhage with a relatively high rate of de novo mutations. 
Although also present in (sporadic) adult onset intracerebral hemorrhage with an inci-
dence of 6%22,23, the role of mutations in this patient cohort seems less prominent. It seems 
important to increase awareness of this disorder among neurologists and internists coping 
with the adult population. Besides the cerebrovascular phenotype, systemic involvement, 
with ocular, renal, muscular and cardiac features must not be underestimated and needs 
screening at diagnosis, even outside the formal HANAC syndrome. The precise role of 
COL4A1 and COL4A2 mutations in cortical malformations needs to be elucidated, but it 
seems to contribute to those malformations that are most likely a result of a vascular insult 
during fetal development49. Follow-up data on COL4A1 and COL4A2 mutation carriers 
are important in order to develop appropriate surveillance protocols and adapt treatment.  
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Figure 1. In this figure, the COL4A1 mutations (A) and COL4A2 mutation (B) in our novel fam-
ilies are depicted on the bottom (red arrows), the mutations reported in literature are depicted 
on the top (blue arrows).
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Figure 2. Pedigrees of the 13 novel families
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Figure 3.  
Selection of brain MRIs 
of novel patients
A. T1-weighted image of A-II.1 
showing porencephaly with 
cortical destruction and white 
matter hyperintensities sug-
gestive of calcifications and/or 
hemorrhage. 
B. T2-weighted image of A-I.2 
showing enlarged perivascu-
lar spaces. 
C and D. T2-weighed image of 
B-III.1 and B-II.1, with classic 
left-sided unilateral poren-
cephaly. 
E. FLAIR image of C-II.1, 
indicating PVL. 
F. FLAIR image of D-II.1 
depicting severe expansive 
porencephaly and severe white 
matter loss. 
G. T2-weighed image of E-II.1 
with left-sided hemorrhage 
with ipsilateral volume loss 
of white matter, thalamus and 
basal ganglia. 
H. T2-weighted image of H-II.1 
showing right-sided schizen-
cephaly and porencephaly and 
a small hemorrhage in the left 
frontal lobe. 
I. T2-weighted image of 
J-II.1with left-sided por-
encephaly with bilateral 
ventricular enlargement and 
leukoencephalopathy. 
J. T2-weighted image of K-II.1 
with left-sided germinal 
matrix hemorrhage leading to 
intraventricular hemorrhage 
and a left-sided venous infarc-
tion. 
K. T2-weighted image of L-II.2 
depicting bilateral severe cer-
ebellar haemorrhage in both 
hemispheres. 
L. FLAIR image of M-II.2 
showing closed-lip schizen-
cephaly and focal cortical 
dysplasia. 
M and N depict post-mor-
tem images of patient E-II., 
showing ventricular dilatation 
and a large intraparenchymal 
hemorrhage.
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, m
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Table 1.  C
linical phenotypes and m
utations of novel identified fam
ilies (continued from
 previous page)
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  COL4A1 
mutations*  
 
(137 carriers)
COL4A2 
mutations*  
 
(15 carriers)
Novel 
COL4A1 
mutations 
(20 carriers)
Novel 
COL4A2 
mutation  
(2 carriers)
Brain MRI findings    
Periventricular 
leukoencephalopathy/ 
small vessel disease 54 3 5
Porencephaly 53 6 11 1
Cerebral calcification 16 2
Microbleeds 16  
Intracerebral hemorrhage 15 5  
Cerebellar atrophy 12 1 4
Intracranial aneursym 8 1  
Lacunar infarct 7 2
Schizencephaly 6 1
Intraventricular hemorrhage  
(without porencephaly) 5  
Dysplastic brain stem 5  
Hydrocephalus 4 1  
Hydranencephaly 4 1
Mild ventriculomegaly 3  
Abnormal basal ganglia 3 3
Gyral abnormalities 2  
Multicystic encephalomalacia 2  
Lissecephaly 1  
Traumatic subarachnoidal  
hemorrhage 1  
Tortuosity of infra-and  
supratentorial vessels 1  
Dandy Walker malformation 1  
Focal cortical dysplasia 1   1
Table 2. Brain MRI findings and Systemic manifestations in COL4A1 and COL4A2 mutations
(continued on next page)
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  COL4A1 
mutations*  
 
(137 carriers)
COL4A2 
mutations*  
 
(15 carriers)
Novel 
COL4A1 
mutations 
(20 carriers)
Novel 
COL4A2 
mutation  
(2 carriers)
Ophthalmological findings    
Cataract 29 6  
Retinal arterial tortuosity 26   1  
Strabism 10    
Iris hypoplasia 10    
Posterior embryotoxon 9   1  
Corneal opacities 8    
Retinal hemorrhage 7    
Anterior segment 7    
Optic atrophy 6 2 1  
Microcornea 5   3  
microphthalmia 5   1  
Glaucoma 2   1  
High myopia 2 1  
Reduced cone and rod  
responses 1    
nystagmus 1    
Optic coloboma 1    
Retinal detachment 1    
Hypermetropia     2  
Renal findings        
Renal cysts 4    
Hematuria 4    
Renal agenesis 1    
Hyperechogenicity of  
renal pyramids 1    
Dilated pyelum     1  
Table 2. Brain MRI findings and Systemic manifestations in COL4A1 and COL4A2 mutations
(continued on next page)
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  COL4A1 
mutations*  
 
(137 carriers)
COL4A2 
mutations*  
 
(15 carriers)
Novel 
COL4A1 
mutations 
(20 carriers)
Novel 
COL4A2 
mutation  
(2 carriers)
Muscular abnormailties        
Elevated CK 25   1  
Muscle cramps 18   2  
Myopathy 2   2  
Muscular atrophy 1   1  
Cardiac abnormalities        
Raynaud 6    
Cardiac (supraventricular)  
arrhytmia 4   1  
Mitral valve prolaps 4    
VSD 1    
Other findings        
Hemolytic anemia 5    
Thymus, liver and 
adrenal hemorrhage 1    
Sensorineural deafness 1    
         
Number indicates reported patients in literature
 
 
Table 3. Screening protocol
Screening protocol
Neurological examination
Brain MRI (upon indication)
Ophthalmological examination
Ultrasound of kidneys
Urine analysis for the presence of hematuria
Renal function test (serum creatinine, estimation of glomerular filtration rate)
Serum CK measurement
  Electrocardiogram (arrhythmias)
Table 2. Brain MRI findings and Systemic manifestations in COL4A1 and COL4A2 mutations
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INTRODUCTION
COL4A1 mutations were initially described in familial porencephaly (OMIM 175780)1-3. The 
phenotypic spectrum of COL4A1 mutations is however wide and includes cerebral white 
matter small vessels disease, cerebral aneurysms, cataract, anterior segment dysgenesis, 
microcornea, nephropathy, muscle cramps and cardiac arrhythmia4-6. Prenatal onset has 
been documented7. Phenotype-genotype correlation has been proposed for the HANAC 
phenotype (OMIM 611773)5.
We report on novel COL4A1 mutations occurring de novo in four Caucasian patients with 
extensive prenatal brain destruction, adding to the wide phenotypic spectrum.
METHODS
COL4A1 sequencing was performed according to the Dutch regulations for genetic diagno-
sis3. Written informed consent for publication was obtained from the parents.
CASE R EPORTS
Case 1. This patient (male) presented antenatally at 27 weeks gestation with asymmetric ven-
triculomegaly and extensive cerebral infarction seen on fetal ultrasound and MRI (figure 
1A,B). At birth (37 weeks’ gestation), apnea, poor feeding and seizures developed, leading to 
death at age 10 days. Postnatal cerebral ultrasound (CUS) and post-mortem MRI confirmed 
severe bilateral ventriculomegaly and tissue atrophy following extensive, putatively deep 
venous infarctions. Absence of the rostral part of the corpus callosum, a poorly gyrated 
cortex, atrophy of the basal ganglia, thalami, brainstem and cerebellum with an enlarged 
fourth ventricle were noted (Figure 1, C and D). Tortuosity of infra- and supratentorial 
vessels (Figure 1C), agenesis of the right kidney, renal artery and femoral vein and left-sided 
renal cystic lesions were also seen (Figure 1E).
Case 2. This patient (female), born at 40 weeks gestation, had severe ventriculomegaly and 
severe cerebellar atrophy seen on fetal ultrasound at 37 weeks gestation and fetal MRI. Post-
natal CUS and MRI confirmed the findings (Figure 1, F,G). Susceptibility-weighted imaging 
(SWI) showed low signal intensity on the ventricular margins suggestive of antenatal hem-
orrhage (Figure 1, F-H). Fundoscopy revealed optic atrophy soon after birth. Abdominal 
ultrasound was normal. Progressive high-pressure hydrocephalus developed. She died at 
11 weeks.
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Case 3. This patient (male) presented with asymmetric ventriculomegaly seen on fetal 
ultrasound at 26 weeks gestation. Fetal MRI showed massive cerebral infarction. At birth 
(40 weeks’ gestation) there were apneas and poor feeding; bilateral small corneas and focal 
central cataracts were noted. Postnatal CUS and MRI showed severe ventriculomegaly and 
a small cerebellum (figure 1I). MRI 2 years later showed no change in the degree of tissue 
loss (figure 1J). Renal ultrasound was normal. He developed cerebral palsy and seizures. 
Case 4. This patient (male), born at 37 weeks’ gestation, was very growth restricted (weight 
1460 gram <<0.4thC and head circumference 27 cm <0.4thC). CUS on postnatal day 1 and 
MRI showed right-sided ventricular dilatation with a large cyst adjacent to the right lateral 
ventricle, an area of cavitation in the left temporal lobe and a small cerebellum (figure 1K). 
Bilateral cataracts were noted.
Results of screening for thrombophilia, maternal infection, and anti-rhesus D antibodies in 
all patients and their mothers were normal.
R ESULTS 
In patient 1, a heterozygous c.2545G>T mutation (p.G808V) in exon 31 of COL4A1 was found. 
Patient 2 harbors a c.2716 +1G>A splice site mutation in exon 33. In patient 3 a c.3022G>A 
mutation (p.G1008R) in exon 36 was detected. Patient 4 showed a c.3130G>C mutation 
(p.G1044R) in exon 37. None of these mutations have been described previously, and they 
were absent in a panel of 200 ethnically matched control subjects. The three glycine sub-
stitutions affect highly conserved G-X-Y collagen repeats1,2. All mutations were absent in 
the parents, suggesting de novo events, except for the mother of patient 3, who was found 
to have a mosaic mutation in the blood. The mutations are located in exons 31, 33, 36 and 37 
and are in the same area covering one fifth of the triple helix domain of the collagen IVα1 
protein (Figure 2). 
DISCUSSION
The COL4A1 mutations of our patients are associated with severe encephaloclastic lesions, 
at first sight resembling hydranencephaly. The type and localization of the lesions might 
suggest a massive MCA territory ischemic stroke, mostly in patients 1 and 3. However, hemo-
siderin deposits on the ventricular margins from SWI data are more specific for venous 
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infarction and suggest a venous component to the damage in all patients. The pathogenesis 
could be a massive germinal matrix and intraventricular hemorrhage followed by extensive 
venous infarction, with compression, edema and secondary ischemia of large parenchymal 
areas leading to destruction of the cerebral white matter and cortex and secondary changes 
in the central gray matter. A similar mechanism could underlie the secondary cerebellar 
atrophy. However, primary arterial involvement is suggested by the renal agenesis of patient 
1 and the previously reported retinal arterial tortuosity and cerebral arterial aneurysms2,5,6. 
Our data show that COL4A1 testing should also be considered in sporadic severe antenatal 
hemorrhagic stroke, resembling hydranencephaly. 
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Figure 1. Magnetic resonance imaging (opposite page) 
Case 1: Fetal MRI at the 28th gestation week. Sagittal (A) and transverse (B) T2-weighed image 
showing massive cerebral infarction extending to the cortex with loss of gray and white matter. 
(C, D) T2-weighed images of post-mortem brain MRI showing severe bilateral ventriculomegaly 
with extensive gray and white matter loss, tortuosity of the cerebral arteries, and cerebellar and 
pontine atrophy. (E) Thoracic and abdominal imaging showing right-sided renal agenesis and 
multiple small cystic lesions in the left kidney (arrow).
Case 2: postnatal sagittal (F) and transverse (G) T1-weighted images showing extensive bilateral 
infarction as well as severe atrophy of the vermis, pons and brainstem.  The areas of low signal 
intensity on the susceptibility-weighed image (H) show remnants of old hemorrhage following 
the venous distribution of the periventricular white matter.
Case 3: neonatal transverse T2-weighted images (I) and coronal fluid-attenuated inversion 
recovery sequence at age 2 years (J), both showing extensive tissue destruction, which is more 
marked on the right. 
Case 4: postnatal transverse inversion recovery images (K) showing bilateral porencephaly with 
cortical destruction. Note the high signal intensity lesions adjacent to the porencephaly and to 
the lateral ventricles, suggestive of previous hemorrhage.
Figure 2. COL4A1 gene and patient mutations
Schematic representation of COL4A1 exons (with numbering of the exons), introns and func-
tional domains, including the location of the mutations in our four patients. 
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TO THE EDITOR 
Anterior segment dysgenesis disorders (ASDD) broadly  affect the cornea, lens and iris. Spe-
cific clinical entities are Axenfeld-Rieger anomaly and Peters anomaly. Axenfeld Rieger 
comprises iris hypoplasia, eccentric pupils (corectopia), iris tears (polycoria), posterior 
embryotoxon and/ or iridocorneal adhesions and a risk of glaucoma Peters anomaly com-
prises a central absence of the corneal endothelium and Descemet’s membrane, leading to 
congenital corneal opacities1. ASDD can be isolated, or  associated with systemic problems 
as part of a syndrome. Both autosomal dominant and autosomal recessive inheritance have 
been described1. We present a family with autosomal dominant ASDD associated with a 
COL4A1 mutation, and underscore the importance of the additional neurological investi-
gations  in reaching a diagnosis.  
We observed a non-consanguineous Dutch family with three affected individuals. The 
index individual was born after an uneventful pregnancy and had a slightly delayed motor 
development. She had congenital cataracts with strabismus. Ophthalmological evaluation 
at the age of 5 years also showed amblyopia and microcornea. At the age of 14 years an 
embryotoxon posterior and a deep anterior chamber were noted with a nystagmus and exo-
tropia of the left eye. Fundoscopy was normal. At the age of 15 years she underwent cataract 
extraction of both eyes. Because of visual field loss with normal funduscopy additional 
investigations were performed. Goldmann perimetry showed tunnel vision, whereas visual 
evoked potentials and electroretinogram were normal. Due to this discrepancy, cerebral 
MRI was performed, which showed periventricular leukomalacia (Figure 1a,b,c). Physical 
examination at the age of 36 years showed joint hyperlaxity, mild pyramidal tract abnor-
malities comprising generalized brisk deep tendon  reflexes with a left-sided Babinski sign 
and bilaterally decreased coordination  skills. Her sister had ophthalmological abnormal-
ities comprising congenital cataract, microcornea, nystagmus but intact peripheral visual 
fields. She had a psychomotor retardation with congenital left-sided spastic hemiplegia, 
left-sided hip dyplasia with coxa valga, scoliosis and seizures. In adulthood she developed 
contractures impairing ambulation. Physical examination at the age of 42 years showed 
small joint hyperlaxity and a left-sided hemiplegia. The mother is known to have micro-
phthalmia, congenital cataract and secondary glaucoma, for which she received numerous 
operations (Figure 1d). Later she developed visual field defects with tunnel vision. Physical 
examination at the age of 74 years showed a soft skin with hyperlaxity of skin and hands, 
without neurological problems.
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Since this combination was previously reported in COL4A1 mutations, the opthalmological 
and neurological abnormalities2, especially the MRI picture of periventricular leukoma-
lacia, prompted us to perform Sanger sequencing of the COL4A1 gene (NM_001845.4) 
on DNA isolated from peripheral blood. Written informed consent was obtained. In all 
three patients, the novel heterozygous COL4A1 missense mutation c.3200G>C in exon 38 
was found, leading to a substitution of glycine into alanine (p.Gly1067Ala). This mutation, 
located in the conserved triple helix Gly-X-Y repeat domain of the gene, was absent in 100 
ethnically matched controls and was predicted to have a damaging effect on the protein 
function by Polyphen2 and SIFT prediction algorithms. 
The COL4A1 and COL4A2 proteins form a heterotrimeric helix that is a major component 
conferring structural integrity to basement membranes. In the eye it is widely expressed 
in the basement membranes of the conjunctiva, corneal epithelium and endothelium, 
Schlemm’s canal, lens, retina and vascular endothelia2,3. 
Figure 1. Brain MRI of the index patient (A,B,C). FLAIR (A,C) and T2- weighed (B) images 
show periventricular leukomalacia. Picture of ocular features of the mother (D), with microph-
thalmia and status after many ocular operations because of congenital cataract and secondary 
glaucoma.    
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COL4A1 and COL4A2 mutations were initially identified in familial hemiplegic porenceph-
aly, but can be associated with different cerebrovascular  phenotypes including small vessel 
disease and stroke. COL4A1, and possibly COL4A2 mutations, can also lead to involve-
ment of other organs, including eye, kidneys, heart and muscles3. The presentation can 
vary even within one family. Ocular findings include ASDD, congenital cataracts, posterior 
embryotoxon, microcornea and glaucoma, as well as retinal arterial tortuosity and optic 
nerve hypoplasia. The ocular abnormalities can also vary within one family since COL4A1 
mutations can show a reduced penetrance2,3.  Our patients  represent the severe end of the 
ocular spectrum with a consistent phenotype among the affected family members.
In this family, the combination of ASDD,  neurological disease and brain MRI findings of 
periventricular leukomalacia is typical of COL4A1 mutations. It may therefore be useful in 
the clinical workup of patients with ASDD to perform a neurological examination and pos-
sibly a brain MRI. Brain MRI may help in the diagnosis of COL4A1 mutations, especially 
since white matter changes and small strokes can be present in absence of neurological 
symptoms.
The frequency of COL4A1 and COL4A2 mutations among patients with ASDD associated 
with neurological abnormalities and/ or hemorrhagic stroke might be much higher than 
appreciated up till now. For instance, it has been suggested that up to 6% of sporadic hem-
orrhagic stroke is related to COL4A1 and COL4A2 mutations4,5. Therefore, we recommend 
a thorough family history with special attention for neurological and cerebrovascular dis-
orders in the diagnostic workup of ASDD, in order to find clues for this disorder. 
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TO THE EDITOR
Heterozygous mutations in COL4A1 have previously been associated with a broad neu-
rological spectrum, ranging from absence of symptoms to severe prenatal disruption as a 
result of cerebral hemorrhage leading to porencephaly or hydranencephaly1-4. Other organs 
may be affected, including eyes, kidneys, heart and muscles. Ophthalmological findings 
include anterior segment dysgenesis, retinal arterial tortuosity and cataract5. In antenatal 
porencephaly, most reported COL4A1 mutations are located in the collagenous triple helix 
domain, although some affect the non-collagenous NC1 domain2,6. The inheritance pattern 
is autosomal dominant, with reduced phenotypic expression and penetrance. Recently we 
encountered  a patient of consanguineous parents with a phenotype compatible with the 
severe-end spectrum of COL4A1 mutations. 
The patient is the third child of healthy, consanguineous parents (second degree cousins) 
of Moroccan ancestry. During pregnancy, ultrasound performed at 22 and 23 gestational 
weeks (GW) was normal. However, a routine ultrasound at 26 GW showed intracerebral 
cysts and microcephaly (head circumference <p5). At 28 GW, an increase in cysts was noted, 
together with an irregular right cerebellar hemisphere and hypercoiling of the umbilical 
cord. Prenatal MRI at 28 GW confirmed the finding of multiple cysts, including in the cer-
ebellum. At 32 GW, polyhydramnios developed. The girl was born at 40 6/7 GW, and had 
Apgar scores of 7, 8 and 8 after 1, 5 and 10 minutes. She was microcephalic (-3.5 SD). Brain 
MRI postpartum showed multiple cerebral and cerebellar (porencephalic) cysts, polymicro-
gyria, periventricular calcifications and a ventricular dilatation (Figure 1). Opthalmological 
examination showed a leftsided corneal clouding, a rightsided conjunctival hemorrhage 
and Rieger anomaly with microcornea, microphthalmus and adhesions between lens and 
iris. Cardiological evaluation, including EEG and echocardiogram were normal, as well 
as abdominal ultrasound. She developed a severe psychomotor retardation with bilat-
eral spasticity. Metabolic screening, screening for TORCH and Parvo-B19 infections and 
anti-thrombocyte antibodies were normal. The porencephaly and opthalmological find-
ings prompted us to test for COL4A1 or COL4A2 mutations. 
A novel bi-allelic c.4901C>A missense change in exon 51 of COL4A1 (13q34) was identified. 
The variant predicts a pAla1634Asp substitution in the noncollagenous NC1 domain, spe-
cifically in the VR3 docking site7. No mutations at this specific locus have previously been 
reported, although one (heterozygous) mutation is located just outside the VR3 docking site 
(c,4881C>G, Asn1627Lys)8. The identified mutation was not present in the dbSNP database, 
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the 1000 Genomes Project or the NHLBI Exome Sequencing Project (ESP), is present in 
a highly conserved region of the gene among species and is predicted to be pathogenic in 
Polyphen2, SIFT and Mutation Taster. The parents refused any additional investigation to 
study segregation. SNP array (Illumina Human CytoSNP 12) showed a female genotype 
with several large regions of homozygosity (ROH), including a 18.4 Mb region on chro-
mosome 13q31.3q34 encompassing COL4A1. The ROH and absence of a deletion strongly 
suggest a homozygous state of the mutation (the approximately 100 Kb large COL4A1 locus 
is covered by multiple SNPs on the used platform).  Other genes known to cause resem-
bling phenotypes (OCLN, RNASET2, SAMHD1, JAM3) were not located in the other ROH 
regions.  The parents are apparently healthy, the family history is negative for cerebrovas-
cular, ocular or renal disorders. 
The patient’s phenotype, comprising severe cerebral and cerebellar multicystic porenceph-
aly, microcephaly and calcifications, together with corneal clouding and Rieger anomaly, fit 
within the severe end of the clinical spectrum associated with COL4A1 mutations. Poly-
microgyria, as seen in our patient, is a developmental disorder of the cerebral cortex of 
presumable vascular origin and belongs to the spectrum of schizencephaly observed in 
COL4A1 mutations9,10. 
In addition, the reported mutation is the first COL4A1 mutation located in the VR3 docking 
site of the COL4A1 NC1 domain. The collagen NC1 domain has an important function in 
the initiation of triple helix formation. In this process, three NC1 domains (two COL4A1 
and one COL4A2) are stabilized through tight and selective interactions between two sites, 
comprising a beta-hairpin motif and its docking site with a variable region (VR3). This 
VR3 is a 15-residue-long variable region with sequence hypervariability across all the chains 
of collagen IV, which is thought to be essential in directing chain recognition in the tri-
merization process11,12, allowing the specific binding of i.e. COL4A1 and COL4A2. Since no 
mutations in this VR3 docking site have been reported7, also not in the highly homologous 
genes COL4A3, COL4A4, COL4A5 or COL4A6, nothing is known about the pathogenic 
effect of VR3 mutations and the mode of inheritance.  It can be postulated that a VR3 muta-
tion, especially in a homozygous form, will disturb chain recognition, trimerization and 
NC1 trimer stabilization of COL4A1 and COL4A2. 
Both autosomal dominant and autosomal recessive inheritance has been described for 
COL4A3 and COL4A4 mutations involved in Alport syndrome. Although mutations in 
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the collagenous triple helix domain are the most frequent cause of (both autosomal reces-
sive and autosomal dominant) Alport disease caused by COL4A3 and COL4A4 mutations, 
mutations in the NC1 domain, however not in its VR3 docking site,  have also been associ-
ated with both recessive and dominant forms.  In the recessive cases, homozygous mutation 
carriers display a severe phenotype, with early onset renal failure and deafness, while het-
erozygous mutation carriers can be mildly affected , or even be asymptomatic. The lack of 
phenotype in the parents of our patient is in line with these observations13-16.
In conclusion, we observed a putatively pathogenic homozygous COL4A1 variant affecting 
the VR3 docking site of the COL4A1 NC1 domain in a patient with severe porencephaly, 
polymicrogyria, corneal clouding, Rieger anomaly and microcephaly. The open question 
remains whether this is the cause of the disease and whether autosomal recessive inher-
itance is a general mechanism in COL4A1, besides COL4A3 and COL4A4 mutations. 
Additional cases are needed to make a definite statement regarding this question, which is 
very important regarding genetic counselling of families.
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Figure 1.
A. T2-weighed image, showing cerebellar cysts and destruction. 
B and C. T2-weighed images depicting multiple cerebral (porencephalic) cysts and leftsided 
polymicrogyria (arrow). D. T1-weighed image demonstrating a normal pons. 
E and F. T1-weighed image with multiple cerebral cysts, surrounded by calcification, and white 
matter calcifications. 
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COL4A2 MUTATION ASSOCIATED WITH 
FAMILIAL PORENCEPHALY AND SMALL-
VESSEL DISEASE
ABSTR ACT
BACKGROUND. Familial porencephaly, leukoencephalopathy and small-vessel 
disease belong to the spectrum of disorders ascribed to dominant mutations in the 
gene encoding for type IV collagen alpha-1 (COL4A1). Mice harbouring mutations 
in either Col4a1 or Col4a2 suffer from porencephaly, hydrocephalus, cerebral and 
ocular bleeding and developmental defects. We observed porencephaly and white 
matter lesions in members from two families that lack COL4A1 mutations. 
METHODS. We hypothesized that COL4A2 mutations confer genetic predisposi-
tion to porencephaly, therefore we sequenced COL4A2 in the family members and 
characterized clinical, neuroradiological and biochemical phenotypes.
RESULTS. Genomic sequencing of COL4A2 identified the heterozygous missense 
G1389R in exon 44 in one family and the c.3206delC change in exon 34 leading to 
frame shift and premature stop, in the second family. 
Fragmentation and duplication of epidermal basement membranes were observed by 
electron microscopy in a c.3206delC patient skin biopsy, consistent with abnormal 
collagen IV network. Collagen chain accumulation and ER stress have been pro-
posed as cellular mechanism in COL4A1 mutations. In COL4A23206delC fibroblasts 
we detected increased rates of apoptosis under stress conditions. Mutation pheno-
types varied including porencephaly, white matter lesions, cerebellar and optic nerve 
hypoplasia and unruptured carotid aneurysm. In the second family however, we 
found evidence for additional factors contributing to the phenotype. 
CONCLUSION. We conclude that dominant COL4A2 mutations are a novel major 
risk factor for cerebrovascular disease, including porencephaly and small-vessel 
disease with reduced penetrance and variable phenotype, which might be also mod-
ified by other contributing factors. 
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INTRODUCTION 
Porencephaly is defined as a cavity in the cerebral parenchyma communicating with the 
lateral ventricles, which results from destruction of the parenchyma after a developmental 
defect or an intracerebral haemorrhage. Porencephaly has both genetic and non-genetic 
causes. Mutations in the COL4A1 gene, coding for the procollagen alpha-1 chain of colla-
gen IV, have been associated with variable phenotypes. COL4A1 mutations predispose to 
germinal matrix haemorrhage in late pregnancy or around birth, which can lead to deep 
venous infarction with subsequent tissue necrosis and porencephalic cavitation. When 
the haemorrhage occurs during gestation or around birth it usually manifests as congen-
ital hemiplegia1-5. Familial porencephaly with congenital hemiplegia has been ascribed 
to autosomal dominantly inherited mutations in the COL4A1 gene. Although a number 
of rare monogenetic disorders may predispose to intracerebral haemorrhage, such as 
CADASIL, Fabry’s disease, autosomal dominant amyloid angiopathy, MELAS, homocys-
tinuria, Ehlers-Danlos syndrome type IV, Marfan and Maeda syndrome1-2,5, only mutations 
of COL4A1 have been associated with familial porencephaly3. The phenotypic manifesta-
tion of COL4A1 mutations is however quite variable both within and among families, with 
different presentations in children or adults. As well as porencephaly, COL4A1 mutations 
predispose to a variety of vascular lesions in the brain and other organs, leading to the con-
clusion that COL4A1 mutation causes a multisystem disease6. The cerebral lesions vary from 
deep intracerebral haemorrhage, to diffuse leukoencephalopathy, or small-vessel disease 
with deep lacunar infarcts, dilated perivascular spaces, silent microbleeds or (unruptured) 
intracranial aneurysms. In mutation carriers symptoms are variable, including congeni-
tal hemiplegia, transient ischaemic attack, adult onset haemorrhagic stroke, rarely brain 
infarction, and may even be absent7-10. At the severe end of the spectrum, massive prena-
tal bleeding leading to apparent hydranencephaly, renal agenesis and early demise have 
been described11. Other organs can also be affected. Ocular features can be associated with 
COL4A1 mutations such as retinal arteriolar tortuosity, ocular cataract, anterior segment 
dysgenesis and microcornea9,12-15. Other manifestations are cardiac arrhythmia, renal cysts, 
haematuria, hepatic cysts, muscle cramps and elevated creatine kinases. The HANAC 
syndrome (hereditary angiopathy, nephropathy, aneurysms and muscle cramps) has been 
specifically associated with mutations in exons 24 and 25 of the COL4A1 gene8,16. COL4A1 
mutations are often described within a familial context, but can also occur de novo, without 
a family history of bleeding11,17. Although heterogeneous, the common association of the 
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symptoms has led to the definition of general criteria for consideration of COL4A1 genetic 
testing6. The identification of a familial COL4A1 mutation helps to monitor complications 
and supports genetic counselling.
Non-fibrillary collagen IV is a major component of the extracellular matrix and base-
ment membranes and consists of six alpha chains, encoded by distinct and tandemly 
located genes respectively on chromosome 13q (COL4A1 and COL4A2), 2q (COL4A3 and 
COL4A4) and Xq (COL4A5 and COL4A6). COL4A3- to 6 mutations all cause Alport syn-
drome and benign familial haematuria. COL4A1 and COL4A2 are under regulation of the 
same promoter and encode for the procollagen IV alpha-1 and IV alpha-2 chains, which 
assemble to form a heterotrimeric helix with a constant 2:1 ratio, [alpha1(IV)]2[alpha2(IV)]. 
Among collagen IV genes, only COL4A1 and COL4A2 are ubiquitously expressed18. This 
explains why the basement membranes of several epithelia and endothelia can be affected 
by a COL4A1 mutation. Mutations in the human COL4A1 gene were originally identified 
after description of the prenatal cerebral and ocular bleeding in mice bearing mutations 
in the homolog Col4a1 gene 3. Because of the common function, mutations in the collagen 
IV alpha-2 gene were supposed to cause similar manifestations and in fact, mice bearing 
heterozygous Col4a2 missense mutations survive the postnatal period but show haemor-
rhage in the eye, brain, and skin and developmental defects of eye and brain19 similar to 
Col4a1 mutants. We observed porencephaly, white matter lesions suggestive of small-ves-
sel disease and aneurysms in members of two families, fulfilling the criteria for COL4A1 
testing, but without evidence for COL4A1 mutation. We therefore explored by a candidate 
gene approach the involvement of COL4A2 and its potential role in human disease.
SUBJECTS/MATERIALS AND METHODS
Patient study
All tested individuals and legal caretakers gave their informed consent for the study, accord-
ing to the Dutch local ethical committee requirements. MRI (magnetic resonance imaging) 
and analysis of DTI (diffusion tensor imaging) data were performed according to Lobel 
et al20-22. Transmission electron microscopy of the skin biopsies was performed in double 
blind experiments and independently scored by two investigators8.
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Genomic COL4A1 sequence analysis was according to Breedveld et al7. Primers were 
designed and analysis performed for the genomic sequence of COL4A2. RT-PCR was 
performed as described21. RT-qPCR was performed using KAPA sybr fast qPCR mix (ABI 
prism) and the CFX96 Real Time System (Biorad). Skin fibroblast culture and test for ER 
stress was conducted by Western Blot and RT-qPCR according to Lin et al23.  Staining for 
the collagen specific chaperon HSP47 and the ER stress marker KDEL26 were performed 
under standard culture condition and after stress induced by DTT in control and patient 
fibroblasts. A fluorescent kit for multiple active caspases was used (FlicaTM apoptosis 
detection kit, Immunochemistry Technologies, LLC). For additional details see the Sup-
plementary data.
R ESULTS
Patient description (Clinical details are summarized in Table 1.)
Family A (Fig. 1A) The proband III-2 was the first of this Caucasian family to present at the 
age of 6 months with a right-sided hemiparesis. Her prenatal course was complicated by 
oligohydramnion. Brain MRI at the age of 3 years and 8 months showed left-sided poren-
cephaly and right-sided periventricular white matter hyperintense lesions on T2 weighted 
images. At the age of 4.5 years she has a moderate learning disability. Eye fundoscopy is 
normal. (Fig. 2A, B). 
Subject III-1 was born at 38 weeks of a normal gestation and developed normally. A brain 
MRI at the age of 8 years revealed patchy white matter lesions. Eye fundoscopy is normal 
(Fig. 2C). 
The mother (II-2) is asymptomatic at the age of 31 years. A brain MRI was normal, while 
MRA revealed bilateral internal carotid artery aneurysms at the level of the cavernous sinus 
(Fig. 2D). Subjects II-4, II-5 and I-1 are all reported to have a right-sided hemiparesis. No 
medical records are available. 
Family B (Fig. 1B) This consanguineous family of Afghani ancestry includes two probands 
(II-2 and II-5). 
Proband II-2 was born at term of a normal gestation with a birth weight of 2500 g (-3 SD). 
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At the age of six months a right-sided hemiparesis was noted. At the age of 16 years he 
has an intelligence quotient of 48, a dystrophic appearance with microcephaly and a right-
sided dystonic paresis. Brain MRI revealed left-sided cerebral atrophy with porencephaly 
and Wallerian degeneration of the brain stem (Fig. 2E, K, L, M). Ophthalmologic examina-
tion showed severe myopia with bilateral amblyopia and small optic discs, but no arteriolar 
tortuosity. Proband II-5’s prenatal course was complicated by maternal diabetes and intra-
uterine growth retardation. A caesarian section was performed at 31 weeks of gestation 
because of fetal distress. Cerebral ultrasound at birth showed a right-sided subependymal 
bleeding with venous infarction. At 6 months brain MRI revealed a porencephalic cyst 
and hypoplastic left cerebellar hemisphere (Fig. 2F, G). Physical examination at the age of 1 
year showed a left-sided hemiparesis and borderline microcephaly (-2 SD). Ophthalmologic 
examination, renal ultrasound and echocardiogram were normal. Screening for coagulop-
athies in the neonatal period showed a suspected protein S deficiency, but no analysis was 
repeated afterwards. The mother (I-2) has hypothyroidism. She was small at birth and had 
feeding difficulties. Ophthalmologic examination showed high myopia, astigmatism and 
tilted optic discs with some peripapillary atrophy. Permission for brain imaging was denied. 
She also delivered two daughters who died of complicated congenital hydrocephalus (sub-
jects II-1 and II-4). Brain MRI of one daughter (II-4) at the age of 2 months showed extreme 
hydrocephalus with periventricular cystic lesions, stenosis of the Sylvius aqueduct and 
periventricular, subcortical and cerebellar calcifications (supplementary Fig. S1). Another 
son (subject II-3) is mildly intellectually disabled with a total intelligence quotient of 62, a 
normal head circumference and normal brain MRI. Her last pregnancy was uneventful, 
was monitored by ultrasound and ended with the birth of a third daughter (subject II-6) 
in the 38th week. At birth cerebral ultrasound revealed a small intraparenchymal bleeding. 
The girl developed a mild hemiparesis, milder than the probands; her brain MRI revealed a 
small right-sided cerebral intraparenchymal cyst (supplementary Fig. S2). Extensive coagu-
lopathy screening at age of 2 years revealed a heterozygote protein S deficiency. 
Sequence analysis and expression data 
COL4A1 
DNA sequence of the 52 coding exons and intron-exon boundaries of COL4A1 in subjects 
III-1 and III-2 of family A and subjects II-5 and I-1 of family B was normal7. A maximum 
number of 13 heterozygote SNPs were observed in the sequence of each individual, which 
excludes the presence of large deletions in one of the COL4A1 alleles.
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COL4A2
Family A. DNA sequencing of part of the 5’ UTR and the 48 exons and intron-exon bound-
aries of COL4A2 was performed in subjects III-1, III-2, III-3 and II-2. In patient III-2, III-1 
and II-2 a heterozygous missense change, c.4165G>A in exon 44, leading to an amino acid 
substitution of glycine by arginine at position 1389 (p.G1389R) was found (Fig. 1C). COL4A2 
was normal in patient III-3. Glycine 1389 is part of the Gly-Xaa-Yaa repeat, which is essential 
for the proper folding of the triple helix18,24, and is highly conserved through species and 
among all the six collagen IV genes. In silico analysis by Polyphen-2 and SIFT prediction 
programs indicated this change as probably damaging.
Family B. Subjects II-2, II-3, II-5, II-6, I-1 and I-2 were tested. In probands II-2, II-5 and 
subject I-2 COL4A2 sequencing showed a heterozygous c.3206delC deletion in exon 34 
leading to a frameshift and premature stop at position +27 (Fig. 1D). The COL4A2 sequence 
was normal in subjects I-1, II-3 and II-6. No DNA was available from patient II-1 and II-4. 
RT-PCR of the COL4A2 transcript in patient II-2’s fibroblasts was performed. Only a tran-
script of the expected wild-type sequence was observed, compatible with degradation of the 
mutant mRNA by nonsense-mediated decay. Quantitative RT-PCR (RT-qPCR) of COL4A2 
and COL4A1 transcript in fibroblasts from the same patient was performed and confirmed 
diminished amount of COL4A2 compared to COL4A1 mRNA (Fig.1E). 
Skin transmission electron microscopy
Electron microscopy of the skin of patient II-2 from family B showed abnormalities of the 
epidermis-dermis junction with scattered thickening, blurring and duplications of the 
basement membrane (Fig. 3 B,C). These abnormalities were not observed in control skin 
(Fig. 3A) and are similar to those seen in COL4A1 patients8.
Test for ER stress response and apoptosis in cells with COL4A23206delC 
mutation 
The mouse Col4a1+/Δ ex40 mutation leads to synthesis of abnormal Col4a1 chains, which 
accumulate in the endoplasmic reticulum (ER) of lens epithelia. This accumulation acti-
vates the unfolded protein response (UPR), a well-known ER stress response preceding 
apoptosis20,25-26. Since the c.3206delC COL4A2 mutation predicts a null-allele and no such 
mutations have been described in human COL4A1 patients, we investigated the pathogenic 
mechanism of this mutation in cultured skin fibroblasts from proband II-2.  We wondered 
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whether ER stress could be induced by abnormal stoichiometry of COL4A1 and COL4A2 
chains, because of reduced COL4A2 synthesis.
ER stress response was analysed by staining fibroblasts with antibodies anti HSP47, a colla-
gen-specific chaperon protein, and anti KDEL, an ER stress marker specific for ER-retained 
proteins. If collagen chains accumulate in patient cells, then increased storage of HSP47 
can be expected25,26 . Under standard culture conditions, HSP47 staining was comparable in 
patient and control cells, suggesting no accumulation of unfolded collagen chains (Supple-
mentary Fig. S3) . Subsequently, we analyzed whether KDEL staining under standard and 
stress conditions, induced by DTT, would detect ER stress in patient cells. Under the DTT 
condition, we know that normal cells slightly increase susceptibility to apoptosis from 10 to 
18% Fig 4C and Supplementary Fig S5 )37. No clear signs of ER stress were detected by KDEL 
staining under DTT in the patient cells (Supplementary Fig S4)26. We then tested whether 
signs of expression of ER stress markers could be detected by western blot analysis using 
antibodies specific for IRE1, cleaved form of ATF6, CHOP, BiP  and by real time-PCR for 
XBP-1 splicing23.  We did not detect expression of the markers, in the patient cells, simi-
larly to a control cell line (Fig. 4A,B). As positive control, tunicamycin-treated control cells 
showed increased expression of markers, which means that the stress response was nega-
tive rather than below detection level. Since ER stress is supposed to trigger apoptotic cell 
death, we studied sensitivity of the cells to apoptosis under standard conditions and stress 
stimuli. Under stress induced by DTT, we observed an abnormally high percentage (>60%) 
of apoptotic cells in the patient compared to five control cell lines (Fig. 4C). No difference 
was observed in the absence of DTT treatment  (Supplementary Fig S5). We conclude that 
COL4A23206delC fibroblasts are more susceptible to apoptosis under stress condition, in vitro.
DISCUSSION 
Pathogenesis of COL4A2 mutations
Using the knowledge of the Col4a2 mouse model, we have used a candidate gene approach 
in our porencephaly families, and we provide evidence that COL4A2 mutations represent a 
novel genetic risk factor for haemorrhagic porencephaly and small vessel disease.  
We describe cerebral abnormalities including porencephaly, small-vessel disease in the 
form of scattered white matter lesions, carotid aneurysm, cerebellar and eye abnormalities 
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in two families, associated with two dominantly inherited changes in COL4A2 (G1389R, 
c.3206delC), all in the triple helix domain of the procollagen IV alpha-2 protein. Carotid 
aneurysm and cerebellar hypoplasia have been observed in a single mutation carrier respec-
tively in family A and B (Table 1), making a causal relationship possible but not definitive. 
Extensive data from several types of collagens have shown that missense and splice site 
mutations in the triple helix domain are highly pathogenic and particularly substitutions 
of the glycine at each third position (G-Xaa-Yaa) disrupt the triple helix structure, with a 
dominant negative effect. These missense mutations lead to abnormal assembly of the triple 
helix with intracellular accumulation of procollagen chains26. The stereotypical nature of 
pathogenic glycine missense mutations in collagens makes therefore mutation recognition 
relatively easy compared to other genes. Considering the cosegregation of the G1389R muta-
tion with the cerebrovascular disease we conclude that this mutation is involved in the 
pathogenesis of the porencephaly and white matter lesions observed in family A. 
The c.3206delC frame-shift mutation found in family B leads to loss of COL4A2 chain 
synthesis from one allele, however the pathogenic mechanism might be different from 
the G-Xaa-Yaa type of mutation, as it is predicted to cause a loss of function and null-al-
leles have not been described in patients harbouring COL4A1-mutations. In support of a 
pathogenic effect of the c.3206delC mutation, we observed an increased susceptibility to 
apoptosis and, in addition, EM of patient skin showed abnormalities of the epidermal base-
ment membranes, suggesting abnormal extracellular collagen-IV synthesis. Heterozygote 
truncating mutations have been already observed in collagen IV-related Alport syndrome, 
but null-alleles for either the C.elegans COL4A1 homologue, emb-9 and COL4A2 homo-
logue let2, cause disruption of the basement membrane and embryonic lethality although 
at a later stage than the G-Xaa-Yaa missense mutations27. 
The non-collagen (NC1) domain of collagen IV alpha-2, but not alpha-1 chain, promotes cell 
adhesion, outgrowth of embryonic neurons and is responsible for strict regulation of the 2:1 
stoichiometry of the triple helix18,28-30.
This could indicate that a disturbed ratio of procollagen alpha-1 and procollagen alpha-2 
chains due to a heterozygous null allele of either COL4A1 or COL4A2 may lead to a dis-
turbed or insufficient heterotrimer assembly and secretion. 
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The mechanism leading to stroke and porencephaly is presumably a decreased resistance of 
the vascular wall to increased mechanic stimuli. In the lens epithelia of Col4a1+/Δ ex40 mice 
accumulation of COL4A1 and COL4A2 in the endoplasmic reticulum (ER) induces an ER 
stress response, a known trigger of apoptosis26. Nevertheless, studies supporting this mech-
anism in human COL4A1 mutations are lacking. We observed increased susceptibility to 
apoptosis of c.3206delC patient fibroblasts, possibly related to ER stress, which anyhow 
could not be detected under our experimental conditions. Future studies are needed to 
address this discrepancy, which might be caused for example by the culture conditions 
compared to experiments performed in mouse tissues20,25. Apoptosis is an important mech-
anism regulating brain development and is involved in the onset of microcephaly31. Some of 
the COL4A2 patients are born microcephalic and the reason is not apparent at the moment, 
but it could be related to susceptibility of the developing brain to apoptosis37. It is also pos-
sible that, independently of the ER stress, COL4A2 and the apoptotic pathways are linked 
since they are developmentally co-regulated. In fact, it has been shown that micro RNA 
mir-29b represses expression of both COL4A2 and antiapoptotic Bcl-2 family member 
Mcl-1 during skeletal development32-33.  
COL4A2 mutation: phenotypic variation and reduced penetrance
COL4A1 and COL4A2 are ubiquitously co-expressed in the basement membrane of epi-
thelia and endothelia and from the observation of mouse Col4a1 and Col4a2 mutations, 
human COL4A1 and COL4A2 mutations could be predicted to result in cerebral bleeding. 
However, only COL4A1 mutations have been identified after linkage in large pedigrees3. 
One of the reasons could be the difficulty to recruit large families with similarly affected 
patients, because of phenotypic variability or reduced penetrance of COL4A2 mutations, 
similarly to other causes of stroke and aneurysm34, which makes linkage analysis quite 
difficult.  
We can assume reduced penetrance of the COL4A2 mutations in both our families. In 
family A subject II-2 has the G1389R mutation and is asymptomatic, but MRI revealed a 
carotid aneurysm, similar to the findings in an obligate carrier of COL4A1 mutation that 
we previously described7. In family B, we also observed an asymptomatic carrier (subject 
I-2) of the c.3206delC  COL4A2 mutation, who presents ocular anomalies but denied an 
MRI. Asymptomatic carriers have been observed also in COL4A1 mutation and although 
this has been interpreted as reduced penetrance of the mutation, extensive investigation has 
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often revealed hidden signs of the disease3, 7. However, considering the wide heterogeneity 
of symptoms, the contribution of other factors, besides the COL4A1 mutation, has been 
suggested as trigger of the pathogenic event3. 
In both our families, a wide intra-familial phenotypic variation has been observed, 
similar to COL4A1 mutations7. In Col4a1 mutant mice it has been shown that the genetic 
background is important to determine the phenotype, probably through the effect of mod-
ifying loci26. Col4a2 mutant mice present with cerebral porencephaly, microphthalmia, lens 
opacity, buphthalmos and renal anomalies, but in general with a milder phenotype com-
pared to Col4a1 deficient mice19.  
Interestingly, in family B we observed an individual (subject II-6), affected by a perinatal 
intraparenchymal bleeding leading to a cyst, who lacks the familial COL4A2 mutation 
(Supplemental figure S2) and additional children died at young age with severe cerebral 
hemorrhage and hydrocephalus, who were not tested for COL4A2 mutations. Subject II-6 
is heterozygote for protein S deficiency, which in itself has not been the cause of the bleed-
ing but might have contributed to the onset of the germinal matrix haemorrhage. As for 
COL4A1 mutation carriers, it is therefore possible that in this family additional factors have 
summed up and contribute to the phenotypic manifestation.
The particular fragility of the cerebral vessels in patients with either COL4A1 or COL4A2 
mutations remains unexplained in light of the ubiquitously expression of COL4A1 and 
COL4A2. However, it could reflect selective expression in subtypes of brain vascular endo-
thelia4. It has been shown that in the kidney expression of COL4A3, COL4A4 and COL4A5 
genes can be cell-type specific35-36. 
In summary, we observed that familial COL4A2 mutations could lead to a wide spectrum 
of cerebrovascular disorders including porencephaly, white matter lesions and possibly 
aneurysm and cerebellar hypoplasia, which might go undiagnosed because of reduced 
penetrance and variable expression. Additional risk factors may influence the course of 
cerebrovascular diseases in families with COL4A2 mutations. 
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Figure 1. Pedigrees of families A and B. 
Different symbols indicate individuals affected with various cerebral vascular disease as indicated in the legend. The 
genotype of the tested individuals is indicated: (A) 4165G/G = wild type sequence; 4165G/A heterozygous mutation; 
(B) 3206C/C = wild type sequence; 3206C/delC = heterozygous mutation. Electroferograms indicate the heterozygous 
mutation in the COL4A2 sequence of family A c.4165G>A (p.G1389R) (C) and family B c.3206delC leading to frame 
shift (D). Quantitative, real time PCR analysis showing relative expression of COL4A1 and COL4A2 mRNA in fibro-
blasts from patient II.2 (family B) with c.3206delC mutation (A2 patient) and a patient bearing a pathogenic c.3321G>C 
(p.G1067A) mutation in exon 38 of COL4A1 (A1 patient), compared to a control cell line. Results are average of two 
separate experiments. For each cell line the highest expression is set as 100% on the Y axis (E).  Position of the muta-
tions within the schematic representation of the COL4A2 genomic organization (F).
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Figure 2. Brain MRI of patients 
with COL4A2 mutations. 
A, B. Axial and coronal T2 of patient 
III.2 from family A at the age of 2 years 
indicate ex-vacuo dilation of the left 
lateral ventricle (porencephaly) (open 
arrow) and periventricular white matter 
lesions (solid arrows) resulting from pre-
sumed perinatal stroke. 
C. FLAIR image illustrates T2 prolon-
gation in the white matter – in patient 
III.1 from family A at the age of 8 years, 
suggesting gliosis (arrow). 
D. MR angiography of their mother 
(subject II.1, family A) at adult age shows 
bilateral internal carotid aneurysms (at 
the level of cavernous sinus). 
E. Axial T2 weighted images of Patient 
II.2, family B, at the age of 15 years show 
a porencephalic dilatation of the left 
occipital ventricle. 
F, G. Axial T2 weighted and coronal 
FLAIR images of patient II.5 from 
family B at the age of 5 months show 
porencephaly of the right ventricle with 
hypoplastic left cerebellar hemisphere. 
H-M. Reconstruction of the white 
matter tracts obtained from magnetic 
resonance diffusion tensor imaging 
(MR-DTI) data.
K,L. Patient II-2 (family B) reveals 
reduced fractional anisotropy in the left 
radiation optica and tractus corticospi-
nalis at the side of the porencephalic 
lesion (encircled), compared with an 
age-matched control 
H,I. A restriction of the total ADC was 
observed in the whole cerebral white 
matter of the patient (M), compared to 
an age-matched control (J). 
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Figure 3. Skin transmission electron microscopy. 
Upper arm skin biopsy of subject II-2 of family B was analysed by transmission electron microscopy according 
to Plaisier et al8 in double blind experiments by two investigators and independently scored. 
A. Control skin biopsy showing illustrative digitations (arrows) of the epidermis-dermis junction with normal 
basement membrane structure. 
B, C. Illustrative areas of the basement membrane of the epidermis-dermis junction in the patient shows areas 
of thickening, blurring, fragmentation and duplication, giving it at times a blebby appearance (arrows). 
Figure 4. COL4A2 c.3206delC mutation does not cause endoplasmic reticulum stress but 
reveals susceptibility to apoptosis. 
A. Western blot analysis for endoplasmic reticulum stress markers (IRE-1, cleaved form of ATF6, CHOP and 
BiP) was negative in patient II-2 (family B) and control skin fibroblasts. 
B. XBP-1 mRNA, which is spliced in response to endoplasmic reticulum stress, was evaluated by RT-PCR. 
Patient and control samples did not show detectable levels of spliced XBP-1. Tunicamycin treated cells were 
included as a positive control (+) in A and B. Untreated cells were used as a negative control (-). 
C. Mean percentage of apoptotic cultured fibroblasts after stress induction by dithiothreitol. WRS: fibroblasts 
from patient with mutation in EIF2AK3 gene with increased susceptibility to apoptosis37. COL4A2: cells from 
patient with c.3206delC mutation. Controls: fibroblast cell lines from 5 healthy individuals. Data are average of 
triplicate experiments. 
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SUPPLEMENTARY DATA
Methods of genomic analysis
Bioinformatics
COL4A1 accession numbers: NM_001845.4; OMIM *1201306.
COL4A2 accession numbers: CCDS41907; Entrez Gene ID 1284; OMIM *120090. Accord-
ing to sequence CCDS 41907, the starting codon is in exon 2 and we used this numbering of 
the exons in the text. Prediction of pathogenicity of the non-synonymous G1389R substitu-
tion was performed by Polyphen-2 (http://genetics.bwh.harvard.edu/pph/), SNAP (snap@
rostlab.org) and SIFT (http://sift.jcvi.org/) programs. All the programs reported the change 
as non-tolerated.
Here the Polyphen-2 scores are reported as probably damaging.
Sanger sequencing
Genomic DNA was isolated from peripheral blood by standard methods. All exons including 
surrounding boundaries of COL4A1 and COL4A2 were amplified by PCR and sequenced 
in both directions.
PCR reactions were carried out in 25 µl containing 1x Invitrogen PCR buffer, 1,5 mM MgCl2, 
0,01% W1 detergent, 0,2mM of each dNTP,  1µM both forward and reserve primer, 0,1 units 
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of Platinum Taq DNA polymerase (Invitrogen) and 50 ng genomic DNA.  Primer sequences 
and annealing conditions are available upon request.
Direct sequencing of both strands was performed using Big Dye Terminator chemis-
try version 3.1, electrophoresis on a ABI 3130 Genetic Analyzer and analysing with DNA 
Sequencing Analysis version 5.2 and SeqScape version 2.1 software (Applied Biosystems).
Fibroblasts from patients and controls were cultured in Dulbecco’s modified Eagle medium, 
supplemented with 10% Fetal calf serum and antibiotics. Total RNA was extracted and 
purified using Trizol reagent (Gibco BRL) according to manufacturer
RT-PCR was performed with 2µg RNA using SuperScript One-Step RT-PCR with Platinum 
Taq (Invitrogen), followed by PCR using overlapping primer-pairs (primer sequences and 
PCR conditions on request).
RT-qPCR  was performed using KAPA sybr fast qPCR mix (ABI prism) and the CFX96 Real 
Time System (Biorad), using ACTB and UBE2D2 as control housekeeping genes according 
to Verkerk et al 200921.
RTqPCR primers
COL4A1 
Primerpair 1;  GAAGGGTTTCCCCGGATTC  CCCGACTGTCCCGTTATGC 
Primerpair 2;  GAGGAGTTTAGAAGTGCGCCATT GGTGGCGAGCCAAAAGCT
COL4A2 
Primerpair 1; CCCTGTGGGCATGAAAGGT  TCCTTTAAATCCAGGGCTTCCT 
Primerpair 2; TGGGACAGATGGGTCCAGTT CAAGTCCTCTGTTGCCTTGCT
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Primer sequences used for COL4A2 sequences
Oligoname Oligo 
length
Oligo sequence
COL4A2 - 1F 36 tgtaaaacgacggccagtccaagcggagacctgagc
COL4A2 - 1R 38 caggaaacagctatgaccctactcccaagcaggagagc
COL4A2 - 2-3F 38 tgtaaaacgacggccagtgggaggctctccttctttcc
COL4A2 - 2-3R 37 caggaaacagctatgaccaacgtcccaaccactctcg
COL4A2 - 4F 40 tgtaaaacgacggccagtttggaaggattctcaacagatg
COL4A2 - 4R 38 caggaaacagctatgaccacagccgggtgtgtagtagg
COL4A2 - 5-6F 44 tgtaaaacgacggccagtccgtaactgatcatgagtatgtattg
COL4A2 - 5-6R 36 caggaaacagctatgacccctaggatgcacgcaatg
COL4A2 - 7F 45 tgtaaaacgacggccagttctcacagttacatgacaactagaagc
COL4A2 - 7R 38 caggaaacagctatgacccagttatgcttccgttctgg
COL4A2 - 8F 38 tgtaaaacgacggccagtgctgcaccgaatgttaatgg
COL4A2 - 8R 38 caggaaacagctatgaccgattatgccgccattctagg
COL4A2 - 9-10F 39 tgtaaaacgacggccagtgggctgatctgtttgatatgc
COL4A2 - 9-10R 38 caggaaacagctatgaccaagaagtggcatctggaagg
COL4A2 - 11F 38 tgtaaaacgacggccagttcagaaacctccatgcatcc
COL4A2 - 11R 40 caggaaacagctatgacctttgcaaacaacaaatcattcc
COL4A2 - 12F 37 tgtaaaacgacggccagtgccgataaataggccttgg
COL4A2 - 12R 39 caggaaacagctatgaccggtgacaacctagcactttgc
COL4A2 - 13F 40 tgtaaaacgacggccagtggccaggttgtatttgtattcg
COL4A2 - 13R 36 caggaaacagctatgaccgccaagttggtggtgagg
COL4A2 - 14F 42 tgtaaaacgacggccagtgaggattgattcagtactttcagc
COL4A2 - 14R 37 caggaaacagctatgacccatctccatgctcccttcc
COL4A2 - 15F 38 tgtaaaacgacggccagtgggctgagaacacagagtcc
COL4A2 - 15R 38 caggaaacagctatgaccatggttcacggattgtagcc
COL4A2 - 16F 40 tgtaaaacgacggccagtgacttgttcaatctgtccatcg
COL4A2 - 16R 38 caggaaacagctatgacctctttcctgagatgccaagg
COL4A2 - 17F 38 tgtaaaacgacggccagtgctcctggttctagcaaagc
COL4A2 - 17R 38 caggaaacagctatgaccgtcagaggccgtgtatttgg
COL4A2 - 18F 37 tgtaaaacgacggccagtgctcgggtttcttctttgg
COL4A2 - 18R 38 caggaaacagctatgaccaggactgtctcaggcacagg
COL4A2 - 19F 38 tgtaaaacgacggccagtacagcatatggagcatttgg
COL4A2 - 19R 38 caggaaacagctatgaccagggttctgtgaaggtgtcc
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Oligoname Oligo 
length
Oligo sequence
COL4A2 - 20F 38 tgtaaaacgacggccagtacccatcggagttattgacg
COL4A2 - 20R 38 caggaaacagctatgacctcactggcctactggattcg
COL4A2 - 21F 36 tgtaaaacgacggccagtatgccctgcatctgtggt
COL4A2 - 21R 38 caggaaacagctatgaccggggatggatttcaccttct
COL4A2 - 22F 38 tgtaaaacgacggccagtcatcagaacaggcagtgtcc
COL4A2 - 22R 36 caggaaacagctatgaccgtgttgccggtctgaagc
COL4A2 - 23-24F 36 tgtaaaacgacggccagtttggtgacgggtgactgc
COL4A2 - 23-24R 38 caggaaacagctatgacctgcacaggttggtttagtgc
COL4A2 - 25F 38 tgtaaaacgacggccagtgaaaggaaacagggaagtcg
COL4A2 - 25R 41 caggaaacagctatgaccggaaacgtctacactgacaaagg
COL4A2 - 26F 38 tgtaaaacgacggccagtacgacacaccttcacacacg
COL4A2 - 26R 37 caggaaacagctatgaccccacgcatactgcaagagc
COL4A2 - 27F 37 tgtaaaacgacggccagtagaatggtagccggtttgc
COL4A2 - 27R 37 caggaaacagctatgacctggacacgaccatgtctgg
COL4A2 - 28F 38 tgtaaaacgacggccagtgtcagatgccaagcatgacc
COL4A2 - 28R 38 caggaaacagctatgaccaatctcccaaggacaaatgc
COL4A2 - 29F 42 tgtaaaacgacggccagttgactcttctcttagaacgtcacc
COL4A2 - 29R 38 caggaaacagctatgacccgctgcttcctaccaaatcc
COL4A2 - 30F 38 tgtaaaacgacggccagtgagtgtgtggagggagatgc
COL4A2 - 30R 39 caggaaacagctatgaccagctccacaagaagacagtgc
COL4A2 - 31F 38 tgtaaaacgacggccagtccacactttggaaactcacc
COL4A2 - 31R 37 caggaaacagctatgaccccagcagagctgtctcagg
COL4A2 - 32F 37 tgtaaaacgacggccagtccgaaatgttacggagacg
COL4A2 - 32R 38 caggaaacagctatgaccgccaccaagaaagggtaagg
COL4A2 - 33F 38 tgtaaaacgacggccagtggccttcacctgtgttctcc
COL4A2 - 33R 38 caggaaacagctatgaccggaaaccgaggttactcagg
COL4A2 - 34F 38 tgtaaaacgacggccagtttcacagcacgtaggacagc
COL4A2 - 34R 38 caggaaacagctatgacctgtccattcacaagcaaagg
COL4A2 - 35F 42 tgtaaaacgacggccagtcaaaccttgagtattgtcgttagc
COL4A2 - 35R 38 caggaaacagctatgacctctgaaattggctcacatgc
COL4A2 - 36F 39 tgtaaaacgacggccagtagacctgcaagtgctgttagg
COL4A2 - 36R 38 caggaaacagctatgaccttgatctgtttggcaagtcg
COL4A2 - 37F 39 tgtaaaacgacggccagttggttctgcacatcctagagc
COL4A2 - 37R 36 caggaaacagctatgaccagggttgggtgtgattgg
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Oligoname Oligo 
length
Oligo sequence
COL4A2 - 38F 40 tgtaaaacgacggccagtcctgtgtgctcagacttaatgc
COL4A2 - 38R 38 caggaaacagctatgaccagaagtcgccctgagagagg
COL4A2 - 39F 36 tgtaaaacgacggccagttttctcccacccagaacc
COL4A2 - 39R 37 caggaaacagctatgaccctctgagaccctccattcc
COL4A2 - 40F 37 tgtaaaacgacggccagtgctgcctctgtttctttgc
COL4A2 - 40R 38 caggaaacagctatgaccgctctttcctgcacttctgc
COL4A2 - 41F 37 tgtaaaacgacggccagtcactgtctcgctcgctagg
COL4A2 - 41R 39 caggaaacagctatgaccaggtgatggaaatgacacagg
COL4A2 - 42F 38 tgtaaaacgacggccagtagagactgtcgcctgaatgg
COL4A2 - 42R 38 caggaaacagctatgaccagggacacgaaagtctgtgg
COL4A2 - 43F 36 tgtaaaacgacggccagtcctggccacagtgagagg
COL4A2 - 43R 37 caggaaacagctatgaccgtgacccatgccagagagg
COL4A2 - 44F 38 tgtaaaacgacggccagtagcacagttgtctgggaagc
COL4A2 - 44R 40 caggaaacagctatgacctccacaaagagaacacaagagg
COL4A2 - 45F 40 tgtaaaacgacggccagtcttgtgttctctttgtggatcg
COL4A2 - 45R 38 caggaaacagctatgaccgctgggcataggagtgtagc
COL4A2 - 46F 38 tgtaaaacgacggccagtggggctgctctctctctctt
COL4A2 - 46R 38 caggaaacagctatgaccctttgatcttggccacttcc
COL4A2 - 47F 39 tgtaaaacgacggccagttccagtaggtggctaaactcc
COL4A2 - 47R 38 caggaaacagctatgacccagctgttcttgctgtgtcc
COL4A2 - 48F 38 tgtaaaacgacggccagttgcacagaagagggctatgc
COL4A2 - 48R 38 caggaaacagctatgaccCTGGATGCAAATTCCTTTGG
Immunofluorescence staining for ER stress detection
Immunofluorescence using antibodies directed against cytochrome P450, HSP47 and KDEL 
was performed on fibroblasts (3 control and 1 patient). The cells from patient II-2 family B 
with COL4A23206delC and 3 control cell lines were seeded onto glass coverslips in a 6 well 
plate, approximately 150 000 cells per well and maintained with Dulbecco’s modified Eagle 
essential medium (DMEM) plus 10% fetal calf serum (FCS). After 24 hours of serum depri-
vation followed by 24 hours exposure to 5mM DTT the cells were fixed in cytoskelfix-20 
(Cytoskeleton) for 10 minutes and washed three times in PBS. The cells were then blocked 
blocking buffer (0.05 M Tris; 0.9 NaCl; 0.25% gelatine;0.5% Triton X100, PH 7.4) and probed 
overnight at 4 degrees with primary antibodies,  KDEL Mouse Monoclonal antibody  raised 
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against a 6 residues synthetic peptide(Stressgen 10C3 1/100) and Cytochrome P450 Rabbit 
polyclonal antibody  raised against the full length P450 1A1 fusion protein (abcam ab3568, 
1/100), or Mouse Monoclonal Antibody Hsp47 raised against full length Hsp47 (stressgen 
M16.10A1 1/50). The samples were then incubated with Cy3-coupled secondary anti-mouse 
antibodies and Cy2-coupled anti-rabbit antibodies (Jackson ImmunoResearch, 1/200) 
for 1 hour at room temperature. Cells were mounted on slides with fluorescent mount-
ing medium (DAKO). Fluorescent images were collected using AXip-Axioplan2 imaging 
microscope (Zeiss) with COOLSNAP-pro camera (Zeiss). 
ER stress tests and susceptibility to apoptosis in cultured fibroblasts
Western blot analysis for endoplasmic reticulum stress markers (IRE-1, cleaved form of 
ATF6, CHOP and BiP) was performed in skin fibroblast cultures of patient II-2 (family B) 
and control skin fibroblasts. . For Western blot, protein lysates from skin fibroblast cells 
(70 mg) were separated by SDS-PAGE and transferred to PVDF membranes. Membranes 
were blocked with 5% non-fat milk for 1 h at room temperature and incubated with anti-IRE1 
(1:2000) (Abcam), anti-ATF6 (1:1000) (Abcam), anti-CHOP (1:250) (Abcam), or anti-BiP 
(1:2000) (Cell Signalling) antibodies in blocking buffer overnight at 4°C. After incubation 
with secondary antibodies conjugated to horseradish peroxidase (Jackson ImmunoRe-
search) for 1 h at room temperature, the signals were visualized using an ECL detection kit 
(Thermo Scientific). XBP-1 mRNA, which is spliced in response to endoplasmic reticulum 
stress, was evaluated by RT-PCR, before and after treatment with 5 microgram/mL tunica-
mycin. RT-PCR XBP-1 splicing analysis was according to Lin et al, 200723.
Susceptibility to apoptosis of cultured skin fibroblasts was measured by fluorescent staining 
of  active caspases using the FlicaTM (Fluorescent-Labeled Inhibitor of CAspases) apoptosis 
multi-caspase detection kit (Immunochemistry Technologies, LLC), which makes use of an 
inhibitor sequence of active caspases, according to the manufacturer instruction. Fluores-
cent cells were scored before and after stress induction by 24 hours serum deprivation and 
then a further 24 hours exposure to 5 mM dithiothreitol (DTT) by two blinded investiga-
tors (CP and RS) as percentage of apoptotic fibroblasts in separate triplicate cultures derived 
from one patient bearing the c.3206delC mutation (II-2, family B), one patient affected by 
Wolcott-Rallison syndrome (OMIM 226980) bearing an EIF2AK3 mutation and 5 healthy 
individuals. Wolcott-Rallison mutations are a known to cause increased susceptibility to 
apoptosis. Necrosis vs apoptosis was tested by vital staining exclusion with PI or 7 AAD. 
The patient with the EIF2AK3 mutation has been described by Poulton et al, 201137.  
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Electronmicroscopy of the skin
For routine transmission electron microscopy the material was fixed in 1% v/v and 4% v/v 
formaldehyde. After complete dehydration in acetone and embedding in Epon the sections 
of 50 nm were made on a Leica Supercut UCT.
The ultra thin sections were collected on 200 mesh formfar filmed copper grids and stained 
with uranyl acetate and lead citrate and examined with a Fei Morgagni 286 electron micro-
scope. Two investigators JdH and GMM independently scored the preparations in double 
blind against three control skin preparations, according to Plaisier et al8.
Supplementary figure 1. Axial T2 weighted MRI images of the brain and cerebellum of 
patient II-4 of family A at the age of 3 months, showing (left panel) hydrocephalus with 
hemosiderine residues in the occipital ventricles and (right panel) subcortical calcification 
in the right cerebellar hemisphere suggestive of massive bleeding. No DNA was available 
for testing. 
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Supplementary Figure 2. FLAIR Coronal MRI section of patient II-6 from family A at birth, 
showing a small cyst in the right parietal lobe adjacent to the lateral ventricle. In her DNA the 
familial c.3206delC COL4A2 mutation was absent.
Supplementary Figure 3. Cultured fibroblasts grown under standard conditions . Immunofluo-
rescent staining for HSP47 (red). A: control; B: patient with COL4A23206delC  mutation.
A B
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Supplementary Figure 4. Cultured fibroblasts after treatment with 5 mM DTT. Immunofluo-
rescent staining for P450 (red), KDEL (green). A and B: control 1. C: merged picture of A and 
B. D,E.F: merged pictures of double staining with KDEL and P450. D: control 2; E: control 3; 
F: patient with COL4A23206delC  mutation.
A B
C D
E F
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Supplementary figure 5. Skin fibroblasts were cultured in 175 cm2 culture flasks in Dulbec-
co’s modified Eagle medium (DMEM, Lonza Biowhittaker) plus 10% FCS until 80% confluence. 
Cultures were obtained from 5 healthy individuals (control), one patient with COL4A23206delC 
mutation (patient) and one individual with confirmed Wolcott-Rallison syndrome bearing an 
EIF2AK3 mutation (WRS) . Before testing apoptosis rates by the Flica multicaspase detection 
kit, the cells were exposed 24 hours to serum deprivation. Data are average of multiple experi-
ments plus SD, as indicated in the methods.
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GENER AL DISCUSSION
In 2007, when this project started, the COL4A1 gene had just been identified as a cause of 
familial porencephaly; it was the first time that isolated prenatal or infantile cerebral intra-
parenchymal hemorrhage, independently of metabolic diseases and coagulopathies, was 
proven to result from a single gene mutation. Before the identification of COL4A1, cases 
of prenatal or infantile isolated cerebral hemorrhage were attributed to extrinsic factors, 
such as prematurity, very low birth weight or infection. The work in this thesis contributes 
to the concept that, besides external factors, several monogenetic factors can underly pre-
natal or infantile/ childhood cerebral hemorrhage. It started by expanding the phenotypic 
spectrum and inheritance mode in COL4A1 mutations, and continued by the identification 
of COL4A2 mutations as a novel genetic cause of cerebral hemorrhage and porencephaly. 
The description of cerebrovascular pathology of a well-known syndrome, Incontinentia 
Pigmenti, and of a newly identified syndrome, which is caused by ACTA2 mutations chang-
ing the R179 amino acid adds to the phenotypic spectrum of childhood cerebrovascular 
disease. Finally, an extensive study in five young patients with cerebral hemorrhage, a pseu-
do-TORCH syndrome and early demise led to the identification of USP18 mutations as a 
novel monogenetic cause of cerebrovascular disease with systemic manifestations. 
Crucial for our identification of new genetic factors in prenatal or infantile/childhood 
stroke, such as COL4A2 and USP18, was the multidisciplinary cooperation between the 
Departments of Clinical Genetics, Child Neurology, Neonatology and Neuroradiology.  An 
approach of early (genetic) consultation of a baby born with cerebral hemorrhage together 
with adequate classification of the type of cerebral pathology,  followed by follow-up in a 
multidisciplinary outpatient clinic proved very efficient in enrolling patients in our research 
project in the diagnostic process of prenatal and/ or neonatal cerebral hemorrhage. Multi-
centre cooperation with other University Medical Centers in The Netherlands was essential 
for our work. 
COL4A1 and COL4A2 mutations
Incidence of COL4A1 and COL4A2 mutations
Our results show the identification of 21 COL4A1 and 3 COL4A2 mutations in a group of 
183 index patients tested at the Dept. of Clinical Genetics of the Erasmus University Medical 
Center Rotterdam, mostly referred for porencephaly or cerebral hemorrhage. This cor-
relates with COL4A1 or COL4A2 mutations in 13% of index patients. A recent study did not 
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show COL4A1 mutations in a cohort of 224 infants with low birth weights (500-1250 g) and 
grade 3-4 intraventricular hemorrhage1. A previous study in a group of 41 preterm infants 
presenting with intraventricular hemorrhage showed one COL4A1 mutation in dizygotic 
twins, born at 24 weeks’ gestation. This was a 6 bp duplication in the NC1-domain, carried 
by an asymptomatic mother and grandmother.  In a cohort of 96 sporadic patients with 
intracerebral hemorrhage not caused by arteriovenous malformations, tumors or impaired 
coagulation, COL4A1 and COL4A2 were tested, leading to the detection of 2 COL4A1 
pathogenic mutations in 2 patients and 3 COL4A2 mutations in 4 patients2,3. These findings 
suggest that COL4A1 and COL4A2 mutations contribute to approximately 6% of sporadic 
late onset intracerebral hemorrhage. These cases may reflect “milder” mutations, since the 
“classic” glycine changes in the adult onset patients have not been identified in this group.  
One of the main conclusions from our review is that the mutations with onset in the 
perinatal period can be associated with developmental defects, such as microphthalmia, 
schizencephaly, hydranencephaly and renal agenesis. Whether these developmental defects 
should be considered as disruptions or malformations is a matter of discussion. 
In summary, the chance of identifying COL4A1 and COL4A2 mutations in extremely pre-
mature infants and infants with very low birth weight seems small. We don’t suggest testing 
until 30 weeks’ gestation, unless the cerebral hemorrhage occurred prenatally without iden-
tifiable causative factors. COL4A1 and COL4A2 testing in infants with porencephaly and/ 
or intracerebral hemorrhage is recommended, since our data show COL4A1 or COL4A2 
mutations in 13% of index patients. Routine testing of  COL4A1 and COL4A2 in adult onset 
stroke seems reasonable; based on the current (limited) data approximately 6% of sporadic 
intracerebral hemorrhage cases might be explained by COL4A1 or COL4A2 mutations. 
Pathogenic mechanisms of COL4A1 and COL4A2 mutations
The general pathogenic mechanism in COL4A1 and COL4A2 mutations is presumed to be 
basement membrane dysfunction. Both COL4A1 and COL4A2 are ubiquitously expressed, 
and can be found in the basement membranes throughout the body. Abnormal basement 
membranes are demonstrated also in tissues that seem unaffected by the mutation, i.e. in 
oesophagus in mice4 or in skin in human patients5-7. The latter is also observed in asymp-
tomatic mutation carriers7. COL4A1 and COL4A2 are major components of all vascular 
basement membranes. One question that remains unanswered is why the vascular pheno-
type of COL4A1 and COL4A2 mutations is most often present in the cerebral vasculature 
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and eye. Of course, one explanation may be a biased testing for COL4A1 and COL4A2 
mutations, limited to patients with cerebrovascular disease. However, to date, family his-
tories of index patients are not suggestive of other vascular pathologies associated with 
mutations. This suggests an additional function and/ or a different interacting environment 
of COL4A1 and COL4A2 in cerebral vasculature or differences in anatomic structures. 
One factor that likely contributes to the predominance of the cerebral phenotype is the 
fragility of the germinal matrix. Most cases of congenital porencephaly originate from 
a germinal matrix hemorrhage with subsequent venous infarction and tissue destruc-
tion, eventually followed by cyst formation. At term gestation, the germinal matrix has 
a subependymal location and contains immature vascular structures. A pathology study 
investigating the origin of germinal matrix hemorrhage indicates that the hemorrhagic foci 
within the germinal matrix tissue were in proximity to venous vessels. The venous vessels 
were all distorted with a loss of structural integrity8. Since the germinal matrix is a fragile 
structure in itself, with immature basal lamina, incomplete glial support and poor matrix 
support, prematurity is an important risk factors for germinal matrix hemorrhage8,9. One 
can postulate, however, that the basement membrane changes in COL4A1 and COL4A2 
mutations increase the loss of structural integrity of the germinal matrix veins, leading to 
an increased risk of hemorrhage in this specific location.
Another theory may be that COL4A1 mutations lead to an altered expression of occludin, 
a major component of tight junctions. COL4A1 plays a regulating role in the formation of 
the tight junctions and the expression of occludin10. The tight junctions play an important 
role in the formation of the blood-brain barrier. Dysfunction of the blood-brain barrier has 
been identified as a cause of cerebral hemorrhage and cerebrovascular disease, i.e. as seen 
in homozygous mutations in occludin itself and in JAM3 mutations11,12. Thus, COL4A1 
mutations may lead to less occludin expression, leading to weakening of the tight junctions 
in the blood-brain barrier and the cerebrovascular phenotype of hemorrhage and small 
vessel disease. 
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Counseling issue
Another important issue regarding COL4A1 and COL4A2 mutations to date is the pheno-
typic variability with reduced penetrance. Besides the HANAC phenotype, with mutations 
in exons 24 and 25 of the COL4A1 gene, which affect the CB3[IV] fragment of COL4A1 
and encompasses a specific integrin-binding site5,13, no genotype-phenotype correlations 
can be made. A high percentage of de novo mutations is identified, and de novo mutations 
appear to have phenotypes in the severe end of the spectrum14. However, severe phenotypes 
can also be appreciated in familial cases. It is therefore not possible to predict the pheno-
type based on the type and location of the mutation. A recent study on an affected child 
with porencephaly and asymptomatic father both carrying a G702D mutation in COL4A2 
interestingly shows basement membrane defects in both carriers, but retention of COL4A2 
in the ER was unique to cells of the affected child. In the child, ER stress and an increased 
apoptosis was present, which were both absent in cells of the asymptomatic father. This 
implicates that, theoretically, the ability of cells to cope with mutant collagen folding and 
ER-retention is dependent on critical, yet unknown modifiers7. The variable phenotypes 
and reduced penetrance are factors that complicate genetic counselling of affected families. 
Future studies on the role of additional modifying factors are therefore needed.   
Possible therapeutic options in COL4A1 and COL4A2 mutations
Treatment of the cultured cells from the same child harbouring the COL4A2 G702D muta-
tion with 4-phenylbutyrate (PBA), a chemical chaperone that can reduce ER stress levels, 
led to a reduced intracellular accumulation of COL4A2 and a decrease in ER volume, as 
well as a decrease in ER stress and UPR  markers and reduced levels of apoptosis7. This may 
be due to an increased protein folding in the ER. Also ascorbic acid (Vitamin C precursor) 
has been shown to improve protein folding, secretion and extracellular deposition of type 
IV collagen in cell cultures15,16. These are interesting findings, however, these results were 
only obtained in an in vitro system. The question whether this would be a future treatment 
option suitable in human disease caused by mutations leading to protein misfolding will 
need further investigation. The problem will mainly be to design an elective chemical chap-
erone that does not interfere with overt post-translational modification.
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USP18 mutations
USP18 mutation phenotype
We identified a new autosomal recessive syndrome due to USP18 mutations, associated 
with severe cerebral hemorrhage and “pseudo-TORCH” syndrome. The family in which 
we identified the first USP18 mutations came to our attention due to the presence of severe 
cerebral hemorrhage in the absence of a COL4A1 or COL4A2 mutation. Essential features 
of the affected individuals were extensive cerebral hemorrhage, presenting either prenatally 
or soon after birth, and early demise. The hemorrhage was predominantly located in the 
area of the basal ganglia, brain stem, cerebellar peduncles and lateral ventricles. Additional 
features were cerebral calcifications, extensive periventricular white matter abnormalities 
and cortical necrosis. It was not until the identification of the second family that we appre-
ciated additional features as clear parts of the phenotypic spectrum. Besides the cerebral 
phenotype, thrombocytopenia, liver failure with ascites and severe respiratory problems 
were overlapping features. Novel findings in the second family were unilateral diaphrag-
matic paresis, thin ribs and cervical and axillary calcifications. These findings indicate that, 
although the cerebrovascular phenotype is most prominent, USP18 mutations cause a sys-
temic disorder. This is in line with the wide expression of USP18, with expression in heart, 
liver, lung, heart, kidney, thymus, spleen, pancreas, bone marrow and brain. However, the 
brain seems to be particularly susceptible. The identification of USP18 mutations with high 
recurrence risk provides the possibility of counselling to the families and prenatal diagno-
sis. 
Both mouse Usp18 knockout models and findings in a patient from our first family indi-
cate ependymal pathology underlying at least part of the cerebral phenotype. Ependymal 
pathology and alterations of the subventricular zone have been described in several mouse 
models with hydrocephalus, cerebral hemorrhage and/ or neuronal migration defects17-24 
and were also identified in human foetuses with a communicating hydrocephalus25, sudden 
infant death syndrome26 and foetal spina bifida aperta27. However, to our knowledge, this 
is the first example of a human gene mutation where the ependymal layer is primary 
involved. It is possible that milder mutations leading to reduced USP18 expression may lead 
to prolonged survival, or, in line with the mouse models, to ependymal dysfunction with 
hydrocephalus due to Silvii aqueduct stenosis. Screening of hydrocephalus patient cohorts 
for USP18 mutations might therefore be warranted.
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Pathogenic mechanisms of USP18 mutations 
USP18 is expressed after IFN type I signalling and acts an inhibitor of the IFNAR-2 recep-
tor. It has an important function in the suppression of the activation of the innate immune 
response, probably in order to reduce toxic effects secondary to this activation in the vul-
nerable brain tissue. 
Differential diagnostic considerations in our patients were a congenital viral infection or 
Aicardi-Goutières syndrome, a known cause of “ pseudo-TORCH” syndrome. The IFN type 
I signalling pathway is also a common pathway involved in these groups of disorders. Upon 
viral infection, an increased IFN type I signalling is observed, leading to an inhibition viral 
replication within the cells. In Aicardi-Goutières syndrome, an inadequate processing of 
cellular nucleic acid debris  eventually triggers the innate immune response, leading to 
induction of IFNα expression and again to an upregulation of the IFN type I signalling 
pathway that in turn leads to cerebrovascular damage28,29. In Aicardi-Goutières syndrome, 
this effect is indirect and the exact mechanism that leads to the upregulated IFN type I 
signalling is not clear. 
USP18 mutations underly a new cerebrovascular disorder with a direct link to the IFN type 
I signalling pathway. USP18 normally functions as a sort of feedback regulator of the IFN 
signalling pathway. As a consequence, in the absence of USP18 the IFN type I signalling 
pathway might be up-regulated. Usp18 mouse knockouts die of hydrocephalus and cerebral 
hemorrhage because of the loss of inhibition of the IFN type I signalling. This mechanism, 
rather than the lack of deISGylation, seems to be the underlying cause of cerebral pheno-
type. However, further studies in humans are needed to address this question. It will be 
interesting to test whether USP18 interacts with the known genes for Aicardi-Goutières, 
which are known to regulate RNA turnover. This question could be approached by testing 
double knock-out animal models or by in vitro proteomics and protein interaction analysis.
Incidence of USP18 mutations
The incidence of USP18 mutations is yet unknown. A review of brain imaging data of 555 
patients admitted to the Dept. of Neonatology with infantile cerebrovascular disease failed 
to identify additional patients with brain phenotypes resembling our patients harbouring 
USP18 mutations. In addition, although the number is small, sequencing of USP18 in a 
cohort of 38 patients with isolated prenatal or infantile cerebral hemorrhage patients did 
not show mutations. 
General discussion 201
Possible therapeutic options in USP18 mutations
For USP18 mutations, interfering in the IFN type I signalling pathway may be a the-
oretically interesting therapeutic approach. IFN type I signalling is also abnormal in 
Aicardi-Goutières syndrome and pathways abnormalities are reflected in specific “inter-
feron signatures” in patient blood30. Mutations in TREX1 can cause both AGS and systemic 
lupus erythematosus (SLE), a common auto-immune disorder with an upregulated IFN 
type I signalling. For SLE, one of the therapeutic options under development is specific 
targeting of the IFN type I signalling pathway. Anti-IFNα monoclonal antibody and an 
IFNα vaccine are used in therapeutical trials31. Another option under development for 
SLE is to use an inhibitor of the IFNAR receptor31. Recently, the BRISC-SHMT complex 
was identified, that localizes to the IFNAR1 and deubiquinates actively engaged IFNAR1. 
This limits its internalization and lysosomal degradation. BRISC deficient cells and mice 
show decreased (but not absent) responses to IFN and seem protected from IFN-associ-
ated immunopathology32. In case of a similar dysregulation of the IFN type I signalling in 
USP18 mutations, a similar therapeutic approach may be justified. 
The question remains whether interference in the IFN type I signalling pathway in the 
USP18 group of patients is a realistic treatment option. Due to the early, even prenatal, 
onset of symptoms, it seems unlikely that the occurrence of symptoms can be prevented. A 
possible slowing of disease progression might be expected, however, whether this will influ-
ence the quality of life of patients in a positive manner remains to be elucidated. However, 
our patients are likely to represent the severe end of the USP18 mutation spectrum. When 
milder phenotypes related to USP18 mutations might be identified, these possible thera-
peutic options may become more realistic. The first therapeutic trials might therefore be 
performed in animal models, for example a transgenic mouse with a milder Usp18 muta-
tion. When treatment options would appear to be present, it is to be expected that a lifelong 
treatment is warranted.     
Genetics of perinatal hemorrhagic stroke and in general cerebrovascular 
disease: Future perspectives
A proper clinical stratification has been instrumental and will be essential in order to 
find genetic factors in childhood cerebral hemorrhage. This requires a multidisciplinary 
approach involving clinical genetics, radiology, neonatology and child neurology. 
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Next generation sequencing (NGS) will increasingly be applied as first tool to identify novel 
genes for these disorders. The challenge remains to prove pathogenicity of identified vari-
ants. Since the mouse model of USP18 mutations proved crucial in the interpretation of the 
identified mutations in our family, the use of known mouse models with cerebral hemor-
rhage may help in data analysis of future patients. Several mouse models exist that show 
cerebral hemorrhage, with knockout of genes that have no matching human phenotypes to 
date (Table 1). 
When mutations in novel candidate genes of unknown function are identified, animal 
models in order to prove pathogenicity will prove invaluable. For cerebral hemorrhage, 
zebrafish models have already proven to be efficient in this respect. A high similarity exists 
between the anatomical form of the developing vasculature and molecular mechanisms 
underlying vessel formation of the zebrafish and humans. By using morpholinos, synthetic 
oligonucleotides of 25 basepairs that can disrupt translation of a specific gene, the effect of 
knockdown of the candidate gene on cerebral vasculature can be studied. The zebrafish has 
been used as an animal model for cerebral hemorrhage, e.g. due to mutations in hereditary 
cerebral cavernous malformations33,34.
In the ideal setting, facilities for high throughput functional studies need to complement 
high throughput genomic analysis tools in order to accelerate the discovery of genetic 
factors in childhood cerebrovascular disorders and ultimately to improve patient care.   
Concluding remarks
In summary, our findings provide additional evidence that genetic mutations can cause a 
broad range of cerebrovascular diseases at young age.
The aim of this study was to describe the spectrum of collagen IV related disease and to 
identify the genetic cause of cerebrovascular disorders at young age, particularly of the 
poorly understood perinatal hemorrhagic stroke. After starting the work, it soon became 
clear that the phenotypic spectrum of the collagen IV disease is much wider than poren-
cephaly, that the genetic cause of hemorrhagic stroke at young age is highly heterogeneous 
and largely undiscovered, that in the perinatal period developmental defects often inter-
mingle with vascular disorders and that genetic causes can underly phenotypes leading to 
both arterial hemorrhagic and ischemic stroke.  
General discussion 203
It can therefore be difficult to classify these disorders when they affect foetuses, newborns 
and young children according to criteria used for adult stroke. I will support this conclu-
sion by some examples.
1. The spectrum of COL4A1 and -2 mutation indicates that the disorders are not restricted 
to congenital porencephaly but can include a wider cerebrovascular disorder, with diffuse 
white matter involvement and functional deficits that go beyond the focal lesions of the 
hemorrhage and even including developmental defects in multiple organs. As shown in 
chapter 4.1, practically the whole brain can be destroyed in the process, or, as described in 
chapter 4.2, the brain can be relatively spared while other organs, such the eyes, can totally 
lack normal structure and lose their function. 
2. In porencephaly caused by COL4A1 and -2 mutations, a presumably early (pre- peri- or 
early postnatal) hemorrhage leads to secundary venous infarction: the occurrence of these 
two events indicates that the border between arterial versus venous and hemorhage versus 
infarct can be blurred. The same can be postulated for the disease caused by ACTA2 muta-
tions (chapter 2.1). Originally ACTA2 mutations have been linked to thoracic aneurysms. 
We show, confirming earlier literature data that mutations in specific amino acids (R179) 
in the protein lead to a totally different systemic disorder with vascular and central and 
peripheral nervous system involvement and no evidence for aneuryms, hereby underscor-
ing the extreme variability of the disorder.
3. In animal models, Usp18 null-mutations cause stenosis of the aqueduct of Sylvius, 
ependymal necrosis and hydrocephalus, while in our family 1 the disorder appears to 
be systemic and to cause essentially early intrauterine haemorrhage and severe cerebral 
destruction, while in the second family, besides destructive lesions, also cerebellar hypopla-
sia and cortical gyral abnormalities were found. The best classification of the human USP18 
“null-disorder” is within pseudo-TORCH syndrome, with a clear hemorrhagic component, 
but we expect that milder mutations might be found among patient with aqueduct stenosis 
and or cerebellar hypoplasia, with or without hemorrhage. 
In Figure 1, the known causes of perinatal, infantile and childhood cerebral hemorrhage 
are summarized. Considering the overlap between the clinical phenotypes of the different 
disorders, it may be useful to develop a targeted NGS panel for perinatal, infantile and 
childhood cerebral hemorrhage. 
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In clinical practice, we still encounter neonates with cerebral hemorrhage, with similar 
brain findings to e.g. COL4A1 and COL4A2 mutations, without clear cause. We there-
fore presume that more, probably rare, genetic contributing factors are to be found. The 
identification of these factors is a challenge, since they may have reduced penetrance and 
variable expression, and may interact with additional, non-genetic factors. Next generation 
sequencing techniques used in large patient cohorts will provide possibilities to identify 
novel genetic factors. The broad knowledge of molecular pathways linked to specific symp-
toms can sustain the clinician in his/her search for an aetiological diagnosis. In view of 
the “genotyping first” approach that will characterize the near future of clinical genetics, 
the modern geneticist might need to subspecialize in molecular mechanisms and become 
a pathway expert that interprets the molecular data in view of this knowledge.  In order to 
prove pathogenicity of identified variants, support of these techniques by facilities for high 
throughput functional studies, for example in animal models, are essential.
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Figure 1. D
ifferential diagnostic considerations in perinatal, infantile and childhood cerebral hem
orrhage. 
A
rteriovenous m
alform
ation is defined as an abnorm
al connection betw
een arteries and veins, bypassing the capillary system
46. C
erebral cavernous m
alfor-
m
ations are vascular m
alform
ation characterised by closely clustered enlarged capillary-like channels w
ith a single layer of endothelium
 w
ithout intervening 
brain parenchym
a
47. M
oyam
oya disease is defined as progressive bilateral stenosis of the distal portion of the internal carotid artery and the proxim
al ante-
rior and m
iddle cerebral arteries 48. Intracerebral hem
orrhage is defined as intraparenchym
al and intraventricular hem
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SUMMARY
In this thesis, our work on genetic causes of childhood cerebrovascular disease is described, 
with a main focus on infantile cerebral hemorrhage. Our primary goal was to improve the 
diagnostics in this group of children, in order to provide better counselling of families. 
Since little was known, we wanted to gain insight in the contribution of genetic factors 
in this group of patients. In addition, when known causes of cerebral hemorrhage were 
excluded, we wanted to identify novel genetic causes for childhood cerebral hemorrhage. 
In chapter 1, the known genetic causes of childhood cerebral hemorrhage are provided. The 
two main pathophysiological processes described in this thesis are introduced, comprising 
structural changes affecting the blood-brain barrier integrity and dysregulation of inflam-
mation. Also, the diseases related to these pathophysiological processes are summarized. 
The outline of the thesis is presented.
Chapter 2 includes descriptions of other causes of childhood cerebrovascular disease.
In chapter 2.1 a case report is provided on a toddler girl with a systemic disorder compris-
ing primary pulmonary hypertension, persistent ductus arteriosus, extensive cerebral white 
matter lesions, fixed dilated pupils, intestinal malrotation, and hypotonic bladder. Recently, 
de novo ACTA2 R179H substitutions were associated with a similar phenotype and addi-
tional cerebral developmental defects. In our patient, an ACTA2 R179C substitution was 
identified. She showed previously undescribed abnormal lobulation of the frontal lobes and 
position of the gyrus cinguli and rostral dysplasis of the corpus callosum together with 
cerebrovascular developmental defects; she died at the age of 3 years during surgery due 
to vascular fragility and rupture of the ductus arteriosus. Altogether these observations 
support a role of ACTA2 in brain development, especially related to the arginine at position 
179. 
Chapter 2.2 comprises a review of literature about neurological complications of Incon-
tinentia Pigmenti, is a rare X-linked multisystem disorder with well described and 
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pathognomonic skin manifestations. Neurological manifestations are found in 30% of IP 
patients, forming one of the major causes of morbidity and mortality of the condition. The 
clinical and brain imaging data of 45 IP patients described in literature with a neurological 
phenotype were  reviewed. Several clinical presentations could be identified, comprising 
seizures, infantile encephalopathy, acute disseminated encephalomyelitis and ischemic 
stroke. Most neurological features presented during the neonatal period. No patients pre-
sented during adolescence or at adult age. Brain MRI findings included periventricular and 
subcortical white matter disease, hemorrhagic changes, corpus callosum hypoplasia, cere-
bral atrophy and cerebellar hypoplasia. Most findings may reflect changes following brain 
injury. Both (ischemic) vascular and inflammatory components may play a role in the cere-
bral and ocular phenotype. However, a role of disturbed apoptosis during development may 
also be a contributing factor.
In chapter 3, an overview is provided of the results of COL4A1 and COL4A2 testing 
of 183 index patients at the Dept. of clinical genetics of the Erasmus University Medical 
Center since 2006. In 13%, a COL4A1 or COL4A2 mutation was detected (21 COL4A1 
and 3 COL4A2 mutations). The clinical data in 13 novel families harbouring COL4A1 or 
COL4A2 mutations are provided. A high percentage of de novo mutations (38%) was found 
in our cohort.  Several clinical phenotypes were identified. Novel findings included the first 
case of focal cortical dysplasia in a patient with a COL4A2 mutation. In addition a review 
of the clinical spectrum of COL4A1 and COL4A2 mutations in literature is provided, and 
several clinical phenotypes are described in more detail. Our cohort did not include cases 
of stroke in young adulthood or sporadic late-onset hemorrhagic stroke, which proba-
bly reflects a referral bias in our cohort. A protocol for initial screening of COL4A1 and 
COL4A2 patients is provided, giving an outline for clinical management. However, clini-
cal follow-up data, also of apparently unaffected mutation carriers, are needed in order to 
develop appropriate screening protocols and adapt treatment.
In chapter 4, our experience with several specific COL4A1 mutation phenotypes is 
described. 
Chapter 4.1 describes the most severe end of the COL4A1 mutation spectrum, comprising 
of severe brain destruction resembling hydranencephaly due to de novo mutations in four 
affected infants .
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Chapter 4.2 gives a description of the severe ophthalmological phenotype of anterior 
segment dysgenesis disorder (ASDD) with cataract, microcornea, microphthalmia and 
tunnel vision in a family with three affected patients. Interestingly, the combination of 
ASDD,  and additional neurological disease in one and brain MRI findings of periventricular 
leukomalacia in a second patient prompted us to test COL4A1. Neurological examination 
and brain MRI are suggested as useful tools in the diagnostic workup of ASDD patients in 
order to suspect the diagnosis of a COL4A1 or COL4A2 mutation.
Chapter 4.3 provides the description of the first putatively pathogenic homozygous COL4A1 
variant affecting the VR3 docking site of the COL4A1 NC1 domain in a patient with severe 
porencephaly, polymicrogyria, corneal clouding, Rieger anomaly and microcephaly. 
Austosomal recessive inheritance has been reported in the very homologous COL4A3 and 
COL4A4 gene, related to Alport syndrome. The open question remains whether this is the 
cause of the disease and whether autosomal recessive inheritance is a general mechanism in 
COL4A1. Additional cases are needed to make a definite statement regarding this question, 
which is very important regarding genetic counselling of families.
In chapter 5, we describe the identification of COL4A2 mutations in two families, using 
a candidate gene approach.  Mutation phenotypes varied, including porencephaly, white 
matter lesions, cerebellar and optic nerve hypoplasia and unruptured carotid aneurysm. 
In the second family however, we found evidence for additional factors contributing to 
the phenotype. Fragmentation and duplication of epidermal basement membranes were 
observed by electron microscopy in a c.3206delC patient skin biopsy, consistent with 
abnormal collagen IV network. Collagen chain accumulation and endoplasmic reticulum 
(ER) stress have been proposed as cellular mechanism in COL4A1 mutations. In COL4A2 
3206delC fibroblasts we detected increased rates of apoptosis but no signs of ER stress. 
Based on our findings, we conclude that dominant COL4A2 mutations are a novel major 
risk factor for familial cerebrovascular disease, including porencephaly and small-vessel 
disease with reduced penetrance and a variable phenotype, which might also be modified 
by other contributing factors.
In chapter 6, the clinical and molecular findings of two families with pseudo-TORCH 
syndrome and in addition severe cerebral hemorrhage and early demise, who harbour auto-
somal recessive  mutations in USP18. Usp18 mouse knockout models have already showed 
cerebral hemorrhage and hydrocephalus with ependymal necrosis. Immunohistochemistry 
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on patient brain tissue shows a very abnormal brain ependyme. Our findings hereby rep-
resent the first genetic disorder linked to ependymal cell dysfunction. USP18, an interferon 
(IFN) stimulated gene, plays a role in immune response, i.e. by inhibiting IFN-type I signal-
ling in cells. The mutation is likely to cause upregulated intracellular IFN type I signalling, 
similar to findings in viral infections or Aicardi Goutières syndrome, both conditions 
that can present with infantile cerebrovascular disease. In Aicardi Goutières syndrome, 
however, this upregulation is an indirect effect triggered by an inadequate processing of 
cellular nucleic acid debris through mechanisms not clarified to date. USP18 mutations 
form the first genetic disease that directly links the increased IFN type I signalling to the 
(cerebrovascular) phenotype of the affected patients. 
Chapter 7 comprises the general discussion of the thesis.  
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SAMENVATTING
Dit proefschrift is een beschrijving van ons werk betreffende genetische oorzaken van 
cerebrovasculaire aandoeningen op de kinderleeftijd, met de nadruk op infantiele her-
senbloedingen. Het belangrijkste doel was om de diagnostiek voor deze patiëntengroep te 
verbeteren, om een betere counseling te kunnen geven aan de betreffende families. Omdat 
nog niet veel bekend was over dit onderwerp, wilden we een beter inzicht krijgen in de 
bijdrage van genetische factoren in deze patiëntengroep. Bovendien wilden we nieuwe gene-
tische factoren betrokken bij bloedingen op de kinderleeftijd identificeren, nadat bekende 
oorzaken werden uitgesloten.
In hoofdstuk 1 worden de bekende oorzaken van cerebrale bloedingen op de kinderleef-
tijd samengevat. De twee belangrijkste pathofysiologische processen die in dit proefschrift 
worden beschreven worden geïntroduceerd, namelijk ten eerste structurele veranderingen 
die de integriteit van de bloed-hersen barrière-aantasten, en ten tweede ontregeling van de 
van de immuunrespons. De bekende cerebrovasculaire aandoeningen die worden veroor-
zaakt door deze processen worden beschreven. Ook wordt een overzicht van de inhoud van 
het proefschrift gegeven.
Hoofdstuk 2 bevat beschrijvingen van een tweetal voorbeelden van ischemische arterio-
pathieën op de kinderleeftijd. Hoofdstuk 6.1 bevat een  beschrijving van een peuter met 
een systemische aandoening met primaire pulmonale hypertensie, persisterende ductus 
arteriosus, uitgebreide afwijkingen van de witte stof van de hersenen, verwijde pupillen, 
malrotatie van de darm en een hypotone blaas. Recent werden nieuw ontstane R179H 
mutaties in ACTA2 geassocieerd met een vergelijkbaar ziektebeeld met hersenontwikke-
lingsstoornissen.  In onze patiënt werd een R179C verandering aangetoond. Ze had een 
afwijkende lobulatie van de frontaalkwabben en afwijkende positie van de gyrus cingulus 
en een afwijkende aanleg van de hersenbalk, ook had ze afwijkingen van de hersenvaten. Ze 
overleed op de leeftijd van 3 jaar tijdens een operatie door extreme zwakte van de vaten en 
scheur van de ductus arteriosus. Deze bevindingen suggereren dat ACTA2 een rol speelt in 
de hersen(vaat)ontwikkeling. Hoofdstuk 2.2 is een review van de literatuur over de neuro-
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logische complicaties van incontinentia pigmenti (IP), een zeldzame geslachtsgebonden 
multisysteemaandoening met goed gedocumenteerde en kenmerkende huidverschijnselen. 
Neurologische verschijnselen worden gevonden in 30% van de patiënten en vormen een van 
de belangrijkste oorzaken van morbiditeit en mortaliteit. De klinische kenmerken, data 
van de beeldvorming van de hersenen en de oogafwijkingen in 45 patiënten met IP met 
een neurologisch beeld die in de literatuur werden beschreven werden bekeken. Verschil-
lende klinische presentaties konden worden geïdentificeerd, waaronder epilepsie, infantiele 
encefalopathie, acute disseminerende encefalomyopathie en ischemische beroerte. De 
meeste neurologische kenmerken begonnen vlak na de geboorte. Bij geen enkele patiënt 
begonnen de verschijnselen tijdens de puberteit of op volwassen leeftijd. Afwijkingen op 
MRI-scans van de hersenen waren periventriculaire en subcorticale wittestofafwijkingen, 
hemorrhagische veranderingen, corpus callosum hypoplasie,  atrofie van de grote hersenen 
en onderontwikkeling van de kleine hersenen. De meeste bevindingen zijn waarschijnlijk 
het gevolg van hersenschade. Zowel (ischemische) vasculaire als ontstekingscomponenten 
kunnen een rol spelen in het ontstaan van de hersenafwijkingen en oogafwijkingen. Moge-
lijk speelt een verstoorde apoptose tijdens de ontwikkeling echter ook een rol.  
In hoofdstuk 3 wordt een overzicht gegeven van de resultaten van het testen van het 
COL4A1 en COL4A2 gen in 183 indexpatiënten, verricht op de afdeling Klinische Gene-
tica van het Erasmus MC vanaf 2006. In 13% van de patiënten werd een COL4A1 of een 
COL4A2 mutatie aangetoond (21 COL4A1 en 3 COL4A2 mutaties). De klinische data van 
13 nieuwe families met een COL4A1 of COL4A2 mutatie worden beschreven. In ons cohort 
werd een hoog percentage (38%) de novo mutaties gevonden.  Verschillende klinische feno-
types werden geïdentificeerd. Nieuwe bevindingen waren onder andere de identificatie van 
een eerste patiënt met een COL4A2 mutatie en focale corticale dysplasie. Aanvullend wordt 
een overzicht van het klinische spectrum van COL4A1 en COL4A2 mutaties vanuit de 
literatuur beschreven, en verschillende klinische fenotypes worden apart beschreven.  In 
ons cohort werden geen patiënten opgenomen met hersenbloedingen op jong volwassen 
leeftijd of op oudere leeftijd, waarschijnlijk omdat de meeste verwijzingen kwamen vanuit 
de kinderneurologie en neonatologie.  Een protocol met screenende onderzoeken die na 
de diagnose geadviseerd worden is beschreven. Het is van groot belang om meer klinische 
gegevens met betrekking tot het beloop van de aandoening te verkrijgen, ook van de perso-
nen die drager zijn van een mutatie zonder dat ze evidente verschijnselen hebben. Op basis 
hiervan is het mogelijk om geschikte protocollen te ontwikkelen voor screenings en om de 
behandeling eventueel aan te passen.  
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Hoofdstuk 4 bevat een beschrijving van onze ervaring met enkele bijzondere fenotypes 
geassocieerd met COL4A1 mutaties. Hoofdstuk 4.1 beschrijft de meest ernstige uitings-
vorm van COL4A1 mutaties in vier baby’s, bestaande uit ernstige destructie van de 
hersenen, wat eruit ziet als hydranencefalie. Dit beeld wordt veroorzaakt door  nieuw ont-
stane mutaties. Hoofdstuk 4.2  geeft een beschrijving van een familie met drie aangedane 
familieleden die allen ernstige oogproblemen hebben bestaande uit een afwijkende aanleg 
van de voorste oogkamer met staar, te kleine ogen en tunnelvisie. Door de combinatie van 
de oogafwijkingen, samen met de aanwezigheid van neurologische afwijkingen bij een van 
de patiënten, en de aanwezigheid van periventriculaire leukomalacie op een MRI-scan bij 
haar zus, werd het COL4A1 gen getest. In patiënten met ontwikkelingsstoornissen van de 
voorste oogkamer is het daarom zinvol om een neurologisch onderzoek en MRI-scan van 
de hersenen te verrichten, om een aanwijzingen voor de aanwezigheid van een COL4A1 of 
COL4A2 mutatie te vinden.  Hoofdstuk 4.3 bevat de eerste beschrijving van een mogelijk 
ziekteveroorzakende homozygote variant in de VR3 docking site van het NC1 domein van 
het COL4A1 gen in een patiënt met ernstige porencefalie, polymicrogyrie, sluiering van 
het hoornvlies, Rieger anomalie en een te kleine hoofdomtrek. Autosomaal recessieve ove-
rerving is beschreven in de zeer homologe genen COL4A3 en COL4A4, betrokken bij het 
Alport syndroom. De vraag blijft vooralsnog of de mutatie de oorzaak is van het ziektebeeld 
in deze patiënt en of autosomaal recessieve overerving van COL4A1 mutaties mogelijk is. 
Aanvullende casus zijn nodig om deze vraag met meer zekerheid  te beantwoorden , hetgeen 
van belang zou zijn voor de counseling van families.   
In hoofdstuk 5 wordt de identificatie van COL4A2 mutaties in twee families beschreven 
als nieuwe oorzaak van erfelijke porencefalie. De ziektebeelden van de aangedane patiën-
ten waren variabel en bevatten porencefalie, wittestofafwijkingen, een aneurysma van de 
halsslagader en onderontwikkeling van de kleine hersenen en van de oogzenuwen.  In de 
tweede familie vonden we aanwijzingen voor aanvullende factoren die een bijdrage geleverd 
kunnen hebben aan het ziektebeeld. In een huidbiopt van een van de patiënten werd met 
electronenmicroscopie afwijkingen gezien in de basale membranen van de huid, passend 
bij een afwijkend collageen IV netwerk. Accumulatie van collageen ketens en endoplas-
matisch reticulum stress  werden eerder beschreven als mogelijk cellulair mechanisme in 
COL4A1 mutaties. In fibroblasten van een van de patiënten met een 3206delC mutatie werd 
een toegenomen celdood (apoptose) gezien, maar tekenen van ER stress werden niet waar-
genomen.  Op basis van onze bevindingen concluderen we dat COL4A2 mutaties  nieuwe 
belangrijke risicofactoren zijn voor familiale cerebrovasculaire aandoeningen, waaronder 
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porencefalie en small vessel disease, met een verminderde penetrantie en variabele uitings-
vormen, waarbij andere bijdragende factoren mogelijk ook een rol spelen.  
In hoofdstuk 6 worden de klinische en moleculaire bevindingen beschreven in twee fami-
lies met ernstige hersenbloedingen en een ernstig pseudo-TORCH syndroom, waarbij 
de aangedane baby’s vroeg overlijden. Autosomaal recessieve mutaties in het USP18 gen 
werden aangetoond. In muismodellen met een uitschakeling van het USP18 gen werden al 
eerder hersenbloedingen en hydrocefalie gezien met necrose van de ependymlaag van de 
hersenventrikels. Immunohistochemie van hersenweefsel van een patiënt toonde een zeer 
afwijkende opbouw van het ependym. USP18 speelt een rol in de immuunrespons en wordt 
gestimuleerd door interferon (IFN) en remt de type I IFN signalling. Door de mutatie is er 
waarschijnlijk een toegenomen IFN type I signalling. Dit is ook het geval in virusinfecties 
en in het Aicardi Goutières syndroom, met overlappende kenmerken. In Aicardi Goutiè-
res syndroom is deze upregulatie echter een indirect effect dat wordt veroorzaakt door de 
afwijkend verlopende verwerking van nucleïnezuren. Waarom dit leidt tot een upregulatie 
van de IFN type I signalling is vooralsnog niet duidelijk. USP18 mutaties vormen de eerste 
genetische aandoening die het verband laat zien tussen een verhoogde IFN type I signalling 
en het (cerebrovasculaire) ziektebeeld van de aangedane patiënten.   
Hoofdstuk 7 bevat de algemene discussie van het proefschrift. 
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bedankt. 
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een of andere manier wel goed zou komen. Dit boekje is hier een voorbeeld van. Samen 
kunnen we de wereld aan…
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Chapter 1
Figure 1. Schematic overview of pathogenic mechanism leading to porencephaly107,108. The 
lateral ventricles with surrounding deep veins are depicted in A. Porencephaly originates from 
a germinal matrix hemorrhage, often followed by intraventricular hemorrhage. This leads to 
deep venous infarctions and destruction of white matter in that area, eventually leading to a cyst 
communicating with the ventricle (B)
Chapter 2.1
Figure 3. An image of the retina shows tortuosity of the retinal vessels.
244
Chapter 3
Figure 1. In this figure, the COL4A1 mutations (A) and COL4A2 mutation (B) in our novel fam-
ilies are depicted on the bottom (red arrows), the mutations reported in literature are depicted 
on the top (blue arrows).
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Chapter 4.2
Figure 1. Brain MRI of the index patient (A,B,C). FLAIR (A,C) and T2- weighed (B) images 
show periventricular leukomalacia. Picture of ocular features of the mother (D), with microph-
thalmia and status after many ocular operations because of congenital cataract and secondary 
glaucoma.    
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Chapter 5
Figure 1. Pedigrees of families A and B. 
Different symbols indicate individuals affected with various cerebral vascular disease as indicated in the legend. The 
genotype of the tested individuals is indicated: (A) 4165G/G = wild type sequence; 4165G/A heterozygous mutation; 
(B) 3206C/C = wild type sequence; 3206C/delC = heterozygous mutation. Electroferograms indicate the heterozygous 
mutation in the COL4A2 sequence of family A c.4165G>A (p.G1389R) (C) and family B c.3206delC leading to frame 
shift (D). Quantitative, real time PCR analysis showing relative expression of COL4A1 and COL4A2 mRNA in fibro-
blasts from patient II.2 (family B) with c.3206delC mutation (A2 patient) and a patient bearing a pathogenic c.3321G>C 
(p.G1067A) mutation in exon 38 of COL4A1 (A1 patient), compared to a control cell line. Results are average of two 
separate experiments. For each cell line the highest expression is set as 100% on the Y axis (E).  Position of the muta-
tions within the schematic representation of the COL4A2 genomic organization (F).
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Figure 2. Brain MRI of patients 
with COL4A2 mutations. 
A, B. Axial and coronal T2 of patient 
III.2 from family A at the age of 2 years 
indicate ex-vacuo dilation of the left 
lateral ventricle (porencephaly) (open 
arrow) and periventricular white matter 
lesions (solid arrows) resulting from pre-
sumed perinatal stroke. 
C. FLAIR image illustrates T2 prolon-
gation in the white matter – in patient 
III.1 from family A at the age of 8 years, 
suggesting gliosis (arrow). 
D. MR angiography of their mother 
(subject II.1, family A) at adult age shows 
bilateral internal carotid aneurysms (at 
the level of cavernous sinus). 
E. Axial T2 weighted images of Patient 
II.2, family B, at the age of 15 years show 
a porencephalic dilatation of the left 
occipital ventricle. 
F, G. Axial T2 weighted and coronal 
FLAIR images of patient II.5 from 
family B at the age of 5 months show 
porencephaly of the right ventricle with 
hypoplastic left cerebellar hemisphere. 
H-M. Reconstruction of the white 
matter tracts obtained from magnetic 
resonance diffusion tensor imaging 
(MR-DTI) data.
K,L. Patient II-2 (family B) reveals 
reduced fractional anisotropy in the left 
radiation optica and tractus corticos-
pinalis at the side of the porencephalic 
lesion (encircled), compared with an 
age-matched control 
H,I. A restriction of the total ADC was 
observed in the whole cerebral white 
matter of the patient (M), compared to 
an age-matched control (J). 
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Supplementary figure 5. Skin fibroblasts were cultured in 175 cm2 culture flasks in Dulbec-
co’s modified Eagle medium (DMEM, Lonza Biowhittaker) plus 10% FCS until 80% confluence. 
Cultures were obtained from 5 healthy individuals (control), one patient with COL4A23206delC 
mutation (patient) and one individual with confirmed Wolcott-Rallison syndrome bearing an 
EIF2AK3 mutation (WRS). Before testing apoptosis rates by the Flica multicaspase detection 
kit, the cells were exposed 24 hours to serum deprivation. Data are average of multiple experi-
ments plus SD, as indicated in the methods.
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Supplementary Figure 3. Cultured fibroblasts grown under standard conditions . Immunofluo-
rescent staining for HSP47 (red). A: control; B: patient with COL4A23206delC  mutation.
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Supplementary Figure 4. Cultured fibroblasts after treatment with 5 mM DTT. Immunofluo-
rescent staining for P450 (red), KDEL (green). A and B: control 1. C: merged picture of A and 
B. D,E.F: merged pictures of double staining with KDEL and P450. D: control 2; E: control 3; 
F: patient with COL4A23206delC mutation.
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Figure 2. Patient ependyme of left lateral ventricle. Haematoxyline & Eosin (H&E) staining of 
patient autopsy material (patient A-V.1) showing abnormal, irregular ependyme with disorgan-
isation of the ventricular zone. 
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Supplementary figure 1. Linkage data and haplotyping of family A
Haplotype analysis of family A, the shared haplotype between the affected individuals is located 
in the red box (A). B shows the linked area on chromosome 22 with LOD score of 2.83 in detail. 
C shows the genome wide linkage, confirming that the linked area on chromosome 22 is the 
only linkage area with a significant LOD score. 
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Supplem
entary figure 2. U
SP18 M
utations
Pedigree of fam
ily A
, w
ith a representation of the U
SP18 m
utations, the heterozygous c.652C>T, p.Q
218X m
utation in IV.1, IV.2 and V.4 (upper 
panel) and the m
utation in hom
ozygous form
 in V.1, V.2 and V.3 (A
). B show
s the pedigree of fam
ily B, w
ith the sam
e U
SP18 c.652C>T, p.Q
218X 
m
utation, present in heterozygous form
 in II.1 and II.2. 
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Supplem
entary figure 6. C
ontrol fibroblast RT-qPCR U
SP18, ISG
15, STAT after IFN
β treatm
ent
qRT-PCR on cD
N
A
 isolated from
 control fibroblasts w
ithout and w
ith overnight treatm
ent w
ith IFN
β (1000U
/l)(Tebu-Bio, Th
e N
etherlands). 
Th
ese data show
 that IFN
β treatm
ent leads to upregulation of U
SP18, ISG
15 and STAT1. Tests in patient fibroblasts are pending. 
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